Heterocyclic inhibitors of ERK1 and ERK2 and their applications in cancer therapy

By developing a new heterocyclic compound formula (I) as an ERK1/2 inhibitor, the problem of ERK1/2 inhibitor in the prior art has not entered the late clinical trials and drug resistance, and effective inhibition of ERK1/2 has been achieved. Potential options for the treatment of a variety of cancers and related diseases are provided.

CN107922387BActive Publication Date: 2024-11-22ASANA BIOSCIENCES LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201680031963.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2015-06-15
Filing Date
2016-06-15
Publication Date
2024-11-22
Estimated Expiration
2036-06-15

AI Technical Summary

Technical Problem

The existing ERK1/2 inhibitors have not yet been effectively entered late-stage clinical trials, and there is a problem of resistance to MEK inhibitors, resulting in the lack of effective modified ERK1/2 inhibitors in cancer treatment.

Method used

A novel heterocyclic compound has been developed, specifically a compound of formula (I) and its pharmaceutically acceptable salts, prodrugs, solvates, hydrates or stereoisomers, for use as inhibitors of ERK1 and ERK2 , used to treat a variety of diseases including cancer, leukemia and lymphoma.

Benefits of technology

This compound can effectively inhibit ERK1/2, overcome the problem of resistance to MEK inhibitors, and provides potential treatment options for a variety of cancers and related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN107922387B_ABST
    Figure CN107922387B_ABST
Patent Text Reader

Abstract

The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof, and also provides methods for preparing the compounds. The compounds can effectively inhibit ERK1 / 2. By administering a therapeutically effective amount of one or more compounds of formula (I) to a patient in need, wherein X, Y, Z, J, M and R 1 To R 8 As defined herein, the compound is effective in treating conditions associated with abnormal regulation of the RAS / RAF / MEK / ERK pathway. A variety of conditions can be treated using the compound, including diseases of abnormal cell proliferation. In one embodiment, the disease is cancer. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to related applications

[0002] This application claims priority to U.S. Provisional Application No. 62 / 175,756, filed June 15, 2015, the disclosure of which is incorporated herein by reference.

[0003] Technical field of the invention

[0004] The present invention relates to novel heterocyclic compounds that are effective as inhibitors of ERK1 and ERK2. The present invention further relates to compositions containing the compounds and methods of using the compositions. Background of the Invention

[0006] ERK1 and ERK2 (collectively referred to as "ERK1 / 2") are related protein serine / threonine kinases that, among other things, participate in the Ras-Raf-MEK-ERK signaling pathway, sometimes also referred to as the mitogen-activated protein kinase (MAPK) pathway. This pathway is generally believed to play a major role in regulating a wide range of fundamental cellular processes, including one or more of cell proliferation, survival, adhesion, cell cycle progression, migration, differentiation, metabolism, transcription, and the like. Activation of the MAPK pathway has been reported in numerous tumor types, including lung, colon, pancreatic, kidney, and ovarian cancers. Therefore, substances that can attenuate activation are of great potential therapeutic interest.

[0007] Activation of ERK1 / 2 appears to be mediated by MEK through phosphorylation of both threonine and tyrosine residues, specifically Tyr204 / 187 and Thr202 / 185. Upon activation, ERK1 / 2 catalyzes the phosphorylation of serine / threonine residues on over 100 substrates and activates cytoplasmic and nuclear proteins associated with hallmarks of cancer phenotypes, including cell growth, proliferation, survival, angiogenesis, and differentiation. Therefore, targeting ERK and developing and administering ERK1 / 2 inhibitors could be beneficial in inhibiting tumor growth.

[0008] Furthermore, ERK inhibitors have utility in combination with other MAPK inhibitors. Recently, researchers reported that dual small-molecule MEK and ERK inhibitors synergistically overcome acquired resistance to MEK inhibitors. See Hatzivassiliou et al., "ERK Inhibition Overcomes Acquired Resistance to MEK Inhibition," Mol. Cancer Ther. 2012, 11, 1143-1154.

[0009] Small molecule ERK inhibitors have been reported in the following literature: U.S. Application No. 6,743,941, U.S. Application No. 8,546,404, and Ren et al., "Discovery of Highly Active, Selective, and Potent Small Molecule ERK1 / 2 Inhibitors," J. Med. Chem. 2015, 58(4), 1976-1991. A few ERK inhibitors (such as BVD-523 and GDC-0994) are in early clinical development. However, no ERK inhibitors have been reported to enter late-stage clinical trials. Therefore, the demand for the development of improved and effective ERK1 / 2 inhibitors for cancer treatment remains unabated. Summary of the Invention

[0010] The present invention discloses a compound of formula (I):

[0011]

[0012] and pharmaceutically acceptable salts, prodrugs, solvates, hydrates or stereoisomers thereof, wherein:

[0013] R 1 is unsubstituted or substituted C 6-12 aryl or unsubstituted or substituted 5- to 10-membered heteroaryl;

[0014] J is selected from -C(R 2 )(R 8 )(CH2) n - a linking group;

[0015] R 2 and R 8 Each independently is H, C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclic group), -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2 or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl, cycloalkyl, heterocyclyl or heteroaryl group is unsubstituted or substituted;

[0016] or R 2 、R 8 and R 2 and R 8 The carbon atoms to which they are attached together form a 3- to 10-membered cycloalkyl ring or a 4- to 10-membered heterocyclyl ring, wherein the cycloalkyl ring or heterocyclyl ring is unsubstituted or substituted;

[0017] n is 0 to 6;

[0018] R 3 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens;

[0019] M is a bond or NH;

[0020] X and Y are each independently CH, CR 7 or N;

[0021] Z is CH or N,

[0022] R 5 It is H, halogen, C 1-6 Alkyl or -OC 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; R 6 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens;

[0023] R 7 It is C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; and

[0024] R 4 is unsubstituted or substituted C 1-6 Alkyl, unsubstituted or substituted C 3-10 Cycloalkyl, unsubstituted or substituted C4-10 cycloalkenyl, unsubstituted or substituted 4- to 10-membered heterocyclyl, unsubstituted or substituted phenyl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted -C 1-6 Alkyl-(4- to 6-membered heterocyclyl), unsubstituted or substituted-C 1-6 alkyl-(5- to 6-membered heteroaryl) or unsubstituted or substituted-C 1-6 Alkyl-phenyl.

[0025] The present invention further discloses a compound of formula (I) and a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof, wherein:

[0026] R 1 is phenyl or 5- to 10-membered heteroaryl, said phenyl or 5- to 10-membered heteroaryl being unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclyl) or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 Alkyl, cycloalkyl, heterocyclyl and / or heteroaryl are unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 alkyl;

[0027] J is -C(R 2 )(R 8 )(CH2) n R 2 and R 8 Each independently is H, C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclic group), -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2 or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl, cycloalkyl, heterocyclyl or heteroaryl groups are unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 alkyl;

[0028] or R 2 、R 8 and R 2 and R 8 The carbon atoms connected together form a 3- to 10-membered cycloalkyl ring or a 4- to 10-membered heterocyclyl ring, wherein the cycloalkyl or heterocyclyl is unsubstituted or substituted by 1 to 3 groups selected from hydroxy, halogen or C 1-6 The alkyl group is substituted with a substituent; n is 0 to 6;

[0029] R 3Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens;

[0030] M is a bond or NH;

[0031] X and Y are each independently CH, CR 7 or N;

[0032] R 7 It is C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens;

[0033] Z is CH or N;

[0034] R 5 It is H, halogen, C 1-6 Alkyl or OC 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; R 6 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; and

[0035] R 4 It is C 1-6 Alkyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-(5- to 6-membered heteroaryl), -C 1-6 Alkyl-(4- to 6-membered heterocyclyl), 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl or phenyl, wherein the alkyl, cycloalkyl, cycloalkenyl, phenyl, heteroaryl or heterocyclyl is unsubstituted or substituted with 1-3 substituents selected from the group consisting of halogen, CN, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N(C 1-6 alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-(4- to 6-membered heterocyclic group), -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, C 2-6 alknyl, hydroxyl, C 1-6Alkoxy or hydroxy C 1-6 Alkyl, and the heterocyclic or heteroaryl is unsubstituted or substituted by 1-3 substituents selected from the following: halogen, C 1-6 Alkyl, -C(O)-C 1-6 an alkyl group or a 4- to 6-membered heterocyclic group.

[0036] The present invention further discloses a compound of formula (I) and a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof, wherein:

[0037] R 1 is phenyl or thienyl which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl or hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl or CN, where C 1-6 Alkyl is unsubstituted or substituted with 1-3 halogens;

[0038] J is -CH(R 2 )-;

[0039] R 2 It is H, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclyl) or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl);

[0040] R 3 It is H;

[0041] M is a key;

[0042] X is CH;

[0043] Y is CH or N;

[0044] Z is N,

[0045] R 5 is H, halogen or C 1-6 alkyl;

[0046] R 6 is H; and

[0047] R 4 is unsubstituted or substituted by 1-3 groups selected from halogen or C1-6 Alkoxy substituent substituted hydroxy C 1-6 alkyl,

[0048]

[0049] The present invention further discloses a compound selected from:

[0050] (S)-1-(2)-(Benzo[d][1,3]dioxol-5-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide;

[0051] 1-(2-(Benzofuran-5-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide;

[0052] 1-(2-(Benzofuran-5-ylamino)-5-methylpyrimidin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-3-carboxamide;

[0053] N-(3-chloro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide;

[0054] (S)-N-(1-(3-chloro-4-fluorophenyl)2-hydroxyethyl)-1-(5-methyl-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[0055] 1-(2-((2,3-dihydrobenzofuran-5-yl)amino)5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide;

[0056] N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-(2,3-dihydrobenzo[b][1,4] ... (6-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[0057] N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[0058] N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(((S)-tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[0059] N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(((R)-tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[0060] 1-(2-(dihydrochromen-6-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide;

[0061] N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-((4-fluoro-3-morpholinylphenyl)amino)-5-methyl-pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[0062] (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[0063] N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)1H-imidazole-4-amide;

[0064] N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((4-morpholinylphenyl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[0065] (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[0066] (R)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[0067] (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[0068] (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-fluoro-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[0069] N-(2-hydroxy-1-(thiophen-2-yl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[0070] (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[0071] (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[0072] (S)-N-(2-(((1H-pyrrol-2-yl)methyl)amino)-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[0073] (S)-N-(3-chloro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-(tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[0074] (S)-N-(1-(3-chlorophenyl)-2-(methylamino)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide;

[0075] (S)-N-(1-(3-chlorophenyl)-2-((2-hydroxyethyl)amino)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide; and

[0076] N-(3-chloro-5-fluoro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide;

[0077] or a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof.

[0078] The present invention further discloses a pharmaceutically acceptable salt of the compound, which is selected from:

[0079] (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide benzenesulfonate;

[0080] (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide benzenesulfonate; and

[0081] (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide benzenesulfonate.

[0082] The present invention further relates to compositions comprising the compounds and methods of using the compositions in treating conditions that can be treated by inhibiting ERK1 / 2.

[0083] In one embodiment, the condition is cancer, leukemia or lymphoma, including cancers of the prostate, head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, bladder, uterus, cervix, breast, ovary, vagina, testicle, skin, thyroid, blood, lymph node, kidney, liver, intestine, pancreas, brain, central nervous system, adrenal gland, skin, etc. DETAILED DESCRIPTION

[0084] The present invention provides novel inhibitors of ERK1 and ERK 2 represented by formula (I)

[0085]

[0086] or a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof, wherein:

[0087] R 1 is phenyl or 5- to 10-membered heteroaryl, wherein the phenyl or 5- to 10-membered heteroaryl is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclyl) or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 Alkyl, cycloalkyl, heterocyclyl and / or heteroaryl are unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 alkyl;

[0088] J is selected from -C(R 2 )(R 8 )(CH2) n - a linking group;

[0089] R 2 and R 8 Each independently is H, C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclic group), -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C1-6 Alkyl)2 or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl, cycloalkyl, heterocyclyl or heteroaryl groups are unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 alkyl;

[0090] or R 2 、R 8 and R 2 and R 8 The carbon atoms connected together form a 3- to 10-membered cycloalkyl ring or a 4- to 10-membered heterocyclyl ring, wherein the cycloalkyl ring or heterocyclyl ring is unsubstituted or substituted with 1-3 substituents selected from the group consisting of hydroxy, halogen or C 1-6 alkyl;

[0091] n is 0 to 6;

[0092] R 3 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens;

[0093] M is a bond or NH;

[0094] X and Y are each independently CH, CR 7 or N;

[0095] Z is CH or N,

[0096] R 5 It is H, halogen, C 1-6 Alkyl or OC 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens;

[0097] R 6 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens;

[0098] R 7 It is C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; and

[0099] R 4 It is C 1-6 Alkyl, C 3-10 Cycloalkyl, C4-10 Cycloalkenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-(5- to 6-membered heteroaryl), C 1-6 Alkyl-(4- to 6-membered heterocyclyl), 4- to 10-membered heterocyclyl, phenyl or 5- to 10-membered heteroaryl, wherein the alkyl, cycloalkyl, cycloalkenyl, phenyl, heteroaryl or heterocyclyl is unsubstituted or substituted with 1-3 substituents selected from the group consisting of halogen, CN, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N(C 1-6 alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-(4- to 6-membered heterocyclic group), -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, C 2-6 alknyl, hydroxyl, C 1-6 Alkoxy or hydroxy C 1-6 Alkyl, and the heterocyclic or heteroaryl is unsubstituted or substituted by 1-3 substituents selected from the following: halogen, C 1-6 Alkyl, -C(O)-C 1-6 an alkyl group or a 4- to 6-membered heterocyclic group.

[0100] In one aspect, the present invention provides novel inhibitors of ERK1 and ERK2 represented by formula (II)

[0101]

[0102] or a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof, wherein:

[0103] R 1 is phenyl or 5- to 10-membered heteroaryl, said phenyl or 5- to 10-membered heteroaryl being unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclyl) or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 Alkyl, cycloalkyl, heterocyclyl and / or heteroaryl are unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 alkyl;

[0104] n is 0 to 6;

[0105] R 2 It is C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6Alkyl-(4- to 6-membered heterocyclic group), -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N(C 1-6 Alkyl)2 or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl, cycloalkyl, heterocyclyl or heteroaryl groups are unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl; and

[0106] R 8 Is H or C 1-6 alkyl;

[0107] Or, R 2 、R 8 and R 2 and R 8 The carbon atoms connected together form a 3- to 10-membered cycloalkyl ring or a 4- to 10-membered heterocyclyl ring, wherein the cycloalkyl or heterocyclyl is unsubstituted or substituted with 1-3 substituents selected from the group consisting of hydroxy, halogen or C 1-6 alkyl;

[0108] R 3 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens;

[0109] M is a bond or NH;

[0110] X and Y are each independently CH, CR 7 or N;

[0111] Z is CH or N,

[0112] R 5 It is H, halogen, C 1-6 Alkyl or OC 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens;

[0113] R 6 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens;

[0114] R 7 It is C 1-6 Alkyl, where C 1-6Alkyl is unsubstituted or substituted with 1-5 halogens; and

[0115] R 4 It is C 1-6 Alkyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-(5- to 6-membered heteroaryl), C 1-6 Alkyl-(4- to 6-membered heterocyclyl), 4- to 10-membered heterocyclyl, phenyl or 5- to 10-membered heteroaryl, wherein the alkyl, cycloalkyl, cycloalkenyl, phenyl, heteroaryl or heterocyclyl is unsubstituted or substituted with 1-3 substituents selected from the group consisting of halogen, CN, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N(C 1-6 alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-(4- to 6-membered heterocyclic group), -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, C 2-6 alknyl, hydroxyl, C 1-6 Alkoxy or hydroxy C 1-6 Alkyl, and the heterocyclic or heteroaryl is unsubstituted or substituted by 1-3 substituents selected from the following: halogen, C 1-6 Alkyl, -C(O)-C 1-6 an alkyl group or a 4- to 6-membered heterocyclic group.

[0116] In one embodiment, the compound of formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof, wherein:

[0117] R 1 is phenyl, pyridyl, thienyl or thiazolyl which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 substituents selected from halogen;

[0118] n is 0 to 1;

[0119] R 2 It is C1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclic group), -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N(C 1-6 Alkyl)2 or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl, cycloalkyl, heterocyclyl or heteroaryl groups are unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl; and

[0120] R 8 Is H or C 1-6 alkyl;

[0121] Or, R 2 、R 8 and R 2 and R 8 The carbon atoms connected together form a 3- to 6-membered cycloalkyl ring or a 4- to 6-membered heterocyclyl ring, wherein the cycloalkyl or heterocyclyl is unsubstituted or substituted with 1-3 substituents selected from the group consisting of hydroxy, halogen or C 1-6 alkyl;

[0122] R 3 Is H or C 1-6 Alkyl, where C 1-6Alkyl is unsubstituted or substituted with 1-3 halogens;

[0123] M is a bond or NH;

[0124] X and Y are each independently CH, CR 7 or N;

[0125] Z is CH or N,

[0126] R 5 It is H, halogen, C 1-6 Alkyl or OC 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-3 halogens; R 6 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-3 halogens;

[0127] R 7 It is C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-3 halogens; and

[0128] R 4 It is C 1-6 Alkyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-(5- to 6-membered heteroaryl), -C 1-6 Alkyl-(4 to 6-membered heterocyclyl), 4- or 10-membered heterocyclyl, phenyl or 5- to 10-membered heteroaryl, wherein the alkyl, cycloalkyl, cycloalkenyl, phenyl, heteroaryl or heterocyclyl is unsubstituted or substituted with 1-3 substituents selected from the group consisting of halogen, CN, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N(C 1-6 alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-(4- to 6-membered heterocyclic group), -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, C 2-6 alknyl, hydroxyl, C 1-6 Alkoxy or hydroxy C 1-6Alkyl, and the heterocyclic or heteroaryl is unsubstituted or substituted by 1-3 substituents selected from the following: halogen, C 1-6 Alkyl, -C(O)-C 1-6 an alkyl group or a 4- to 6-membered heterocyclic group.

[0129] In one embodiment, R 1 is unsubstituted or substituted C 6-12 Aryl or unsubstituted or substituted 5- to 10-membered heteroaryl. In one embodiment, R 1 is phenyl or a 5- to 6-membered heteroaryl group containing 1 to 2 ring heteroatoms selected from O, N or S, wherein the phenyl or heteroaryl group is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclyl) or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl, cycloalkyl, heterocyclyl, and / or heteroaryl groups are unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 In one embodiment, R 1 is phenyl, pyridyl, thienyl or thiazolyl which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-3 substituents selected from halogen. In one embodiment, R 1 is phenyl, pyridyl, thienyl or thiazolyl which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, C 1-3 Alkyl, CN, hydroxy C 1-3 Alkyl or amino C 1-3 Alkyl, where C 1-3 The alkyl group is unsubstituted or substituted with 1-3 substituents selected from F. In one embodiment, R 1 is phenyl, pyridyl, thienyl or thiazolyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CH3, -C(CH3)3, CF3, -CH2OH, -CH2CH2OH, CH2NH2, CN or -C(CH3)2OH. In one embodiment, R 1 is phenyl, which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CH3, -C(CH3)3, CF3, -CH2OH, -CH2CH2OH, CH2NH2, CN or -C(CH3)2OH.

[0130] In one embodiment, n is 0 to 6. In one embodiment, n is 0 to 2. In one embodiment, n is 0 to 1. In one embodiment, n is 0.

[0131] In one embodiment, R 2 It is C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclic group), -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N(C 1-6 Alkyl)2 or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl, cycloalkyl, heterocyclyl or heteroaryl groups are unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 alkyl; and R 8 Is H or C 1-6 In one embodiment, R 2 It is C 1-3 Alkyl, hydroxyl C 1-3 Alkyl, amino C 1-3 Alkyl, -C 1-3 Alkyl-OC 1-3 Alkyl, -C 1-3 Alkyl-NH-C 1-3 Alkyl, -C 1-3 Alkyl-N-(C 1-3 Alkyl)2, -C 1-3 Alkyl-NH-C 1-3 Alkyl-OH, -C 1-3 Alkyl-NH-C 1-3 Alkyl-C 3-6 Cycloalkyl, -C 1-3 Alkyl-NH-C 1-3 Alkyl-NH-C 1-3 Alkyl, -C 1-3 Alkyl-NH-C(O)-C 1-3 Alkyl, -C 1-3 Alkyl-OC(O)-C 1-3 Alkyl, -C 1-3 Alkyl-NH-C 0-3 Alkyl-(4- to 6-membered heterocyclic group), -C(O)-NH2, -C(O)-NH-C 1-3 Alkyl, -C(O)-N(C 1-3 Alkyl)2 or -C 1-3 Alkyl-NH-C 0-3 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-3 The alkyl, cycloalkyl, heterocyclyl or heteroaryl groups are unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C 1-3 Alkyl, NH2, hydroxyl C1-3 Alkyl or amino C 1-3 alkyl; and R 8 Is H or C 1-3 In one embodiment, R 2 It is C 1-3 Alkyl, hydroxyl C 1-3 Alkyl, amino C 1-3 Alkyl, -C 1-3 Alkyl-NH-C 1-3 Alkyl, -C 1-3 Alkyl-NH-C 1-3 Alkyl-OH, -C 1-3 Alkyl-NH-C 0-3 Alkyl-(4- to 6-membered heterocyclyl) or -C 1-3 Alkyl-NH-C 0-3 alkyl-(5- to 6-membered heteroaryl); and R 8 is H. In one embodiment, R 2 is CH3, -CH2OH, -CH2NH2, -CH2OCH3, -CH2N(CH3)2, -CH2NH(CH3), -CH2NHCH2CH2OH, -CH2NHC(O)CH3, -CH2OC(O)CH(NH2)CH2CH(CH3)2, -C(O)NH2, -CH2NH-(tetrahydro-2H-pyran), or -CH2NHCH2-(pyrrole); and R 8 is H. In one embodiment, R 2 is CH3, -CH2OH, -CH2NH2, -CH2NH(CH3), -CH2NHCH2CH2OH, -CH2NH-(tetrahydro-2H-pyran), or -CH2NHCH2-(pyrrole); and R 8 is H. In one embodiment, R 2 is -CH2OH or -CH2NH2; and R 8 It’s H.

[0132] In another embodiment, R 2 、R 8 and R 2 and R 8 The carbon atoms connected together form a 3- to 6-membered cycloalkyl ring or a 4- to 6-membered heterocyclyl ring, wherein the cycloalkyl or heterocyclyl is unsubstituted or substituted with 1-3 substituents selected from the group consisting of hydroxy, halogen or C 1-6 In one embodiment, R 2 、R 8 and R 2 and R 8The carbon atoms connected together form a 3- to 6-membered cycloalkyl group which is unsubstituted or substituted with 1-3 substituents selected from hydroxy. 2 、R 8 and R 2 and R 8 The linked carbon atoms together form a cyclobutyl group which is unsubstituted or substituted with a hydroxy group.

[0133] In one embodiment, R 3 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens. In one embodiment, R 3 Is H or C 1-3 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-3 halogens. In one embodiment, R 3 It is H or CH3.

[0134] In one embodiment, M is a bond or NH. In one embodiment, M is a bond.

[0135] In one embodiment, X and Y are each independently CH, CR 7 or N. In one embodiment, X is CH, C-CH 3 or N. In one embodiment, X is CH. In one embodiment, Y is CH, C-CH 3 or N. In one embodiment, Y is N.

[0136] In one embodiment, R 7 It is C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens. In one embodiment, R 7 It is C 1-6 In one embodiment, R 7 It is CH3.

[0137] In one embodiment, Z is CH or N. In one embodiment, Z is N.

[0138] In one embodiment, R 5 It is H, halogen, C 1-6 Alkyl or OC 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens. In one embodiment, R 5 It is H, Cl, F, C 1-3 Alkyl or -OC 1-3 Alkyl, where C 1-3 Alkyl is unsubstituted or substituted with 1-3 halogens. In one embodiment, R5 It is H, Cl, F, CH3 or -OCH3.

[0139] In one embodiment, R 6 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens. In one embodiment, R 6 is H or CH3. In one embodiment, R 6 It’s H.

[0140] In one embodiment, R 4 It is C 1-6 Alkyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-(5- to 6-membered heteroaryl), -C 1-6 Alkyl-(4 to 6-membered heterocyclyl), 4- or 10-membered heterocyclyl, phenyl or 5- to 10-membered heteroaryl, wherein the alkyl, cycloalkyl, cycloalkenyl, phenyl, heteroaryl or heterocyclyl is unsubstituted or substituted with 1-3 substituents selected from the group consisting of halogen, CN, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N(C 1-6 alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-(4- to 6-membered heterocyclic group), -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, C 2-6 alknyl, hydroxyl, C 1-6 Alkoxy or hydroxy C 1-6 Alkyl, and the heterocyclic or heteroaryl is unsubstituted or substituted by 1-3 substituents selected from the following: halogen, C 1-6 Alkyl, -C(O)-C 1-6 an alkyl group or a 4- to 6-membered heterocyclic group.

[0141] In one embodiment, R 4 yes

[0142]

[0143]

[0144]

[0145] Wherein each L is independently selected from halogen, CN, C 2-6 alknyl, C 1-6 Alkoxy, -C(O)NHC 1-6 Alkyl, -C(O)NH(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NHC 1-6 Alkyl or -OC 1-6 Alkyl-N(C 1-6 alkyl)2, and x is 0, 1, 2 or 3.

[0146] In one embodiment, R 4 It is C 1-6 Alkyl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of hydroxyl or C 1-6 In one embodiment, R 4 yes

[0147]

[0148] In one embodiment, R 4 It is C 3-10 Cycloalkyl or C 4-10 Cycloalkenyl, the C 3-10 Cycloalkyl or C 4-10 The cycloalkenyl group is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of hydroxy, halogen or hydroxyC 1-6 In one embodiment, R 4 It is C 3-6 Cycloalkyl or C 4-6 Cycloalkenyl, the C 3-6 Cycloalkyl or C 4-6 The cycloalkenyl group is unsubstituted or substituted by 1-3 groups selected from hydroxy, F, Cl or hydroxyC 1-3 In one embodiment, R 4 yes

[0149]

[0150] In one embodiment, R 4 is a 4- to 10-membered monocyclic or bicyclic heterocyclic group containing 1-2 ring heteroatoms or hetero groups selected from O, N, S, S(=O), S(=O)2 or C(=O), wherein the 4- to 10-membered monocyclic or bicyclic heterocyclic group is unsubstituted or substituted by 1-2 ring heteroatoms or hetero groups selected from C 1-6 In one embodiment, R 4is a 4- to 6-membered monocyclic heterocyclic group containing 1-2 ring heteroatoms or hetero groups selected from O, N or S(=O)2, wherein the 4- to 6-membered monocyclic heterocyclic group is unsubstituted or selected from C 1-3 In one embodiment, R 4 yes

[0151]

[0152] In one embodiment, R 4 is phenyl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, CN, C 2-6 alknyl, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N(C 1-6 alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-(4- to 6-membered heterocyclic group), -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy or hydroxy C 1-6 Alkyl, and the heterocyclic or heteroaryl is unsubstituted or substituted by 1-3 substituents selected from the following: halogen, C 1-6 Alkyl, -C(O)-C 1-6 alkyl or 4- to 6-membered heterocyclic group. In one embodiment, R 4 yes

[0153]

[0154] Wherein each L is independently selected from halogen, CN, C 2-6 alknyl, C 1-6 Alkoxy, C(O)NHC 1-6 Alkyl or C(O)NH(C 1-6 alkyl) 2, and n is 0, 1, 2 or 3. In one embodiment, each L is independently selected from F, Cl, CN, C 1-3 alkoxy, -C(O)N(CH3)2, and x is 0, 1, 2 or 3.

[0155] In one embodiment, R 4is a 5- or 10-membered monocyclic or bicyclic heteroaryl group containing 1-2 heteroatoms or hetero groups selected from N, O, C(=O) or S, wherein the 5- or 10-membered monocyclic or bicyclic heteroaryl group is unsubstituted or substituted with 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl or C 4-6 In one embodiment, R 4 is a 5- or 6-membered monocyclic heteroaryl group containing 1-2 heteroatoms selected from N or O, wherein the 5- or 6-membered monocyclic heteroaryl group is unsubstituted or substituted with 1-3 substituents selected from the following: halogen or CH3. In one embodiment, R 4 yes

[0156]

[0157] In one embodiment, R 4 Yes-C 1-6 Alkyl-(5- to 6-membered heteroaryl), which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of halogen or C 1-6 In one embodiment, R 4 yes

[0158]

[0159] In one embodiment, R 4 Yes-C 1-6 Alkyl-phenyl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen or C 1-6 In one embodiment, R 4 is -CH2-phenyl, which is unsubstituted or substituted with CH3.

[0160] In one embodiment, R 4 yes

[0161]

[0162] In one embodiment, R 4 Yes-C 1-6 Alkyl-(4- to 6-membered heterocyclyl), which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of halogen or C 1-6 In one embodiment, R 4 yes

[0163]

[0164] In one embodiment, R 4 yes

[0165]

[0166] In one embodiment, R 4 yes

[0167]

[0168] In one embodiment, R 4 yes

[0169]

[0170] In one embodiment, the compound of formula (II) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

[0171] R 1 is phenyl, pyridyl, thienyl or thiazolyl, wherein the phenyl, pyridyl, thienyl or thiazolyl is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 substituents selected from halogen;

[0172] n is 0;

[0173] R 2 It is C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclic group), -C(O)-NH2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C(O)-NH-C 1-6 Alkyl, -C(O)-N(C 1-6 Alkyl)2 or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl, cycloalkyl, heterocyclyl or heteroaryl groups are unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 alkyl; and R8 It is H;

[0174] R 3 It is H;

[0175] M is a key;

[0176] X is CH;

[0177] Y is CH or N;

[0178] Z is N;

[0179] R 5 is H, halogen or C 1-6 alkyl;

[0180] R 6 is H; and

[0181] R 4 is unsubstituted or substituted by 1-3 groups selected from halogen or C 1-6 Alkoxy substituent substituted

[0182]

[0183] In one embodiment, the compound of formula (II) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

[0184] R 1 is phenyl or thienyl, said phenyl or thienyl being unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 substituents selected from halogen;

[0185] n is 0;

[0186] R 2 It is C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclic group), -C(O)-NH2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6Alkyl, -C(O)-NH-C 1-6 Alkyl, -C(O)-N(C 1-6 Alkyl)2 or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl, cycloalkyl, heterocyclyl or heteroaryl groups are unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 alkyl; and R 8 It is H;

[0187] R 3 It is H;

[0188] M is a key;

[0189] X is CH;

[0190] Y is CH or N;

[0191] Z is N;

[0192] R 5 is H, halogen or C 1-6 alkyl

[0193] R 6 is H; and

[0194] R 4 is unsubstituted or substituted by 1-3 groups selected from halogen or C 1-6 Alkoxy substituent substituted

[0195]

[0196] In one embodiment, the compound of formula (II) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

[0197] R 1 is phenyl, which is unsubstituted or substituted with 1 to 3 substituents selected from F or Cl;

[0198] n is 0;

[0199] R 2 is CH2OH, CH2NH2, -CH2NH(CH3), -CH2NHCH2CH2OH, -C(O)NH2, -CH2NH-(tetrahydro-2H-pyran), or -CH2NH-CH2-(1H-pyrrole); and

[0200] R 8 It is H;

[0201] R 3 It is H;

[0202] M is a key;

[0203] X is CH;

[0204] Y is N;

[0205] Z is N;

[0206] R 5 It is CH3;

[0207] R 6 is H; and

[0208] R 4 yes

[0209]

[0210] In one aspect, the present invention provides novel inhibitors of ERK1 and ERK2 represented by formula (III)

[0211]

[0212] or a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof, wherein:

[0213] R 1 is phenyl or 5- to 10-membered heteroaryl, wherein the phenyl or heteroaryl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6Alkyl-(4 to 6-membered heterocyclic group), -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl or -C(O)-N(C 1-6 Alkyl)2, wherein C 1-6 Alkyl, cycloalkyl, heterocyclyl and / or heteroaryl are unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, hydroxyl C 1-6 Alkyl or amino C 1-6 alkyl;

[0214] n is 0 to 6;

[0215] R 3 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens;

[0216] M is a bond or NH;

[0217] X and Y are each independently CH, CR 7 or N;

[0218] Z is CH or N,

[0219] R 5 It is H, halogen, C 1-6 Alkyl or OC 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens;

[0220] R 6 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens;

[0221] R 7 It is C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; and

[0222] R 4 It is C 1-6 Alkyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-(5- to 6-membered heteroaryl), -C 1-6Alkyl-(4- to 6-membered heterocyclyl), 4- to 10-membered heterocyclyl, phenyl or 5- to 10-membered heteroaryl, wherein the alkyl, cycloalkyl, cycloalkenyl, phenyl, heteroaryl or heterocyclyl is unsubstituted or substituted with 1-3 substituents selected from the group consisting of halogen, CN, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N-(C 1-6 alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-(4 to 6-membered heterocyclic group), -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, C 2-6 alknyl, hydroxyl, C 1-6 Alkoxy or hydroxy C 1-6 Alkyl, and the heterocyclic or heteroaryl is unsubstituted or substituted by 1-3 substituents selected from the following: halogen, C 1-6 Alkyl, C-(O)-C 1-6 an alkyl group or a 4- to 6-membered heterocyclic group.

[0223] In one embodiment, the compound of formula (III) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

[0224] R 1 is phenyl, pyridyl, thienyl or thiazolyl, wherein the phenyl, pyridyl, thienyl or thiazolyl is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 substituents selected from halogen;

[0225] n is 1 to 2;

[0226] R 3 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-3 halogens;

[0227] M is a bond or NH;

[0228] X and Y are each independently CH, CR 7 or N;

[0229] Z is CH or N,

[0230] R 5 It is H, halogen, C 1-6 Alkyl or OC 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-3 halogens;

[0231] R 6 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-3 halogens;

[0232] R 7 It is C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-3 halogens; and

[0233] R 4 It is C 1-6 Alkyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-(5- to 6-membered heteroaryl), -C 1-6 Alkyl-(4 to 6-membered heterocyclyl), 4- or 10-membered heterocyclyl, phenyl or 5- to 10-membered heteroaryl, wherein the alkyl, cycloalkyl, cycloalkenyl, phenyl, heteroaryl or heterocyclyl is unsubstituted or substituted with 1-3 substituents selected from the group consisting of halogen, CN, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N(C 1-6 alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-(4- to 6-membered heterocyclic group), -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, C 2-6 alknyl, hydroxyl, C 1-6 Alkoxy or hydroxy C 1-6 Alkyl, and the heterocyclic or heteroaryl is unsubstituted or substituted by 1-3 substituents selected from the following: halogen, C 1-6 Alkyl, -C(O)-C 1-6 an alkyl group or a 4- to 6-membered heterocyclic group.

[0234] In one embodiment, R 1 is unsubstituted or substituted C 6-12 Aryl or unsubstituted or substituted 5- to 10-membered heteroaryl. In one embodiment, R 1 is phenyl or a 5- to 6-membered heteroaryl group containing 1-2 ring heteroatoms selected from O, N or S, wherein the phenyl or heteroaryl group is unsubstituted or substituted with 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclic group), -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), C(O)-NH2, -C(O)-NH-C 1-6 Alkyl or -C(O)-N(C 1-6 Alkyl)2, wherein C 1-6 Alkyl, cycloalkyl, heterocyclyl and / or heteroaryl are unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 In one embodiment, R 1 is phenyl, pyridyl, thienyl or thiazolyl, wherein the phenyl, pyridyl, thienyl or thiazolyl is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl or amino C 1-6 Alkyl, where C1-6 Alkyl is unsubstituted or substituted with 1-3 substituents selected from halogen. In one embodiment, R 1 is phenyl, pyridyl, thienyl or thiazolyl, wherein the phenyl, pyridyl, thienyl or thiazolyl is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, C 1-3 Alkyl, CN, hydroxy C 1-3 Alkyl or amino C 1-3 Alkyl, where C 1-3 The alkyl group is unsubstituted or substituted with 1-3 substituents selected from F. In one embodiment, R 1 is phenyl, pyridyl, thienyl or thiazolyl, wherein the phenyl, pyridyl, thienyl or thiazolyl is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CH3, -C(CH3)3, CF3, -CH2OH, -CH2CH2OH, CH2NH2, CN or -C(CH3)2OH. In one embodiment, R 1 is phenyl, which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CH3, -C(CH3)3, CF3, -CH2OH, -CH2CH2OH, CH2NH2, CN or -C(CH3)2OH.

[0235] In one embodiment, n is 0 to 6. In one embodiment, n is 0 to 2. In one embodiment, n is 0 to 1.

[0236] In one embodiment, R 3 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens. In one embodiment, R 3 Is H or C 1-3 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-3 halogens. In one embodiment, R 3 It is H or CH3.

[0237] In one embodiment, M is a bond or NH. In one embodiment, M is a bond.

[0238] In one embodiment, X and Y are each independently CH, CR 7 or N. In one embodiment, X is CH, C-CH 3 or N. In one embodiment, X is CH. In one embodiment, Y is CH, C-CH 3 or N. In one embodiment, Y is N.

[0239] In one embodiment, R 7 It is C 1-6 Alkyl, where C1-6 Alkyl is unsubstituted or substituted with 1-5 halogens. In one embodiment, R 7 It is C 1-6 In one embodiment, R 7 It is CH3.

[0240] In one embodiment, Z is CH or N. In one embodiment, Z is N.

[0241] In one embodiment, R 5 It is H, halogen, C 1-6 Alkyl or OC 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens. In one embodiment, R 5 It is H, Cl, F, C 1-3 Alkyl or -OC 1-3 Alkyl, where C 1-3 Alkyl is unsubstituted or substituted with 1-3 halogens. In one embodiment, R 5 It is H, Cl, F, CH3 or –OCH3.

[0242] In one embodiment, R 6 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens. In one embodiment, R 6 is H or CH3. In one embodiment, R 6 It’s H.

[0243] In one embodiment, R 4 It is C 1-6 Alkyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-(5- to 6-membered heteroaryl), -C 1-6 Alkyl-(4 to 6-membered heterocyclyl), 4- or 10-membered heterocyclyl, phenyl or 5- to 10-membered heteroaryl, wherein the alkyl, cycloalkyl, cycloalkenyl, phenyl, heteroaryl or heterocyclyl is unsubstituted or substituted with 1-3 substituents selected from the group consisting of halogen, CN, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N(C 1-6alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-(4- to 6-membered heterocyclic group), -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, C 2-6 alknyl, hydroxyl, C 1-6 Alkoxy or hydroxy C 1-6 Alkyl, and the heterocyclic or heteroaryl is unsubstituted or substituted by 1-3 substituents selected from the following: halogen, C 1-6 Alkyl, -C(O)-C 1-6 an alkyl group or a 4- to 6-membered heterocyclic group.

[0244] In one embodiment, R 4 yes

[0245]

[0246]

[0247] Wherein each L is independently selected from halogen, CN, C 2-6 alknyl, C 1-6 Alkoxy, -C(O)NHC 1-6 Alkyl, -C(O)NH(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NHC 1-6 Alkyl or -OC 1-6 Alkyl-N(C 1-6 alkyl)2, and x is 0, 1, 2 or 3.

[0248] In one embodiment, R 4 It is C 1-6 Alkyl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of hydroxyl or C 1-6 In one embodiment, R 4 yes

[0249]

[0250] In one embodiment, R 4 It is C 3-10 Cycloalkyl or C 4-10 Cycloalkenyl, the C 3-10 Cycloalkyl or C 4-10 The cycloalkenyl group is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of hydroxy, halogen or hydroxyC 1-6 In one embodiment, R 4 It is C 3-6 Cycloalkyl or C 4-6 Cycloalkenyl, the C3-6 Cycloalkyl or C 4-6 The cycloalkenyl group is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of hydroxy, F, Cl or hydroxyC 1-3 In one embodiment, R 4 yes

[0251]

[0252] In one embodiment, R 4 is a 4- to 10-membered heterocyclic group containing 1-2 ring heteroatoms or hetero groups selected from O, N, S, S(=O), S(=O)2 or C(=O), wherein the 4- to 10-membered heterocyclic group is unsubstituted or replaced by 1-2 ring heteroatoms or hetero groups selected from C 1-6 In one embodiment, R 4 is a 4- to 6-membered monocyclic heterocyclic group containing 1-2 ring heteroatoms or hetero groups selected from O, N or S(O)2, wherein the 4- to 6-membered monocyclic heterocyclic group is unsubstituted or substituted by 1-2 ring heteroatoms or hetero groups selected from C 1-3 In one embodiment, R 4 yes

[0253]

[0254] In one embodiment, R 4 is phenyl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 2-6 alknyl, CN, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N(C 1-6 alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-(4- to 6-membered heterocyclic group), -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy or hydroxy C 1-6 Alkyl, and the heterocyclic or heteroaryl is unsubstituted or substituted by 1-3 substituents selected from the following: halogen, C 1-6 Alkyl, -C(O)-C 1-6 alkyl or 4- to 6-membered heterocyclic group. In one embodiment, R 4 yes

[0255]

[0256] Wherein each L is independently selected from halogen, CN, C 2-6 alknyl, C 1-6 Alkoxy, C(O)NHC 1-6 Alkyl or C(O)NH(C 1-6 alkyl) 2, and n is 0, 1, 2 or 3. In one embodiment, each L is independently selected from F, Cl, CN, C 1-3 alkoxy, -C(O)N(CH3)2, and x is 0, 1, 2 or 3.

[0257] In one embodiment, R 4 is a 5- or 10-membered monocyclic or bicyclic heteroaryl group containing 1-2 ring heteroatoms or hetero groups selected from O, N, S, S(=O), S(=O)2 or C(=O), wherein the 5- or 10-membered monocyclic or bicyclic heteroaryl group is unsubstituted or substituted with 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl or C 4-6 In one embodiment, R 4 is a 5- or 6-membered monocyclic heteroaryl group containing 1-2 ring heteroatoms selected from N or O, wherein the 5- or 6-membered monocyclic heteroaryl group is unsubstituted or substituted with 1-3 substituents selected from halogen or CH3. In one embodiment, R 4 yes

[0258]

[0259] In one embodiment, R 4 is unsubstituted or substituted by 1-3 groups selected from halogen or C 1-6 Alkyl substituent substituted -C 1-6 In one embodiment, R 4 yes

[0260]

[0261] In one embodiment, R 4 is unsubstituted or substituted by 1-3 groups selected from halogen or C 1-6 Alkyl substituent substituted -C 1-6 In one embodiment, R 4 is unsubstituted or substituted -CH2-phenyl. In one embodiment, R 4 yes

[0262]

[0263] In one embodiment, R4 is unsubstituted or substituted by 1-3 groups selected from halogen or C 1-6 Alkyl substituent substituted -C 1-6 In one embodiment, R 4 yes

[0264]

[0265] In one embodiment, R 4 yes

[0266]

[0267] In one embodiment, R 4 yes

[0268]

[0269] In one embodiment, R 4 yes

[0270]

[0271] In one embodiment, the compound of formula (III) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

[0272] R 1 is phenyl or thienyl, said phenyl or thienyl being unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 substituents selected from halogen;

[0273] n is 1;

[0274] R 3 It is H;

[0275] M is a key;

[0276] X is CH;

[0277] Y is N;

[0278] Z is N,

[0279] R 5 is H, halogen or C 1-6 alkyl;

[0280] R 6 is H; and

[0281] R 4is unsubstituted or substituted by 1-3 groups selected from halogen or C 1-6 Alkoxy substituent substituted

[0282]

[0283] In one embodiment, the compound of formula (III) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

[0284] R 1 is phenyl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 substituents selected from halogen;

[0285] n is 1;

[0286] R 3 It is H;

[0287] M is a key;

[0288] X is CH;

[0289] Y is N;

[0290] Z is N,

[0291] R 5 It is CH3;

[0292] R 6 is H; and

[0293] R 4 is unsubstituted or substituted by 1-3 groups selected from halogen or C 1-6 Alkoxy substituent substituted

[0294]

[0295] In one embodiment, the compound of formula (III) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

[0296] R 1 is phenyl, which is unsubstituted or substituted with 1-3 substituents selected from halogen, CH2OH or CH2NH2; n is 1;

[0297] R 3 It is H;

[0298] M is a key;

[0299] X is CH;

[0300] Y is N;

[0301] Z is N,

[0302] R 5 It is CH3;

[0303] R 6 is H; and

[0304] R 4 is unsubstituted or substituted by 1-3 groups selected from halogen or C 1-6 Alkoxy substituent substituted

[0305]

[0306] In one embodiment, the compound of formula (III) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

[0307] R 1 is phenyl, substituted by 1-3 substituents selected from the group consisting of F, Cl, CH2OH or CH2NH2, and at least one ortho position is substituted;

[0308] n is 1;

[0309] R 3 It is H;

[0310] M is a key;

[0311] X is CH;

[0312] Y is N;

[0313] Z is N,

[0314] R 5 It is CH3;

[0315] R 6 is H; and

[0316] R 4 yes

[0317]

[0318] In one embodiment, the compound of formula (III) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

[0319] R 1 is phenyl, which is substituted by 1-3 substituents selected from the group consisting of F, Cl, CH2OH or CH2NH2, and at least one ortho position is substituted by CH2OH or CH2NH2;

[0320] n is 1;

[0321] R 3 It is H;

[0322] M is a key;

[0323] X is CH;

[0324] Y is N;

[0325] Z is N,

[0326] R 5 It is CH3;

[0327] R 6 is H; and

[0328] R 4 yes

[0329]

[0330] In one embodiment, the compound is selected from:

[0331] (S)-1-(2)-(Benzo[d][1,3]dioxol-5-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide;

[0332] 1-(2-(Benzofuran-5-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide;

[0333] 1-(2-(Benzofuran-5-ylamino)-5-methylpyrimidin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-3-carboxamide;

[0334] N-(3-chloro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-carboxamide; (S)-N-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[0335] 1-(2-((2,3-dihydrobenzofuran-5-yl)amino)5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-((2,3-dihydrobenzo[b][1,4]dihydro)pyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide (6-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[0336] N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide; N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(((S)-tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[0337] N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(((R)-tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[0338] 1-(2-(Dihydrochromen-6-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-((4-fluoro-3-morpholinylphenyl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide; N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((4-fluorophenyl) -amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-amide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)-amino)pyrimidin-4-yl)-1H-imidazole-4-amide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((4-morpholinylphenyl)-amino)pyrimidin-4-yl)-1H-pyrrole-3-amide;

[0339] (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide;

[0340] (R)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[0341] (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[0342] (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-fluoro-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[0343] N-(2-hydroxy-1-(thiophen-2-yl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[0344] (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[0345] (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[0346] (S)-N-(2-(((1H-pyrrol-2-yl)methyl)amino)-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[0347] (S)-N-(3-chloro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-(tetrahydrofuran-3-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide; (S)-N-(1-(3-chlorophenyl)-2-(methylamino)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide;

[0348] (S)-N-(1-(3-chlorophenyl)-2-((2-hydroxyethyl)amino)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[0349] N-(3-chloro-5-fluoro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide;

[0350] or a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof.

[0351] Compounds of formula (I-III) are limited to chemically feasible and stable compounds. Therefore, combinations of substitutions or modifications of the compounds described above are permitted only if they result in stable and chemically feasible compounds. Stable compounds or chemically feasible compounds must be able to be stored at or below 40°C, free from moisture or other chemically reactive conditions, for at least one week without substantial change in their chemical structure.

[0352] As far as practicable, unless otherwise stated or inconsistent with the context, the compounds of formula (I-III) and their respective species, alone or in combination, also include their salts, prodrugs, solvates, hydrates, racemates, enantiomers, diastereomers, metabolites and mixtures.

[0353] Typically "pharmaceutically acceptable salts" include, but are not limited to, water-soluble or water-insoluble salts. In one embodiment, the salt is a base salt. The salt can be a salt of a base selected from the group consisting of an alkali metal base such as sodium, lithium or potassium salt, and an organic base such as ammonium, mono-, di- and trimethylammonium, mono-, di- and triethylammonium, mono-, di- and tripropylammonium, ethyldimethylammonium, benzyldimethylammonium, cyclohexylammonium, benzylammonium, dibenzylammonium, piperidinium, morpholinium, pyrrolidinium, piperazinium, 1-methylpiperidinium, 4-ethylmorpholinium, 1-isopropylpyrrolidinium, 1,4-dimethylpiperazinium, 1-n-butylpiperidinium, 2-methylpiperidinium, 1-ethyl-2-methylpiperidinium, mono-, di- and triethanolammonium, ethyldiethanolammonium, n-butylmonoethanolammonium, tris(hydroxymethyl)methylammonium, phenylmonoethanolammonium base, and the like. In another embodiment, the salt is a salt of an acid. The salt can be a salt of an acid selected from the group consisting of acetic acid, propionic acid, lactic acid, citric acid, tartaric acid, succinic acid, fumaric acid, maleic acid, malonic acid, mandelic acid, malic acid, phthalic acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, methanesulfonic acid, naphthalenesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, trifluoroacetic acid, camphorsulfonic acid, etc. Alternatively, the compound of the present invention may include a pharmaceutically acceptable salt as well as the free base form of the compound of the present invention.

[0354] Prodrugs of compounds of formula (I-III) can be used to modulate pharmacokinetic properties by using various methods known to those skilled in the art. For example, Jarkko Rautio et al., Nature Reviews Drug Discovery, 7:255-270 (2008), which is incorporated herein by reference. In the case of drugs containing amine groups, such as when R 2is CH2NH2, various prodrug methods have been reviewed by AL Simplício in Molecules, 13: 519-547 (2008), which is incorporated herein by reference. More specifically, (alkoxycarbonyloxy) alkylcarbamates, (acyloxy) alkylcarbamates, and (oxodioxinyl) alkylcarbamates as effective prodrug schemes for amines were reported by Zhong Li in Bioorg. Med. Chem. Lett., 7: 2909-2912 (1997); J. Alexander in J. Med. Chem. 34: 78-81 (1991); J. Alexander in J. Med. Chem., 31: 318-322 (1988) and J. Alexander in J. Med. Chem., 39: 480-486 (1996), all of which are incorporated herein by reference. In one embodiment, the prodrug is an amide of formula (I-III). In one embodiment, when R 2 is CH2NH2, the amide is (C 1-6 alkyl), wherein C 1-6 In another embodiment, the prodrug is an ester of formula (I-III). In one embodiment, when R 2 is CH2OH, the ester is (C 1-6 alkyl), wherein C 1-6 The alkyl group may be optionally substituted.

[0355] In another embodiment, the compounds of the present invention may be solvates. As used herein, "solvates" do not significantly change the physiological activity or toxicity of the compounds and, accordingly, can be used as pharmacological equivalents of the non-solvent compounds of the present invention. The term "solvate" as used herein refers to the combination, physical association and / or dissolution of the compounds of the present invention with solvent molecules. The physical association involves varying degrees of ionic or covalent bonding, including hydrogen bonding. In specific instances, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystal, the solvate may be independent. Therefore, "solvate" includes a liquid phase and independent solvates. Hydrates are a special form of solvate that include water combined into water of crystallization in a specific ratio.

[0356] The compounds described herein may contain asymmetric centers and may therefore exist as enantiomers. When the compounds described herein have two or more asymmetric centers, they may exist as diastereomers. When the bonds at the chiral centers are depicted as straight lines in the molecular formulas of the present invention, it is understood that both the (R) and (S) configurations are included, and therefore enantiomers and mixtures thereof are also included. Unless the specific stereochemistry is otherwise specified, the present invention includes all such possible stereoisomers. It is well known in the art to prepare substantially pure stereoisomers by methods such as resolving racemates or synthesizing from optically active starting materials. In one embodiment, the compound of formula (I-III) is a substantially pure stereoisomer. "Substantially pure stereoisomer" refers to a stereoisomer that is at least 95% pure relative to other stereoisomers of the same structure.

[0357] The following definitions apply with respect to the compounds described herein. Generally, the number of carbon atoms present in a particular group is expressed as "C x-y ”, wherein x and y are the lower limit and the upper limit, respectively. The number of carbon atoms used in the definitions herein refers to the carbon backbone and carbon branches, but does not include carbon atoms in substituents such as alkoxy substituents. Unless otherwise stated, substituents not explicitly defined herein are named by naming the terminal portion of the functional group from left to right, followed by the connected functional group toward the point of attachment. As used herein, “selective substitution” means that at least one hydrogen atom on a particular atom, such as a carbon atom or a nitrogen atom, is selectively replaced by other substituents without exceeding the normal valence state of the atom to form a stable compound. When more than one substituent is present on an atom or group, the substituents selected are independent of each other (i.e., the same or different).

[0358] "Alkyl" refers to a hydrocarbon chain, which may be straight or branched. In one embodiment, "C 1-7 "Alkyl" refers to an alkyl group containing 1 to 7 (inclusive) carbon atoms. In another embodiment, "C 1-6 "Alkyl" refers to an alkyl group containing 1 to 6 (inclusive) carbon atoms. In yet another embodiment, "C 1-4 "Alkyl" refers to an alkyl group containing from 1 to 4 carbon atoms (inclusive). Examples of alkyl groups that are hydrocarbon chains include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, and heptyl and all of their anticipated isomers.

[0359] "Substituted alkyl" refers to an alkyl group as defined above substituted with a group including, but not limited to, one or more F, one or two Cl, one or two OH, an amino group, a (C 1-6 Alkyl)amino (such as C 1-6 Alkyl-NH-), one (di-C 1-6Alkyl)amino (such as (alkyl) 2N-), one or two C 1-6 Alkoxy, one -NH-C(O)-C 1-6 Alkyl, a -C(O)-NH2 group, a -C(O)-NH-(C 1-6 alkyl) group, a -C(O)-N-(C 1-6 alkyl)2 group or a cyano group or any combination of the above substituents. "Substituted" means that one or more hydrogen atoms of the alkyl group are replaced by the substituents listed above.

[0360] "Hydroxyalkyl" refers to -(alkyl)OH, wherein the alkyl group is optionally substituted and as defined above. The OH group of the hydroxyalkyl group can be attached to any carbon atom, for example, any internal carbon atom or a terminal carbon atom of the hydrocarbylalkyl chain. Examples of hydroxyalkyl groups include, but are not limited to, -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH2CH2CH2OH, -CH2CH(OH)CH3, -CH(OH)CH2CH3, -C(OH)(CH3)2, -(2-hydroxy)-cyclopentyl, (3-hydroxy)-cyclobutyl, and the like.

[0361] “C 3-10 "Cycloalkyl" refers to a saturated cycloalkyl group, which may be a monocyclic, bicyclic, polycyclic or fused / bridged ring structure comprising 3 to 10 carbon atoms. Typically, cycloalkyl includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc. Typical bridged cycloalkyls include, but are not limited to, adamantyl, n-adamantyl, bicyclo[1.1.0]butyl, n-bornyl (bicyclo[2.2.1]heptyl), etc. C 3-10 The cycloalkyl group may be unsubstituted or substituted by one or more groups including but not limited to hydroxy, halogen or C 1-6 The alkyl group is substituted with a substituent.

[0362] “C 4-10 "Cycloalkenyl" refers to an unsaturated or partially saturated non-aromatic alkyl group, which may be a monocyclic, bicyclic, polycyclic or fused / bridged ring structure comprising 4 to 10 carbon atoms. Typically, cycloalkyl includes but is not limited to cyclobutene, cyclopentene, cyclohexene, cyclohexa-1,4-diene, etc. "C 2-6 "Alkenyl" refers to a linear or branched monovalent hydrocarbon radical containing 2 to 6 carbon atoms and including at least one double bond. Typically, cycloalkenyl includes, but is not limited to, ethenyl, propenyl, and the like.

[0363] “C 2-6 "Alkynyl" refers to a linear or branched monovalent hydrocarbon radical containing 2 to 6 carbon atoms and including at least one triple bond. Typically, cycloalkyl includes but is not limited to ethynyl, propynyl, and the like.

[0364] "Alkoxy" refers to an (alkyl)O group, wherein the alkyl group is optionally substituted and is as defined above. For example, alkoxy includes, but is not limited to, methoxy, ethoxy, propoxy, and butoxy. The alkyl group in the alkoxy group can be unsubstituted or substituted as defined above.

[0365] "Aryl" refers to a monocyclic, bicyclic or polycyclic aromatic hydrocarbon group containing carbon atoms. In one embodiment, the aryl group contains 6-12 carbon atoms. In one embodiment, the aryl group is a phenyl group. In one embodiment, the aryl group is an aromatic or partially aromatic bicyclic group. In another embodiment, the aryl group is a naphthyl group (such as α-naphthyl or β-naphthyl), 1,2,3,4-tetrahydronaphthyl or dihydroindanyl. The aryl group may be unsubstituted or substituted with one or more groups including but not limited to the following: halogen, C 1-6 Alkyl, C 2-6 alknyl, CN, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclyl) or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 Alkyl, cycloalkyl, heterocyclyl and / or heteroaryl are unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, hydroxyl C 1-6 Alkyl or amino C 1-6In one embodiment, the aryl group may be substituted by one or more groups including but not limited to: halogen, CN, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N(C 1-6 alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-(4- to 6-membered heterocyclic group), -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, C 2-6 alknyl, hydroxyl, C 1-6 Alkoxy or hydroxy C 1-6 Alkyl, wherein the heterocyclic or heteroaryl group is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, C(O)-C 1-6 an alkyl group or a 4- to 6-membered heterocyclic group.

[0366] "Substituted phenyl" refers to a phenyl group substituted with one or more groups including, but not limited to, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6Alkyl-(4- to 6-membered heterocyclyl) or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 Alkyl, cycloalkyl, heterocyclyl and / or heteroaryl are unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, hydroxyl C 1-6 Alkyl or amino C 1-6 In one embodiment, the phenyl group may be substituted with one or more groups including but not limited to: halogen, CN, C 2-6 alknyl, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N(C 1-6 alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-(4- to 6-membered heterocyclic group), -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy or hydroxy C 1-6 Alkyl, wherein the heterocyclic or heteroaryl group is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, C(O)-C 1-6 an alkyl group or a 4- to 6-membered heterocyclic group.

[0367] "Halogen" refers to F, Cl, Br or I.

[0368] "Heteroaryl" refers to a monocyclic, bicyclic or polycyclic aromatic or partially aromatic ring system containing 1-3 heteroatoms or hetero groups selected from O, N, S, S(=O), S(=O)2 or C(=O). "Partially aromatic" refers to a polycyclic fused ring group in which at least one but not all rings are aromatic, such as a benzophenone group. In one embodiment, the heteroaryl group is a 5- to 10-membered ring system. In another embodiment, the heteroaryl group is a 5- to 6-membered ring system. Typical heteroaryl ring groups include, but are not limited to, furyl, Azolyl, iso oxazolyl, isothiazolyl, imidazolyl, triazolyl, thiophenyl, thiazolyl, pyridyl, pyrimidinyl, thiazinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, imidazothiazolyl, oxadiazolyl, indolidinyl, indolinyl, indazolyl, chromanyl, oxindolinyl, indolyl, oxindolinyl, quinolinyl, 3,4-dihydroisoquinolin-2(1H)-yl, quinoxalinyl, benzofuranyl, benzo oxazolyl, benzo[d]iso oxazolyl, benzo[d]thiazolyl, benzo[d][1,3]dioxolyl, 1H-benzo[d][1,2,3]triazolyl, 2H-indazolyl, 1H-indazolyl, quinoxalin-2-yl, 1H-benzo[d]imidazolyl, pyrazolo[1,5-a]pyridinyl, dihydrobenzo[b][1,4]dioxolyl, (5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-7-yl) yl), 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinyl, 5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazinyl, hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, 5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazinyl, pyrazolo[1,5-a]pyridinyl, etc.

[0369] "Substituted heteroaryl" refers to a heteroaryl group, as defined above, substituted with one or more substituents including, but not limited to, halogen, C 1-6 Alkyl, CN, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclyl) or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6Alkyl, cycloalkyl, heterocyclyl and / or heteroaryl are unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, hydroxyl C 1-6 Alkyl or amino C 1-6 In one embodiment, the heteroaryl group may be substituted by one or more substituents including but not limited to the following: halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 In one embodiment, the heteroaryl group may be substituted with one or more substituents including but not limited to halogen, CN, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N(C 1-6 alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-(4- to 6-membered heterocyclic group), -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy or hydroxy C 1-6 Alkyl, wherein the heterocyclic or heteroaryl group is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, C(O)-C 1-6 an alkyl group or a 4- to 6-membered heterocyclic group.

[0370] "Heterocycle" or "heterocyclyl" refers to a monocyclic, bicyclic or polycyclic saturated ring system containing 1-3 heteroatoms or hetero groups selected from O, N, S, S(=O), S(=O)2 or C(=O). Monocyclic heterocycles can be 4- to 10-membered rings, but bicyclic heterocycles contain two fused or bridged 4- to 6-membered rings having 5-10 ring atoms. Typical heterocyclyl groups include, but are not limited to, azetidinyl, azepanyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl (thiolanyl), piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydro-2H-pyranyl, morpholinyl, thiomorpholinyl, dihydrofuranyl, tetra ... Alkyl, 2,5-diazabicyclo[2.2.1]heptane, 2,5-diazabicyclo[2.2.2]octane, etc.

[0371] "Substituted heterocycle" or "substituted heterocyclyl" refers to a heterocycle or heterocyclyl group substituted with one or more of the following groups, including but not limited to halogen, CN, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N-(C 1-6 Alkyl)2, -OC 1-6 Alkyl-NH2, -OC 1-6 Alkyl-NH-(C 1-6 Alkyl), -OC 1-6 Alkyl-N-(C 1-6 alkyl) 2, 4- to 6-membered heterocyclic group, -C(O)-heterocyclic group, -O-phenyl, -OC 1-6 Alkyl-(4- to 6-membered heterocyclyl), C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy or hydroxy C 1-6 Alkyl, wherein the heterocyclic or heteroaryl group is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, C-(O)-C 1-6 In one embodiment, the heterocyclic group may be substituted by one or more groups including but not limited to: halogen, C 1-6 Alkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 In one embodiment, the heterocyclic group may be substituted by one or more groups including but not limited to: hydroxyl, halogen or C 1-6 alkyl.

[0372] The word “comprising” is to be understood as inclusive and not exclusive. The word “consisting of” is to be understood as exclusive and not inclusive.

[0373] As used herein, unless otherwise indicated, "about" refers to a 10% variation from a given reference.

[0374] A "patient" or "subject" is a mammal such as a human or a veterinary patient or subject such as a mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate such as a monkey, chimpanzee, baboon, or gorilla.

[0375] The term "treatment" includes administering a compound of the invention to a subject to improve one or more symptoms of a disease or disorder, and also includes end-of-life care. "Therapeutically effective dose" refers to the minimum dose of active compound that can achieve therapeutic purposes.

[0376] The pharmaceutical compositions useful herein comprise at least one or more compounds of formula (I-III) or pharmaceutically acceptable salts, prodrugs, solvates, hydrates or stereoisomers thereof in a pharmaceutically acceptable carrier, and optionally other pharmaceutically inert or inactive ingredients. In another embodiment, the compounds of formula (I-III) are presented in a single composition. In another embodiment, the compounds of formula (I-III) are combined with one or more excipients and / or other therapeutic agents described below.

[0377] The pharmaceutical composition of the present invention comprises a certain amount of at least one or more compounds of formula (I-III) or pharmaceutically acceptable salts, prodrugs, solvates, hydrates or stereoisomers thereof that can effectively treat a condition that can be treated by inhibiting ERK1 / 2 in a subject in need thereof. Specifically, the dosage of the compound of formula (I-III) that can achieve therapeutic effect depends on the pharmaceutical dosage form, the patient's age, weight, sex and mode of administration. It is anticipated that the dosage and treatment of the compound of formula (I-III) can be administered in unit dosage form, and those skilled in the art can adjust the unit dosage form accordingly to reflect the relative level of activity. A general physician can determine the specific dose (and the number of doses per day) to be used, and the dose may vary by titrating the dose to produce the desired therapeutic effect in specific circumstances. In one embodiment, the therapeutically effective dose is approximately 0.01 mg / kg-10 mg / kg body weight. In another embodiment, the therapeutically effective dose is less than about 5 g / kg, about 500 mg / kg, about 400 mg / kg, about 300 mg / kg, about 200 mg / kg, about 100 mg / kg, about 50 mg / kg, about 25 mg / kg, about 10 mg / kg, about 1 mg / kg, about 0.5 mg / kg, about 0.25 mg / kg, about 0.1 mg / kg, about 100 μg / kg, about 75 μg / kg, about 50 μg / kg, about 25 μg / kg, about 10 μg / kg, or about 1 μg / kg. However, the therapeutically effective dose of a compound of Formula (I-III) can be determined by the attending physician and depends on the condition being treated, the compound being administered, the route of administration, the age, weight, severity of the patient's symptoms, and the type of patient response.

[0378] A therapeutically effective dose can be provided based on a fixed schedule such as daily, weekly, monthly or annually, or based on an unfixed schedule of different dosing days, weeks, months, etc. Alternatively, the therapeutically effective dose administered may vary. In one embodiment, the first therapeutically effective dose is more than the subsequent one or more therapeutically effective doses. In another embodiment, the first therapeutically effective dose is less than the subsequent one or more therapeutically effective doses. Equivalent doses can be administered at different time intervals, including but not limited to about every 2 hours, about every 6 hours, about every 8 hours, about every 12 hours, about every 24 hours, about every 36 hours, about every 48 hours, about every 72 hours, about every week, about every 2 weeks, about every 3 weeks, about every month, about every 2 months. The number and frequency of administrations corresponding to a complete course of treatment are determined based on the judgment of the healthcare practitioner. The therapeutically effective dose described herein refers to the total amount administered within a specific time period. In other words, if more than one compound of Formula (I-III) or a pharmaceutically acceptable salt, prodrug or solvate thereof is administered, the therapeutically effective dose is equivalent to the total amount administered.

[0379] Pharmaceutical compositions containing compounds of formula (I-III) can be formulated alone or with one or more pharmaceutical carriers for administration. The amount of pharmaceutical carrier used depends on the solubility and chemical properties of the compound of formula (I-III), the selected route of administration, and standard pharmacological practice. The pharmaceutical carrier can be solid or liquid, and can be combined with solid and liquid carriers. There are many known suitable liquid carriers, from which those skilled in the art can easily select. Such carriers may include, for example, DMSO, saline, buffered saline, cyclodextrin, and mixtures thereof. Similarly, a variety of solid carriers and excipients are known to those skilled in the art. Taking into account the specific condition for which the compound of formula (I-III) is selected, the compound can be administered by any route. The compound of formula (I-III) can be administered orally, by injection, by inhalation (including through the mouth, nose, trachea), or via the eye, skin, blood vessels, subcutaneous, intramuscular, sublingual, intracranial, epidural, rectal, vaginal, etc.

[0380] Although the compounds of formula (I-III) can be administered alone, they can also be administered in the presence of one or more physiologically compatible pharmaceutical carriers. The carrier can be in dry or liquid form and must be pharmaceutically acceptable. Liquid pharmaceutical compositions are typically sterile solutions or suspensions. When the liquid carrier is for parenteral administration, a sterile liquid is preferred. Liquid carriers are typically used to prepare solutions, suspensions, emulsions, syrups, and elixirs. In one embodiment, the compound of formula (I-III) is dissolved in the liquid carrier. In another embodiment, the compound of formula (I-III) is suspended in the liquid carrier. Those skilled in the art of formulation can select a suitable liquid carrier based on the route of administration. The compounds of formula (I-III) can also be formulated in a solid carrier. In one embodiment, the composition can be compressed into a unit dosage form, i.e., a tablet or caplet. In another embodiment, the composition can be added to a unit dosage form, i.e., a capsule. In another embodiment, the composition can be formulated as a powder for administration. The solid carrier can perform multiple functions, i.e., it can perform the functions of two or more of the following excipients. For example, a solid carrier can also act as a flavoring agent, lubricant, solubilizer, suspending agent, filler, glidant, compression aid, binder, disintegrating agent, or an encapsulating material.

[0381] The composition may also be further subdivided to contain appropriate quantities of a compound of formula (I-III).For example, the unit dosage may be a packaged composition, such as packaged powders, liquid vials, ampoules, pre-filled syringes or sachets.

[0382] Examples of excipients that can be combined with one or more compounds of Formula (I-III) include, but are not limited to, cosolvents, antioxidants, binders, buffers, coatings, colorants, compression aids, diluents, disintegrants, emulsifiers, emollients, encapsulating materials, fillers, flavorings, glidants, granulating agents, lubricants, metal chelators, osmotic regulators, pH regulators, solubilizers, sorbents, stabilizers, sweeteners, surfactants, suspending agents, syrups, thickeners, or viscosity modifiers. See the excipients described in "Handbook of Pharmaceutical Excipients," 5th edition, edited by Rowe, Sheskey, and Owen, published by APhA, Washington, D.C., December 14, 2005, which is incorporated herein by reference.

[0383] In one embodiment, the composition can be used as an inhalant. For this route of administration, the composition can be prepared as a liquid unit dose of the compound of formula (I-III), and the administration medium can be atomized spray pump or dry powder insufflation.

[0384] In another embodiment, the composition can be used as an aerosol, i.e., an oral or intranasal aerosol. For this route of administration, the composition can be prepared for use in a pressurized aerosol container with a gaseous or liquefied compressed gas, such as dichlorodifluoromethane, carbon dioxide, nitrogen, propane, or the like. Single or multiple dose dosing is also provided.

[0385] In another embodiment, the composition can be administered by a continuous delivery device. As used herein, "continuous delivery" refers to delayed or controlled delivery of a compound of Formula (I-III). Suitable continuous delivery devices are known to those skilled in the art. For use with such continuous delivery devices, the preparation of a compound of Formula (I-III) is as described herein.

[0386] In addition to the above-mentioned ingredients for the compositions and compounds of formula (I-III), the compositions and kits described herein may include one or more drugs or therapeutic agents. In one embodiment, the compositions and kits described herein may include one or more drugs or therapeutic agents for treating cancer, including, for example, cancers characterized by tumors, including solid tumors and "fluid" or non-solid tumor cancers (such as lymphomas). In one embodiment, the drug is a chemotherapy. Examples of chemotherapy include the therapies cited in "The Physician's Desk Reference" 64th edition, Thomson Reuters, 2010, the contents of which are incorporated herein by reference. The therapeutically effective dosage of additional drugs or therapeutic agents is well known to those skilled in the art. However, the attending physician can determine the dosage of other drugs to be administered.

[0387] The compounds of formula (I-III) and / or other drugs or therapeutic agents can be administered in the same composition. However, the present invention is not limited thereto. In other embodiments, the compounds of formula (I-III) can be administered in one or more dosage forms independent of other compounds of formula (I-III), chemotherapeutic agents, or other desired agents.

[0388] Also provided herein are kits or packages containing pharmaceutical preparations of the compounds of formula (I-III) or the compositions described herein, wherein the kits are used to indicate the single preparation or combination of preparations to be taken at each desired time.

[0389] Suitably, the kit comprises packaging or a container containing a compound of formula (I-III) formulated for the desired route of administration. Suitably, the kit comprises dosage instructions and instructions regarding the active ingredient. The kit may optionally further comprise instructions for monitoring circulating levels of the product and materials for performing such analysis, including, for example, reagents, well plates, containers, markers or labels, etc. Such kits are conveniently packaged in a manner suitable for handling the desired indications. For example, the kit may also comprise instructions for use of a spray pump or other drug delivery device. Other components suitable for inclusion in the kit will be apparent to those skilled in the art, taking into account the desired indications and route of administration.

[0390] The compound of formula (I-III) or composition described herein may be a single dose, or may be administered continuously or intermittently in cycles. For continuous administration, the packaging or kit may include a compound of formula (I-III) per dosage unit (such as a solution, lotion, tablet, pill or other unit described above or other units that may be used for drug delivery) and optionally a predetermined or specified duration of daily, weekly or monthly dosage instructions. When the compound of formula (I-III) is administered in an intermittent manner, the packaging or kit may include a placebo during which the compound of formula (I-III) is not administered. When the relative proportions of the compound of formula (I-III) or the medicament in the concentration of the composition, the concentration of the component of the composition or the composition need to change over time, the packaging or kit may include a series of dosage units that provide the desired variability.

[0391] There are a large number of known packages or kits for periodic oral dispensing of pharmaceutical preparations in the art. In one embodiment, the package has indicators at each stage. In another embodiment, the package is a blister package with a label, a dispenser package with a scale, or a bottle.

[0392] The kit may be packaged in a manner that allows for internal gear connections for administration, such as an inhaler, syringe, pipette, pipette, eye dropper, or other such device, whereby the formulation can be administered to an injured part of the body, such as the lungs, injected into a subject, or even applied to and mixed with other components of the kit.

[0393] The components of such kits may also be provided in dry or lyophilized form. When a reagent or component is provided in dry form, reconstitution is typically achieved by adding an appropriate solvent. The solvent is also expected to be provided in other packaging.

[0394] Typically, the kits of the present invention also include a device for receiving the vials, such as injection or blow-molded plastic containers, which contain the vials. Regardless of the number and type of packaging, as described above, the kits may also include a separate instrument that aids in the injection / administration or placement of the composition into an animal, or be packaged together with the instrument. Such an instrument may be an inhaler, syringe, pipette, forceps, measuring spoon, eye dropper, or any other such medically approved drug delivery device.

[0395] In one embodiment, a kit is provided comprising a compound of formula (I-III). The compound of formula (I-III) may be present in the presence or absence of one or more carriers or excipients described above. The kit may optionally include instructions for administering the drug and the compound of formula (I-III) to a subject suffering from a disease characterized by dysregulation of the RAS / RAF / MEK / ERK pathway.

[0396] In another embodiment, a kit is provided comprising a second dosage unit of a compound of Formula (I-III) and a third dosage unit of one or more carriers or excipients described above. The kit may optionally include instructions for administering the drug and the compound of Formula (I-III) to a subject suffering from a disease characterized by dysregulation of the RAS / RAF / MEK / ERK pathway.

[0397] The compounds described herein can effectively modulate conditions associated with the RAS / RAF / MEK / ERK pathway. In one embodiment, such diseases are associated with abnormal cell proliferation. The term "abnormal cell proliferation" refers to uncontrolled cell growth, a phenomenon that occurs naturally in mammals. In one embodiment, the disease characterized by abnormal cell proliferation is cancer, including but not limited to cancer, leukemia or lymphoma, including cancers of the prostate, head, neck, eye, mouth, throat, esophagus, bronchi, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, bladder, uterus, cervix, breast, ovary, vagina, testicle, skin, thyroid, blood, lymph nodes, kidney, liver, intestine, pancreas, brain, central nervous system, adrenal gland, skin, etc. In one embodiment, the disease characterized by abnormal cell proliferation is melanoma skin cancer or cancer of the lung, colon, breast or prostate, etc. In another embodiment, abnormal cell proliferation is associated with solid tumors or hematological cancers.

[0398] As used herein, the term "modulate" or variations of "modulate" refers to the ability of a compound of Formula (I-III) to inhibit one or more components of a biological pathway. In one embodiment, "modulate" refers to inhibiting ERK1 / 2 activity. In another embodiment, modulating comprises inhibiting the RAS / RAF / MEK / ERK pathway.

[0399] A variety of in vitro and in vivo assays have confirmed the activity of the compounds of formula (I-III). For example, biochemical assays using homogeneous time-resolved fluorescence (HTRF) technology have demonstrated that the compounds of the present invention can inhibit the enzymatic activity of ERK1 and ERK2, with representative data shown in Table 2. Furthermore, cell-based kinetic assays have also demonstrated the activity of the compounds of the present invention. In other words, enzyme-linked immunosorbent assay (ELISA) has shown that the compounds of the present invention can inhibit phosphorylation of RSK1 (S380), a downstream target of ERK1 / 2, with representative data shown in Table 2. The activity of the compounds of formula (I-III) has demonstrated their functional utility in an in vitro tumor cell proliferation assay of a group of tumor cell lines with RAS / BRAF / MEK / ERK channel mutations, with representative data shown in Table 2. The compounds of formula (I-III) show inhibitory activity on ERK1 / 2 and can therefore be used to inhibit abnormal cell growth associated with the RAS / RAF / MEK / ERK channel. Therefore, the compounds of formula (I-III) can effectively treat disorders such as cancer associated with abnormal cell growth caused by abnormal RAS / RAF / MEK / ERK regulation. Those skilled in the art will appreciate that there is a definite correlation between activity in in vitro tumor cell proliferation assays and anti-tumor activity in clinical settings. For example, in vitro tumor proliferation assays have demonstrated the efficacy of several pharmaceutical agents, including paclitaxel (Silvestrini, Stem Cells, Vol. 6, No. 11, 1993, pp. 528-535), docetaxel (Bissery, Anti Cancer Drugs, Vol. 3, No. 6, 1995, p. 330), and topoisomerase inhibitors (Edelman, Cancer Chemother. Pharmacol., Vol. 5, No. 37, 1996, pp. 385-39).

[0400] Finally, compounds of Formulas (I-III) were demonstrated to inhibit tumor growth in vivo by administering doses of the compounds in human tumor xenograft models, such as the A375 human melanoma xenograft model with the B-RAF V600E mutation, the HT-29 human colon cancer xenograft model with the B-RAF V600E mutation, the HCT116 human colon cancer xenograft model with the KRAS mutation, the A549 human lung cancer xenograft model with the KRAS mutation, and the BxPC3 human pancreatic cancer xenograft model. In the A375 xenograft model, treatment with the compounds also demonstrated inhibition of tumor phosphorylated-RSK levels, demonstrating the potent inhibitory effects of the compounds on the target protein ERK1 / 2 in vivo. Those skilled in the art will appreciate that there is a clear correlation between activity in human xenograft models and anti-tumor activity in clinical settings.

[0401] The compounds of formula (I-III) have clear utility prospects as demonstrated by the assays described herein. For example, the compounds of formula (I-III) showed IC 50 The IC value was lower than 100nM in the phosphorylated-RSK1 cell proliferation assay. 50 Values ​​below 500 nM, causing 40% or greater inhibition of tumor growth in one or more human tumor xenograft models, demonstrate that the compounds of the present invention are indeed effective.

[0402] In one embodiment, a method of modulating the RAS / RAF / MEK / ERK pathway is provided, comprising administering to a patient in need thereof a therapeutically effective dose of a compound of Formula (I-III).

[0403] In another embodiment, a method of inhibiting ERK1 / 2 is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I-III).

[0404] In another preferred embodiment, a method for treating a disease characterized by abnormal cell growth caused by dysregulation of the RAS / RAF / MEK / ERK pathway is provided, comprising administering a therapeutically effective dose of a compound of formula (I-III) to a patient in need thereof.

[0405] In another preferred embodiment, a method for treating a disease state treatable by inhibiting ERK1 / 2 is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I-III).

[0406] As described herein, when used to treat a disease, a "therapeutically effective dose" of a compound is an amount that at least slows the progression of the disease. When used to treat cancer, a "therapeutically effective dose" of a compound is an amount that at least slows the progression of the cancer, reduces the number of cancer cells in a body fluid (e.g., blood, peripheral blood, or lymph), reduces tumor size, inhibits metastasis, inhibits tumor growth, and / or improves one or more symptoms of cancer. The effectiveness of a cancer treatment can be determined, for example, by assessing the progression of the disease over time and / or measuring the remission rate.

[0407] Compound preparation process

[0408] The methods for preparing the compounds of formula (I-III) are listed in the examples and summarized in the following schemes. It will be appreciated by those skilled in the art that the schemes can be adapted to prepare other compounds of formula (I-III) and pharmaceutically acceptable salts, prodrugs, solvates, hydrates or stereoisomers thereof.

[0409] In the following reactions describing the preparation of compounds described herein, it may be necessary to protect functional groups, such as hydroxyl, amino, imino, sulfhydryl, or carboxyl groups, that are reactive in the final product to prevent them from participating in undesired reactions. Conventional protecting groups can be used according to standard practice, as described, for example, in Green et al., "Protective Groups in Organic Chemistry," John Wiley & Sons, 1991.

[0410] The following schemes summarize the synthesis of compounds of formula (I-III). The following examples are provided as typical examples of the preparation of each scheme and should not be construed as limiting the scope of the present invention.

[0411] The following abbreviations are used in this document and are defined as follows: MHz, megahertz (frequency), m, multiplet, t, peak, d, doublet, s, singlet, br, broad, CDCl3, deuterated chloroform, calcd, calculated, min, minute, h, hour, g, mmol, millimole, mL, milliliter, N, equivalent (concentration), M, molar (concentration), μM, micromolar, ee, enantiomeric excess, °C, HPLC, high performance liquid chromatography, LC-MS, liquid chromatography-mass spectrometry, mp, melting point, NMR, nuclear magnetic resonance, TLC, thin-layer chromatography, THF, tetrahydrofuran, MeOH, methanol, DCM, dichloromethane, DMF, N,N-dimethylformamide. wherein the alkyl group represents 4-nitro-2-nitropropene, 4-nitro-2-nitropropene, 4-nitro-3-nitropropene, 4-nitro-4-nitropropene, 4-nitro-5-nitropropene, 4-nitro-6-nitropropene, 4-nitro-7-nitropropene, 4-nitro-8-nitropropene, 4-nitro-9-nitropropene, 4-nitro-10-nitropropene, 4-nitro-20-nitropropene, 4-nitro-11-nitropropene, 4-nitro-22-nitropropene, 4-nitro-12-nitropropene, 4-nitro-13-nitropropene, 4-nitro-24-nitropropene, 4-nitro-14-nitropropene, 4-nitro-25-nitropropene, 4-nitro-15-nitropropene, 4-nitro-26-nitropropene, 4-nitro-16-nitropropene, 4-nitro-17-nitropropene, 4-nitro-18-nitropropene, 4-nitro-29-nitropropene, 4-nitro-20-nitropropene, 4-nitro-21-nitropropene, 4-nitro-19-nitropropene, 4-nitro-20-nitropropene, 4-nitro-11-nitropropene, 4-nitro-12-nitropropene, 4-nitro-13-nitropropene, 4-nitro-14-nitropropene, 4-nitro-15-nitropropene, 4-nitro-16-nitropropene, 4-nitro-17-nitropropene, 4-nitro-18-nitropropene, 4-nitro-19-ni

[0412] plan

[0413] Solution 1

[0414]

[0415] Scheme 1 describes a synthetic method for preparing compounds of formula (I) wherein M is NH, Z=N, X=N, J=-CH(R 2 )-or-CH(R 2 )CH2-,R 2 =H、C 1-4Alkyl, CH2OH, CH2OC 1-6 Alkyl or CH2N(C 1-6 In one embodiment, 4-nitropyrazole [A] reacts with 2,4-dichloropyrimidine [B] to generate pyrazolyl-pyrimidine [C]. The above reaction is carried out in the presence of a base (such as potassium carbonate) in an appropriate solvent (such as acetone or dichloropyrimidine). The reaction can be carried out at an elevated temperature up to the reflux temperature of the solvent. The intermediate [C] is then reacted with an amine R 4 -NH2 reaction to generate intermediate [D]. The coupling reaction can be carried out in the presence of a palladium catalyst (such as Pd2(dba)3(tris(dibenzylideneacetone)dipalladium(0))), BINAP (2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl) and potassium carbonate in an appropriate solvent (such as diphenylphosphino) The reaction can be carried out at high temperature, for example, at 90°C in a sealed glass tube. The nitro group in [D] is then reduced to form the amino-pyrazolyl intermediate [E]. This reduction can be achieved by reacting with zinc powder and ammonium chloride at a temperature of 0°C to 25°C in a solvent such as THF:ethanol (2:1). The amine intermediate [E] is then reacted with an amine [F] to form a compound of the present invention, namely, carbonamide (IA). This coupling reaction can be carried out using CDI (1,1'-carbonyldiimidazole) in a solvent such as THF. The reaction can be carried out at an elevated temperature, such as 85°C to 120°C in THF under microwave irradiation. The coupling reaction can also be carried out using 4-nitrophenyl chloroformate, pyridine, and DIPEA (diisopropylethylamine) instead of CDI.

[0416] Option 2

[0417]

[0418] Scheme 2 describes an alternative synthesis method for preparing compounds of formula (I). In this example, M is NH, Z=N, X=N, J=-CH(R 2 )-or-CH(R 2 )CH2-,R 2 =H、C 1-4 Alkyl, CH2OH, CH2OC 1-6 Alkyl or CH2N(C 1-6alkyl)2, Y=CH. In this method, intermediate [C] is prepared as described in Scheme 1 and then reduced to amino-pyrazole [G]. The reduction process can be achieved by reaction with zinc powder and ammonium chloride at a temperature of, for example, 0°C-25°C in a solvent such as THF and methanol (2:1). The amine intermediate [G] is then reacted with an amine [F] to form a carbonamide intermediate [H]. The reaction can be carried out using 4-nitrophenyl chloroformate, pyridine and DIPEA (diisopropylethylamine) at a temperature of, for example, 0°C-25°C in a suitable solvent such as DCM (dichloromethane). Intermediate [H] is then reacted with an amine R 4 -NH2 reaction to generate a compound (IA) of the present invention. The coupling reaction can be carried out in the presence of a palladium catalyst (e.g., Pd2(dba)3), BINAP and potassium carbonate in the presence of, for example, dihydrogen phosphate. The reaction can be carried out at high temperature, for example, at 90°C in a sealed glass tube. The final replacement step is to make the intermediate [H] react with the amine R 4 -NH2 is heated and reacted in ethanol or isopropanol in a sealed glass tube, and DIPEA is added as appropriate.

[0419] Option 3

[0420]

[0421] Scheme 3 describes a synthetic method for preparing compounds of formula (I). In this example, M is a bond, Z = N, and J = -CH(R 2 )-or-CH(R 2 )CH2-,R 2 =H、C 1-4 Alkyl, CH2OH, CH2OC 1-6 Alkyl or CH2N(C 1-6 alkyl)2, Y=CR 7 In this method, 2,4-dichloropyrimidine or 2-chloro-4-bromopyrimidine [B] reacts with a heterocyclic ester [J] to form an intermediate [K]. The above reaction can be carried out in the presence of a base (such as potassium carbonate) in a suitable solvent (such as acetonitrile). The reaction can be carried out at an elevated temperature up to the reflux temperature of the solvent. The intermediate [K] is then reacted with an amine R 4 -NH2 reaction to generate intermediate [L]. The coupling reaction can be carried out in the presence of a palladium catalyst (e.g. Pd2(dba)3), BINAP and potassium carbonate in an appropriate solvent (e.g. dichloromethane). The reaction can be carried out at high temperature, for example, at 90°C to 100°C in a sealed glass tube. An alternative method for producing intermediate [L] is to react intermediate [K] with amine R 4 -NH2 is heated in ethanol or isopropanol in a sealed glass tube and reacted, optionally with the addition of DIPEA. The ester group in intermediate [L] is hydrolyzed to produce the corresponding carboxylic acid [M], for example, by treatment with aqueous sodium hydroxide or lithium hydroxide in methanol or THF at a temperature between 0°C and 50°C. Intermediate [M] is then coupled with an amine [F] to produce a compound of the present invention, namely, amide (IB). The amide-coupling reaction can be carried out in a suitable solvent such as NMP (N-methyl-2-pyrrolidone) using the amide-coupling reagent EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), optionally with the addition of HOBt (1-hydroxybenzotriazole) and triethylamine. The reaction can be carried out at a temperature between 0°C and 25°C. The coupling reaction can also be carried out using any of several other amide-coupling reagents known to those skilled in the art, such as T3P (propylphosphonic anhydride).

[0422] Option 3a

[0423]

[0424] Scheme 3a describes a variant of Scheme 3, wherein the amide coupling reaction with the amine [F] is carried out first, followed by the reaction with the pyrimidine [B], and then by the reaction with the amine R 4 -NH2 to produce a compound of the present invention, namely amide (IB).

[0425] Option 4

[0426]

[0427] Scheme 4 describes an alternative synthesis method for preparing compounds of formula (I) wherein M is a bond and R 2 =CH2NH2, Z=N, X=CR 7 In this method, 2,4-dichloropyrimidine or 2-chloro-4-bromopyrimidine [B] is coupled with a heterocyclic ester [N] to produce intermediate [O] by a method similar to the preparation of [K] in Scheme 3. Compound [O] is reacted with an amine R by a method similar to the preparation of [L] in Scheme 3. 4-NH2 reaction to produce intermediate [P]. The ester group in [P] is hydrolyzed by a method similar to the preparation of [M] in Scheme 3 to produce the corresponding carboxylic acid [Q]. Intermediate [Q] is then coupled with amine [R] using the amide-coupling method described in Scheme 3 to prepare (IB) to produce amide [S]. Alternatively, the ester intermediate [P] can be directly converted to (S) by reacting with amine [R] in the presence of trimethylaluminum in a suitable solvent such as toluene. The reaction is carried out at a temperature of, for example, 0°C to 100°C, optionally with microwave irradiation. The nitrile group in [S] is reduced by hydrogenation using Raney nickel in methanolamine to produce the corresponding amine (IC), a compound of the present invention. The reaction can be carried out, for example, at room temperature under 25 psi of hydrogen for 16 hours.

[0428] Option 5

[0429]

[0430] Scheme 5 describes another method for synthesizing compounds of formula (I). In this example, M is a bond, Z = N, and J = -CH(R 2 )-or-CH(R 2 )CH2-,R 2 =H,C 1-4 Alkyl, CH2OH, CH2OC 1-6 Alkyl or CH2N(C 1-6 alkyl)2, Y=N, X=CR 7 In this method, the aldehyde building block [T] reacts with 2,4-dichloropyrimidine (or 2-chloro-4-bromopyrimidine) to prepare the aldehyde intermediate [U], which is converted to the corresponding carboxylic acid intermediate [V] by methods known in the art. Intermediate [V] is then coupled with amine [F] by the amide-coupling method described in Scheme 3 to produce amine intermediate [W]. [W] is then coupled with R by the method described in Scheme 3 to produce [L]. 4 -NH2 reaction to produce a compound (ID) of the present invention.

[0431] Option 6

[0432]

[0433] Scheme 6 describes another method for synthesizing compounds of formula (I) wherein M is a bond, Z = N, J = -CH(R 2 )-or-CH(R 2 )CH2-,R 2 =H,C 1-4 Alkyl, CH2OH, CH2OC 1-6 Alkyl or CH2N(C 1-6 alkyl)2, X=CR 7In this method, the preparation of intermediate [X] is similar to the method used to prepare intermediate [P] in Scheme 4. The ester intermediate [X] is then reacted with amine [F] in the presence of trimethylaluminum in a suitable solvent such as toluene. The reaction is carried out at a temperature of, for example, 0°C to 100°C, optionally with microwave irradiation, to produce a compound (IE) of the present invention. 4 This approach is particularly effective when the substitution is selectively by alkyl groups.

[0434] Option 7

[0435]

[0436] Scheme 7 describes one method for preparing compounds of formula (I). In this example, M is a bond, Z = N, and J = -CH(R 2 )-or-CH(R 2 )CH2-,R 2 =H,C 1-4 Alkyl, CH2OH, CH2OC 1-6 Alkyl or CH2N(C 1-6 alkyl)2, X=CR 7 In this method, 2-amino-4-bromopyridine [Y] is reacted with an iodine compound R 4 -I is reacted in the presence of a palladium (0) catalyst to produce a pyridine intermediate [Z]. Intermediate [Z] is then reacted with a heterocyclic ester [AA] to produce intermediate [AB]. The reaction is carried out in the presence of copper (I) iodide, L-proline and potassium phosphate at a temperature of, for example, 25°C to 150°C in a sealed glass tube in a solvent such as DMF. The ester group in intermediate [AB] is hydrolyzed by the method for preparing [M] in Scheme 3, and the carboxylic acid intermediate [AC] is then reacted with [F] by the amide-coupling method described in Scheme 3 to produce a compound (IF) of the present invention. Alternatively, the ester intermediate [AB] can be directly converted to (IF) using trimethylaluminum in a suitable solvent such as toluene using the method described in Scheme 6.

[0437] Option 8

[0438]

[0439] Scheme 8 describes another method for preparing compounds of formula (I), in this example, M is a bond, Z = CH, J = -CH (R 2 )-or-CH(R 2 )CH2-,R 2 =H,C 1-4 Alkyl, CH2OH, CH2OC 1-6 Alkyl or CH2N(C 1-6In this method, 2-chloropyridine [AD] is oxidized, nitrated, and then reacted with an amine R 4 The 4-nitro-pyridine N-oxide intermediate [AG] is generated by reacting with NH2. The N-oxyl group and the nitro group in [AG] are reduced to produce the 4-amino group in [AH], which is then converted to a bromo group. The 4-bromo-pyridine intermediate [AI] is then reacted with a suitable heterocycle, such as a pyrrole derivative [AJ], to produce a compound of the present invention (IG).

[0440] Option 9

[0441]

[0442] Scheme 9 describes a method for preparing compounds of formula (I) wherein M is a bond, Z=CH, X=CR 7 , J=-CH(R 2 )-,R 2 =CH2NH2. This method utilizes and combines aspects of the general methods described in Schemes 4 and 7 to produce a compound of the present invention (IH).

[0443] Plan 10

[0444]

[0445] Scheme 10 describes one method for preparing compounds of formula (I). In this example, M is a bond, Z = CH, J = -CH (R 2 )-or-CH(R 2 )CH2-,R 2 =H、C 1-4 Alkyl, CH2OH, CH2OC 1-6 Alkyl or CH2N(C 1-6 Alkyl)2, R 5 =Cl, X=CR 7 , Y = N. In this method, 4-chloro-pyridine [AL] is converted to 3,4-dichloro-pyridine [AO] in three steps and in subsequent steps to a compound of the present invention (IJ) using a method similar to that described in the above scheme.

[0446] Plan 11

[0447]

[0448] Scheme 11 describes a method for preparing compounds of formula (I). In this example, M is a bond, Z = CH, and R 2 =CH2NH2, X=CR 7, Y=N. In this method, 2,4-dichloro-pyridine or 2-chloro-4-bromopyridine [AT] is reacted with a heterocyclic ester [AQ] in the presence of a base such as potassium carbonate in a suitable solvent such as DMF. The reaction can be carried out at a temperature between room temperature and an elevated temperature such as 100°C or at the reflux temperature of the solvent. The 2-chloro-pyridine intermediate [AU] is then reacted with an amine R 4 -NH2 reaction to generate intermediate [AV]. The coupling reaction is carried out in the presence of a palladium catalyst such as Pd2(dba)3, BINAP and potassium carbonate. The reaction is carried out in an appropriate solvent containing alkane. The reaction can be carried out at elevated temperatures, for example, in a sealed glass tube at 90°C or at 100°C using microwave irradiation. The ester group of intermediate [AV] is then hydrolyzed to the corresponding carboxylic acid [AW], for example, by treatment with aqueous sodium hydroxide or potassium hydroxide in methanol or THF at temperatures between 0°C and 50°C. The carboxylic acid [AW] is then coupled with an amine [R] using the amide-coupling method described in Scheme 3 for the preparation of (IB) to produce the amide [AX]. The nitrile group in [AX] is reduced by hydrogenation using Raney nickel in methanolic amine to produce the corresponding amine (IK), a compound of the present invention. The reaction can be carried out at approximately room temperature under 15-25 psi of hydrogen for approximately 6-16 hours.

[0449] Plan 12

[0450]

[0451] Scheme 12 describes a method for preparing compounds of formula (I). In this example, M is a bond, Z=CH, X=N, and Y=N. In this method, 2,4-dichloropyridine (or 2-chloro-4-bromopyridine) [AT] reacts with sodium azide to form 4-azidopyridine [AY]. 4-azidopyridine [AY] is then condensed with methyl propiolate to form the triazole intermediate [AZ]. The ester group in intermediate [AZ] is hydrolyzed as described in Scheme 11, and the corresponding carboxylic acid is reacted with an amine such as [F] via an amide-coupling method as described in Scheme 10, or with an amine such as [R] via an amide-coupling method followed by reduction as described in Scheme 11 to produce a compound (IL) of the present invention.

[0452] Plan 13

[0453]

[0454] Scheme 13 describes one method for preparing compounds of formula (I). In this example, M is a bond, Z = CH, and R 5 =H,X=CR 7 In this method, 2-fluoro-4-iodo-pyridine [BA] is reacted with an amine R 4-NH2 reaction to produce intermediate [BB]. The reaction is carried out in a suitable solution such as DMF or NMP, and can be carried out at an elevated temperature, for example, in a sealed glass tube at 90°C-100°C. Intermediate [BB] is then reacted with a heterocyclic ester [N] to produce intermediate [BC]. The reaction is carried out in the presence of L-proline, copper (I) iodide, and a base such as potassium carbonate, at an elevated temperature between 25°C and 100°C-150°C, in a sealed glass tube in a suitable solution such as DMF or NMP. The ester group in intermediate [BC] is hydrolyzed by the method described in Scheme 11, and the corresponding carboxylic acid is then reacted with an amine such as [F] by an amide-coupling method as described in Scheme 10, or with an amine such as [R] by an amide-coupling method followed by reduction by the method described in Scheme 11, to produce a compound (IM) of the present invention.

[0455] An effective method for preparing the building blocks for synthesizing compounds of formula (I) is set forth in the following schemes. One skilled in the art will appreciate that the schemes can be adapted to prepare other compounds of formula (I) and pharmaceutically acceptable salts, prodrugs, solvates, hydrates or stereoisomers of compounds of formula (I).

[0456] Plan 14

[0457]

[0458] Plan 15

[0459]

[0460] Plan 16

[0461]

[0462] Plan 17

[0463]

[0464] Examples of effective methods for preparing compounds such as (IN) and (IO) that can serve as prodrugs of compounds of formula (I) are shown in the following Schemes 18 and 19. One skilled in the art will appreciate that the schemes can be adjusted to generate other compounds that can serve as prodrugs of compounds of formula (I).

[0465] Plan 18

[0466]

[0467] Plan 19

[0468]

[0469] Plan 20

[0470]

[0471] Scheme 20 depicts another method for preparing compounds of formula (I), in this example, M is a bond, R 2 =CH2NH2, Z=N, X=CR 7 . This method is an alternative to the method described in Scheme 4. In this method, the amino-alcohol (in this example, a single enantiomer) [BD] is converted to the N-Boc protected analogue [BE] by standard methods, and then the hydroxyl group is converted to the corresponding mesylate, for example by reaction with methanesulfonyl chloride and triethylamine in a solvent such as dichloromethane. The mesylate compound [BF] is then reacted with sodium azide to form the corresponding azide derivative [BG]. The azidation reaction is carried out in a suitable solvent such as DMF or NMP, and can be carried out at an elevated temperature such as about 50°C. Subsequently, the N-Boc group is removed by standard methods, for example by The amine azide [BH] is then coupled with the intermediate [Q] using the amide coupling method described in Scheme 3 for the preparation of (IB) to produce the amide [BI]. The azide group is reduced by reaction with zinc powder and ammonium chloride in a solvent such as methanol to produce a compound of the present invention (IP), in this example as a single enantiomer.

[0472] Example

[0473] Unless otherwise noted, all reactions are carried out under dry nitrogen and / or argon atmosphere, and all raw materials, solvents and reagents are purchased (such as Avocado Research Chemicals, Apollo Scientific Limited, Bepharma Ltd., Combi-Blocks Inc., Sigma Aldrich Chemicals Pvt. Ltd., Ultra Labs, Toronto Research Chemicals Inc., Chemical House, RFCL Limited, Spectro Chem Pvt. Ltd., Leonid Chemicals, Loba Chemie, Changzhou Yangyuan, NeoSynth., Rankem etc. companies) by commercial sources, and without further purification before use, or reagent can be synthesized by steps known in the art. Typically, each reaction process is monitored by TLC analysis.

[0474] Biotage One and The crude product was typically purified using a fully automated flash purification system from Teledyne Isco using the eluent combinations mentioned in each step. Flash chromatography was performed using silica gel columns (60-100, 100-200, and 230-400 mesh) from ChemLabs, with nitrogen and / or compressed air used to flow the pressurized eluent. Preparative thin-layer chromatography (preparative TLC) was performed using silica gel columns (GF 1500 μM 20 × 20 cm and GF 2000 μM 20 × 20 cm Prep-scored plates, Analtech, Inc., Delaware, USA). Analytical thin-layer chromatography (TLC) was performed using precoated silica gel plates (Merck 60F254). Visual detection was performed using ultraviolet light, p-anisaldehyde stain, ninhydrin stain, dinitrophenylhydrazine stain, potassium permanganate stain, or iodine. Reactions at low temperatures were performed using cooling baths, such as water / ice at 0°C and acetone / dry ice at -78°C. Reactions were performed under microwave conditions using a CEM Discover SP 909155 microwave oven, and melting points were determined using a LabIndia MR-VIS visual melting point apparatus. 1 H NMR spectra were recorded at 400 MHz using tetramethylsilane as an internal standard on a Varian V400 spectrometer Bruker 400 (unless otherwise stated) at room temperature. Chemical shift values ​​are expressed in δ (ratios per million). Mass spectra of all intermediates and final compounds were recorded using UPLC-SQD (Waters) and Agilent's 1290 with 6150SQD UHPLC instrument. HPLC spectra were recorded using Agilent 1290 UHPLC and Alliance (Waters) system. LCMS spectra were recorded using Agilent LCMS, Agilent with diode array detector (DAD) detection UHPLC-SQD, LC-MS instrument using BEH C18 column and HD C18 column (50mm×2.1mm×1.7μm) & (50mm×2.1mm×1.8μm), mobile phase was 0.01% formic acid and acetonitrile or 0.01% trifluoroacetic acid and acetonitrile, flow rate was 0.3mL / min, column temperature was 70 or 50℃, and running time was 3-5 minutes. The purity of each final compound was determined using SQD PDA and 6150SQD DAD instrument, and the following conditions were used:

[0475] Condition 1: Column: BEH C18 (Waters); Mobile phase: 0.01% acetic acid and acetonitrile & 0.01% acetic acid and methanol; Gradient: (B / %T): 0 / 0, 1.2 / 100, 2.5 / 100, 2.8 / 0, 3.0 / 0; Flow rate: 0.3 mL / min; Temperature: 70°C; Run time: 3.0 min. Condition 2: Column: HD C18; mobile phase: 0.01% acetic acid and acetonitrile & 0.01% acetic acid and methanol; gradient: (B / %T): 0 / 0, 2.5 / 100, 4.5 / 100, 4.8 / 0, 5.0 / 0; flow rate: 0.3 mL / min; temperature: 50°C; run time: 5.0 minutes.

[0476] For use in preparing specific compounds of the present invention, the following intermediates were prepared as follows.

[0477] Preparation 1: 2-Amino-2-(3-chlorophenyl)acetonitrile

[0478]

[0479] A solution of 3-chlorobenzaldehyde (5 g, 35.0 mmol) in methanol (100 mL) was purged with ammonia gas at room temperature for 2 h. The mixture was cooled to 0°C and trimethylsilyl cyanide (5.293 g, 53.0 mmol) was added. The mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography using a gradient method with ethyl acetate in hexane as the eluent to provide 2-amino-2-(3-chlorophenyl)acetonitrile as a yellow solid (4.8 g, 81% yield). 1H NMR (400 MHz, DMSO-d6): δ 7.57 (s, 1H), 7.47–7.40 (m, 3H), 5.06 (s, 1H), 2.92 (s, 2H).

[0480] Preparation 2: 2-Amino-3-phenylpropionitrile

[0481]

[0482] To a solution of 2-phenylethyl ether (10.0 g, 83.33 mmol) dissolved in methanol (50 mL) was added NH₃ and Ti(OiPr)₄ (30.7 g, 108.33 mmol) dissolved in methanol (80.0 mL) with stirring, and the resulting solution was stirred at room temperature for 2 h. Trimethylsilyl cyanide (TMSCN) (14.88 g, 149.9 mmol) was then added to the reaction mixture, and the reaction mixture was stirred at room temperature for 20 h. The reaction mixture was quenched with water, and the resulting white precipitate was filtered off. The filtrate was concentrated under reduced pressure, mixed with ethyl acetate, and washed with concentrated hydrochloric acid (2 x 15 mL). The organic layer was dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by combiflash eluting with MeOH in DCM to yield 2-amino-3-phenylpropionitrile (5.4 g, 45%). 1HNMR (400 MHz, DMSO-d6): δ 7.37-7.21 (m, 5H), 3.93 (t, J=7.2 Hz, 1H), 3.33-3.23 (m, 2H), 2.36 (br s, 2H). LC-MS calculated molecular weight 146.08, found m / z 147.04 [M+H] + .

[0483] Typical example of scheme 1:

[0484] Example 1: (S)-1-(1-(3-chlorophenyl)-2-hydroxyethyl)-3-(1-(2-(2-chlorophenyl)amino)-5-methylpyrimidin-4-yl)-1H-pyrazol-4-yl)carboxamide (Compound #2).

[0485] Step 1: 2-Chloro-5-methyl-4-(4-nitro-1H-pyrazol-1-yl)pyrimidine

[0486]

[0487] A reaction mixture of 4-nitro-1H-pyrazole (1.0 g, 8.8 mmol), 2,4-dichloro-5-methylpyrimidine (1.18 g, 7.96 mmol), potassium carbonate (3.6 g, 26.4 mmol), and acetone (30 mL) was heated at 65°C for 6 h. The reaction mixture was evaporated, and the residue was suspended in water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and evaporated. The residue was purified by column chromatography on silica gel using ethyl acetate in hexane as the eluent to yield 2-chloro-5-methyl-4-(4-nitro-1H-pyrazol-1-yl)pyrimidine (0.73 g, 56%). 1HNMR (400 MHz, CDCl3): 9.32 (s, 1H), 8.62 (s, 1H), 8.31 (s, 1H), 2.69 (s, 3H). LC-MS calculated molecular weight: 239.02, observed m / z: 240.1 [M+H] + .

[0488] Step 2: N-(2-chlorophenyl)-5-methyl-4-(4-nitro-1H-pyrazol-1-yl)pyrimidin-2-amine

[0489]

[0490] The reaction mixture in a glass tube was mixed with 2-chloro-5-methyl-4-(4-nitro-1H-pyrazol-1-yl)pyrimidine (0.4 g, 1.67 mmol), 2-chloroaniline (0.19 mL, 1.84 mmol), potassium carbonate (0.34 g, 2.5 mmol) and dichloroaniline. The mixture was purged with nitrogen for 20 minutes with 15 mL of oxane. Tris(dibenzylideneacetone)dipalladium(0) (0.076 g, 0.083 mmol) and BINAP (0.103 g, 0.167 mmol) were added to the reaction mixture and purged with nitrogen for an additional 15 minutes. The tube was then sealed and heated at 90°C for 4 hours. The reaction mixture was filtered through celite and the filtrate was evaporated. The residue was suspended in water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and evaporated. The residue was purified by column chromatography on silica gel using 20% ​​ethyl acetate in hexane as the eluent to yield N-(2-chlorophenyl)-5-methyl-4-(4-nitro-1H-pyrazol-1-yl)pyrimidin-2-amine (0.33 g, 60%). 1H NMR (400 MHz, DMSO-d6): 9.23 (s, 1H), 9.17 (s, 1H), 8.61 (s, 1H), 8.54 (s, 1H), 7.78 (d, J = 8 Hz, 1H), 7.51 (d, J = 8 Hz, 1H), 7.35 (t, J = 8 Hz, 1H), 7.18 (t, 1H, J = 8 Hz), 2.38 (s, 3H). LC-MS calculated molecular weight 330.06, found m / z 331.1 [M+H] + .

[0491] Step 3: 4-(4-amino-1H-pyrazol-1-yl)-N-(2-chlorophenyl)-5-methylpyrimidin-2-amine

[0492]

[0493] To a solution of N-(2-chlorophenyl)-5-methyl-4-(4-nitro-1H-pyrazol-1-yl)pyrimidin-2-amine (0.33 g, 1.0 mmol) in THF:methanol (2:1) (10 mL) cooled to 0°C was added zinc powder (0.39 g, 6.0 mmol) and ammonium chloride (0.43 g, 8.0 mmol). The mixture was stirred at room temperature for 30 minutes. The reaction mixture was filtered through celite and the filtrate evaporated; the residue was suspended in water and extracted with DCM. The organic layer was dried over sodium sulfate and evaporated to yield 4-(4-amino-1H-pyrazol-1-yl)-N-(2-chlorophenyl)-5-methylpyrimidin-2-amine (0.24 g, 80%). The product was used in the next step without further purification. 1H NMR (400 MHz, DMSO-d6): 8.63 (s, 1H), 8.26 (s, 1H), 7.83 (t, J = 8 Hz, 1H), 7.72 (s, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.42 (s, 1H), 7.38-7.32 (m, 1H), 7.13-7.11 (m, 1H), 4.39 (s, 2H), 2.40 (s, 3H). LC-MS calculated molecular weight 300.09, found m / z 301.1 [M+H] + .

[0494] Step 4: (S)-1-(1-(3-chlorophenyl)-2-hydroxyethyl)-3-(1-(2-(2-chlorophenyl)amino)-5-methylpyrimidin-4-yl)-1H-pyrazol-4-yl)carboxamide

[0495]

[0496] A reaction mixture of 4-(4-amino-1H-pyrazol-1-yl)-N-(2-chlorophenyl)-5-methylpyrimidin-2-amine (0.15 g, 0.5 mmol), 1,1'-carbonyldiimidazole (0.32 g, 2.0 mmol), and THF (5 mL) was stirred at 85°C for 20 minutes in a CEM microwave vial. (S)-2-amino-2-(3-chlorophenyl)ethanol (0.25 g, 1.5 mmol) was added to the reaction mixture and stirred at 120°C in a CEM microwave for 20 minutes. The reaction mixture was evaporated, and the residue was suspended in water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and evaporated, and the residue was purified by preparative thin layer chromatography using methanol in DCM as eluent to yield (S)-1-(1-(3-chlorophenyl)-2-hydroxyethyl)-3-(1-(2-(2-chlorophenyl)amino)-5-methylpyrimidin-4-yl)-1H-pyrazol-4-yl)carboxamide (0.02 g, 8%). 1H NMR (400 MHz, DMSO-d6): δ 8.79 (s, 1H), 8.63 (s, 1H), 8.46 ( s, 1H), 8.31 (s, 1H), 7.79 (s, 1H), 7.78 (s, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.35-7.26 (m, 4H), 7.13 (t, J = 7.8 Hz, 1H), 6.79 (d, J = 8 Hz, 1H), 4.99-4.91 (m, 1H), 4.74-4.72 (m, 1H), 3.65-3.55 (m, 2H), 2.41 (s, 3H). LC-MS m / z calculated exact molecular weight 497.11, found m / z 498.3 [M+H] + ; HPLC purity 99.17%.

[0497] Typical example of scheme 2:

[0498] Example 2: (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-4-(5-methoxy-1H-indol-3-yl)-1H-pyrrole-2-carboxamide (Compound #20).

[0499] Step 1: 2-Chloro-4-(4-nitro-1H-pyrazol-1-yl)pyrimidine

[0500]

[0501] A reaction mixture of 4-nitro-1H-pyrazole (4.0 g, 35.3 mmol), 2,4-dichloropyrimidine (5.23 g, 35.3 mmol), potassium carbonate (14.6 g, 106 mmol), and acetone (200 mL) was heated at 65°C for 4 h. The reaction mixture was evaporated, and the residue was suspended in water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, evaporated, and the residue was purified by column chromatography on silica gel using ethyl acetate in hexane as the eluent to yield 2-chloro-4-(4-nitro-1H-pyrazol-1-yl)pyrimidine (1.7 g, 21%). 1H NMR (400 MHz, CDCl3): 9.30 (s, 1H), 8.78 (d, J = 5.6 Hz, 1H), 8.32 (s, 1H), 7.74 (d, J = 5.2 Hz, 1H).

[0502] Step 2: 1-(2-chloropyrimidin-4-yl)-1H-pyrazol-4-amine

[0503]

[0504] To a solution of 2-chloro-4-(4-nitro-1H-pyrazol-1-yl)pyrimidine (0.4 g, 1.77 mmol) in THF:methanol (2:1) (20 mL) cooled to 0°C was added zinc powder (0.7 g, 10.6 mmol) and ammonium chloride (0.75 g, 14.16 mmol). The mixture was stirred at room temperature for 30 minutes. The reaction mixture was filtered through celite and the filtrate was evaporated; the residue was suspended in water and extracted with DCM. The organic layer was dried over sodium sulfate and evaporated to yield 1-(2-chloropyrimidin-4-yl)-1H-pyrazol-4-amine (0.33 g, 97%). The product was used in the next step without further purification. 1H NMR (400 MHz, DMSO-d6): 8.60 (d, J = 5.6 Hz, 1H), 7.76 (s, 1H), 7.71 (d, J = 8 Hz, 1H), 7.58 (s, 1H), 5.21 (br s, 2H). LC-MS calculated molecular weight 195.03, found m / z 196.1 [M+H] + .

[0505] Step 3: (S)-1-(1-(3-chlorophenyl)-2-hydroxyethyl)-3-(1-(2-chloropyrimidin-4-yl)-1H-pyrazol-4-yl)carboxamide

[0506]

[0507] A mixture of 1-(2-chloropyrimidin-4-yl)-1H-pyrazol-4-amine (0.1 g, 0.51 mmol) and pyridine (0.041 mL, 0.51 mmol) in DCM (6 mL) was cooled to 0°C, and 4-nitrophenyl chloroformate (0.102 g, 0.51 mmol) was added. The mixture was stirred at room temperature for 1.5 h. The reaction mixture was cooled to 0°C, and DIPEA (0.28 mL, 1.53 mmol) and (S)-2-amino-2-(3-chlorophenyl)ethanol (0.088 g, 0.51 mmol) were added. The mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with DCM and washed with water and brine. The organic layer was dried over sodium sulfate, evaporated, and the residue was purified by column chromatography on silica gel using 60% ethyl acetate in hexane as eluent to give (S)-1-(1-(3-chlorophenyl)-2-hydroxyethyl)-3-(1-(2-chloropyrimidin-4-yl)-1H-pyrazol-4-yl)carboxamide (0.045 g, 23%). 1H NMR (400 MHz, DMSO-d6): 8.74 (s, 1H), 8.68 (d, J = 5.6 Hz, 1H), 8.45 (s, 1H), 7.92 (s, 1H), 7.80 (d, J = 5.6 Hz, 1H), 7.36-7.32 (m, 2H), 7.28 (d, J = 7.6 Hz, 2H), 6.96 (d, J = 8 Hz, 1H), 5.00-4.98 (m, 1H), 4.76-4.72 (m, 1H), 3.65-3.58 (m, 2H). LC-MS calculated molecular weight: 392.06, found: m / z 393.1 [M+H]. + .

[0508] Step 4: (S)-1-(1-(2-(2-chloro-4-fluorophenyl)amino)pyrimidin-4-yl)-1H-pyrazol-4-yl)-3-(1-(3-chlorophenyl)-2-hydroxyethyl)carboxamide

[0509]

[0510] (S)-1-(1-(3-chlorophenyl)-2-hydroxyethyl)-3-(1-(2-chloropyrimidin-4-yl)-1H-pyrazol-4-yl)carboxamide (0.02 g, 0.05 mmol), 2-chloro-4-fluoroaniline (0.009 g, 0.6 mmol), potassium carbonate (0.01 g, 0.075 mmol) and dichlorobenzene were added to the glass tube. A mixture of 2,4-dioxane (2 mL) was purged with nitrogen for 20 minutes. Tris(dibenzylideneacetone)dipalladium(0) (0.002 g, 0.0025 mmol) and BINAP (0.003 g, 0.005 mmol) were added to the reaction mixture, and the reaction mixture was purged with nitrogen for an additional 15 minutes. The glass tube was sealed and heated at 90°C for 4 hours. The reaction mixture was filtered through celite, and the filtrate was evaporated; the residue was suspended in water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, evaporated, and the residue was purified by column chromatography on silica gel using 60% ethyl acetate in hexane as the eluent to yield (S)-1-(1-(2-(2-chloro-4-fluorophenyl)amino)pyrimidin-4-yl)-1H-pyrazol-4-yl)-3-(1-(3-chlorophenyl)-2-hydroxyethyl)carboxamide (0.003 g, 12%). 1H NMR (400 MHz, CDCl3, with a few drops of MeOD): 8.50 (s, 1H), 8.33 (d, J = 5.2 Hz, 1H), 8.27-8.25 (m, 1H), 7.51 (s, 1H), 7.28-7.19 (m, 1H), 7.23-7.12 (m, 3H), 7.12-7.10 (m, 1H) 7.04-6.99 (m, 1H), 6.23 (d, J = 6.8 Hz, 1H) 4.87-4.84 (m, 1H), 3.81-3.77 (m, 1H), 3.64-3.61 (m, 1H). LC-MS calculated molecular weight: 501.09, found: m / z 502.3 [M+H]. + .HPLC purity 98.17%.

[0511] Example 3: (S)-1-(1-(2-(Benzo[d][1,3]dioxol-5-ylamino)-5-methylpyrimidin-4-yl)-1H-pyrazol-4-yl)-3-(2-hydroxy-1-phenylethyl)carboxamide (Compound #55).

[0512] Step 1: 2-Chloro-5-methyl-4-(4-nitro-1H-pyrazol-1-yl)pyrimidine

[0513]

[0514] To a stirred solution of 4-nitro-1H-pyrazole (4.0 g, 35.36 mmol) in acetone (100 mL) was added potassium carbonate (14.66 g, 106.1 mmol). The mixture was stirred at room temperature for 15 minutes, followed by the addition of 2,4-dichloro-5-methylpyrimidine (5.76 g, 35.36 mmol), and the reaction mixture was stirred at 70°C for 8 hours. The reaction mixture was quenched with water (100 mL), extracted with ethyl acetate (3 x 100 mL), and then washed with brine (30 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by gradient column chromatography using 8% ethyl acetate in n-hexane as the eluent to yield 2-chloro-5-methyl-4-(4-nitro-1H-pyrazol-1-yl)pyrimidine (4.2 g, 50% yield) as a colorless solid. 1HNMR (400MHz CDCl3): δ9.31(s,1H),8.61(s,1H),8.31(s,1H),2.68(s,3H). LC-MS calculated molecular weight 239.02, found m / z 240.2[M+H] + .

[0515] Step 2: 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrazol-4-amine

[0516]

[0517] To a stirred solution of 2-chloro-5-methyl-4-(4-nitro-1H-pyrazol-1-yl)pyrimidine (4.2 g, 17.2 mmol) in THF:methanol (50:25 mL) was added ammonium chloride (6.85 g, 172.0 mmol) and zinc powder (5.28 g, 87.4 mmol). The reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was filtered through celite with methanol (50 mL), and the filtrate was evaporated under reduced pressure. The mixture was then combined with water and extracted with ethyl acetate (3 x 100 mL) followed by brine (50 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to yield 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrazol-4-amine as an off-white solid (3.0 g, 82% yield). 1HNMR (400MHz CDCl3): δ8.36 (s, 1H), 8.11 (s, 1H), 7.49 (d, J=8 Hz, 1H), 3.19 (s, 2H), 2.62 (s, 3H). LC-MS calculated molecular weight 209.04, found m / z 210.2 [M+H] + .

[0518] Step 3: (S)-1-(1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrazol-4-yl)-3-(2-hydroxy-1-phenylethyl)carboxamide

[0519]

[0520] To a stirred solution of 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrazol-4-amine (0.2 g, 0.95 mmol) in DCM (15 mL) at 0°C was added 4-nitrophenyl chloroformate (0.23 g, 0.11 mmol), and the mixture was stirred at room temperature for 2 h. DIPEA (0.5 mL, 2.86 mmol) and (S)-2-amino-2-phenylethanol (0.13 g, 0.95 mmol) and pyridine (0.08 mL, 0.95 mmol) in DCM (3 mL) were then added to the mixture, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with water (25 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure, washed with ether, and dried under high vacuum to yield (S)-1-(1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrazol-4-yl)-3-(2-hydroxy-1-phenylethyl)carboxamide (0.1 g, 28%) as an off-white solid. 1H NMR (400 MHz DMSO-d6): δ 8.68 (s, 1H), 8.61 (s, 1H), 8.52 (s, 1H), 7.89 (s, 1H), 7.3 (d, J = 4.4 Hz, 4H), 7.24-7.19 (m, 1H), 6.83 (d, J = 7.6 Hz, 1H), 4.93 (t, J = 5.2 Hz, 1H), 4.75-4.71 (m, 1H), 3.65-3.55 (m, 2H), 2.48 (s, 3H). LC-MS calculated molecular weight 372.11, found m / z 373.1 [M+H] + .

[0521] Step 4: (S)-1-(1-(2-(Benzo[d][1,3]dioxol-5-ylamino)-5-methylpyrimidin-4-yl)-1H-pyrazol-4-yl)-3-(2-hydroxy-1-phenylethyl)carboxamide

[0522]

[0523] Under stirring, dissolve in To a solution of (S)-1-(1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrazol-4-yl)-3-(2-hydroxy-1-phenylethyl)carboxamide in 1,2-dioxol-5-amine (5 mL) was added potassium carbonate (0.055 g, 0.40 mmol), benzo[d][1,3]dioxol-5-amine (0.044 g, 0.32 mmol), and (2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl) (0.016 g, 0.026 mmol). The mixture was then degassed with argon for 20 minutes, and tris(dibenzylideneacetone)dipalladium(0) (0.012 g, 0.013 mmol) was added. The mixture was stirred in a sealed glass tube at 100°C for 4 hours. The reaction mixture was filtered through a pad of celite, and the filtrate was quenched with water (15 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography eluting with 3.5% methanol in DCM to yield (S)-1-(1-(2-(benzo[d][1,3]dioxol-5-ylamino)-5-methylpyrimidin-4-yl)-1H-pyrazol-4-yl)-3-(2-hydroxy-1-phenylethyl)carboxamide (4 mg, 4%) as an off-white solid. 1HNMR (400MHz, DMSO-d6): δ9.44(s,1H),8.81(s,1H),8.56(s,1H),8.34(d, J=12.4Hz,1H),7.77(s,1H),7.37(d,J=1.6Hz,1H),7.31-7.29(m,4H),7.23 -7.19(m,1H)7.12-7.09(m,1H),6.9(d,J=7.6Hz,1H),6.8(d,J=8Hz,1H),5. 97(s,2H),4.95(s,1H),4.74-4.69(m,1H),3.63-3.55(m,2H),2.45(s,3H). LC-MS accurate molecular weight calculated value 473.18, experimental value m / z 474.5 [M+H] + HPLC purity 98.33%, chiral HPLC purity 99.01%, mp 208.3℃.

[0524] Typical example of Option 3:

[0525] Example 4: (S)-1-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-3-carboxamide (Compound #29).

[0526] Step 1: 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylic acid methyl ester

[0527]

[0528] To a solution of 1H-pyrrole-3-carbonic acid methyl ester (3.0 g, 24 mmol) in acetonitrile (100 mL) was added 2,4-dichloro-5-methylpyrimidine (5.9 g, 36 mmol) and potassium carbonate (6.6 g, 48 mmol). The reaction mixture was stirred at reflux for 12 h. The reaction mixture was diluted with ethyl acetate (500 mL) and washed with water and brine. The ethyl acetate layer was dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in hexane as the eluent to afford 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylic acid methyl ester (3.2 g, 53%) as an off-white solid. 1 HNMR (400 MHz, CDCl3): δ8.51 (s, 1H), 8.0 (s, 1H), 7.41 (d, J = 2.4 Hz, 1H,), 6.79 (t, J = 1.2 Hz, 1H,), 3.85 (s, 3H), 2.51 (s, 3H). LC-MS calculated molecular weight 251.05, found m / z 252.2 [M+H] + .

[0529] Step 2: Methyl 1-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylate

[0530]

[0531] Dissolve in two To a solution of methyl 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylate (0.3 g, 0.1195 mmol) in 1,2-dioxane (10 mL) were added 2-chloro-4-fluoroaniline (0.17 g, 0.1195 mmol) and potassium carbonate (0.24 g, 1.17 mmol). The resulting reaction mixture was purged with nitrogen for 15 minutes, followed by the addition of (2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl) (0.074 g, 0.119 mmol) and palladium(dibenzylideneacetone)dipalladium(0) (0.054 g, 0.059 mmol). The reaction mixture was stirred at 100°C for 12 hours. The reaction mixture was diluted with ethyl acetate (200 mL) and filtered through a pad of celite. The pad was washed with ethyl acetate (2 x 50 mL). The filtrate was washed several times with cold water and then with brine. The organic layer was dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in hexanes as eluent to give methyl 1-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylate (0.25 g, 58%) as an off-white solid. 1 HNMR (400 MHz, CDCl3): δ8.40–8.36 (m, 2H), 7.95 (s, 1H), 7.51 (s, 1H), 7.40-7.34 (m, 1H), 7.19 -7.16 (m, 1H), 7.07–6.99 (m, 1H), 6.77-6.76 (m, 1H), 3.86 (s, 3H), 2.40 (s, 3H). LC-MS calculated molecular weight 360.08, found m / z 361.3 [M+H] + .

[0532] Step 3: 1-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylic acid

[0533] To a solution of methyl 1-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylate (0.25 g, 0.833 mmol) in methanol (20.0 mL) was added 2N sodium hydroxide solution (10 mL). The reaction mixture was stirred at 50°C for 2 h. The methanol was removed under reduced pressure, and the pH was adjusted to pH ~6.5-7 by adding dilute hydrochloric acid. The aqueous layer was extracted with ethyl acetate (3 x 50 mL), and the combined organic layers were dried over sodium sulfate, filtered, and evaporated under reduced pressure to yield 1-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylic acid (0.17 g, 71%) as an off-white solid. 1HNMR (400 MHz, DMSO-d6): δ 12.14 (s, 1H), 9.06 (s, 1H), 8.39 (s, 1H), 7.86 (s, 1H), 7.67-7.64 (m, 1H), 7.50-7.48 (m, 1H), 7.36 (t, J = 2.8 Hz, 1H), 7.24-7.19 (m, 1H), 6.57 (t, J = 2.0 Hz, 2H), 2.27 (s, 3H). LC-MS calculated molecular weight 346.06, found m / z 347.3 [M+H] + .

[0534] Step 4: (S)-1-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-3-carboxamide

[0535]

[0536] To a solution of 1-(2-(2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylic acid (0.05 g, 0.144 mmol) in NMP (2.0 mL) were added (S)-2-amino-2-(3-chlorophenyl)ethanol (0.029 g, 0.173 mmol), EDC (0.055 g, 0.288 mmol), and HOBt (0.005 g, 0.043 mmol). To the resulting reaction mixture was added triethylamine (0.04 g, 0.432 mmol) dropwise at room temperature. The reaction mixture was stirred at room temperature for 15 h. The reaction mixture was poured into cold water (10 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was dissolved in a small amount of DCM and diluted with diethyl ether. The solvent was transferred to another container. The resulting solid was washed with ether and n-pentane to give (S)-1-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-3-carboxamide (0.022 g, 31%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ8.99 (s, 1H), 8.37 (s, 1H), 8.25 (d, J=8.4 Hz, 1H), 7.95 (s, 1H), 7.69-7.65 (m, 1H), 7.49-7.41 (m, 1H), 7.37–7.18 (m, 6H), 6.75 (s, 1H), 5.04-4.99 (m, 1H), 4.92 (br s, 1H), 3.65-3.64 (m, 2H), 2.28 (s, 3H). LC-MS calculated molecular weight: 499.10, found: m / z 500.3 [M+H]. + ; HPLC purity: 99.03%, chiral HPLC: 99.66%.

[0537] Example 5: (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-(cyclopropylamino)-5-methylpyrimidin-4-yl)-1H-pyrazole-4-carboxamide (Compound #39).

[0538] Step 1: Methyl 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrazole-4-carboxylate

[0539]

[0540] To a solution of methyl 1H-pyrazole-4-carboxylate (1.00 g, 6.134 mmol) in acetonitrile (20 mL) was added potassium carbonate (2.543 g, 18.40 mmol), and the mixture was stirred at room temperature for 5 minutes. To this mixture was added 2,4-dichloro-5-methylpyrimidine (0.773 g, 6.134 mmol), and the mixture was stirred at 80°C overnight. The mixture was cooled, water (15 mL) was added, and the mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in n-hexane as the eluent to afford methyl 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrazole-4-carboxylate (0.65 g, 42%) as a colorless solid. 1HNMR (400MHz, CDCl3): δ9.08(s,1H),8.54(s,1H),8.15(s,1H),3.89(s,3H),2.67(s,3H).

[0541] Step 2: Methyl 1-(2-(cyclopropylamino)-5-methylpyrimidin-4-yl)-1H-pyrazole-4-carboxylate

[0542]

[0543] To a solution of methyl 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrazole-4-carboxylate (0.3 g, 1.18 mmol) in isopropanol (7 mL) was added DIPEA (0.43 mL, 2.47 mmol) and cyclopropylamine (0.09 mL, 1.3 mmol). The reaction mixture was stirred overnight at 85°C in a sealed glass tube. The reaction mixture was cooled, quenched with water (10 mL), and extracted with ethyl acetate (3 x 10 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in n-hexane as the eluent to afford methyl 1-(2-(cyclopropylamino)-5-methylpyrimidin-4-yl)-1H-pyrazole-4-carboxylate (0.17 g, 52%) as a colorless solid. 1HNMR (400 MHz, CDCl3): δ8.97 (s, 1H), 8.27 (s, 1H), 8.09 (s, 1H), 5.26 (s, 1H), 3.87 (s, 3H), 2.80-2.76 (m, 1H), 2.47 (s, 3H), 0.87-0.83 (m, 2H), 0.56 (t, J = 7.2 Hz, 2H). LC-MS calculated molecular weight 273.12, found m / z 274.6 [M+H] + .

[0544] Step 3: 1-(2-(Cyclopropylamino)-5-methylpyrimidin-4-yl)-1H-pyrazole-4-carboxylic acid

[0545]

[0546] To a stirred solution of methyl 1-(2-(cyclopropylamino)-5-methylpyrimidin-4-yl)-1H-pyrazole-4-carboxylate (0.2 g, 0.72 mmol) in THF (7 mL) and water (1 mL) was added lithium hydroxide monohydrate (0.306 g, 7.29 mmol). The reaction mixture was stirred at 50°C for 4 h. The mixture was cooled, concentrated under reduced pressure, and neutralized by adding 1N HCl (pH ~7). The resulting solid was filtered to provide 1-(2-(cyclopropylamino)-5-methylpyrimidin-4-yl)-1H-pyrazole-4-carboxylic acid (0.122 g, 65%) as a colorless solid. 1HNMR (400 MHz, DMSO-d6): δ12.0 (br s, 1H), 8.82 (s, 1H), 8.31 (s, 1H), 8.09 (s, 1H), 7.48 (s, 1H), 2.74-2.71 (m, 1H), 2.30 (s, 3H), 0.69-0.65 (m, 2H), 0.48-0.44 (m, 2H). LC-MS calculated molecular weight 259.11, found m / z 260.2 [M+H] + .

[0547] Step 4: (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-(cyclopropylamino)-5-methylpyrimidin-4-yl)-1H-pyrazole-4-carboxamide

[0548]

[0549] To a stirred solution of 1-(2-(cyclopropylamino)-5-methylpyrimidin-4-yl)-1H-pyrazole-4-carboxylic acid (0.035 g, 0.134 mmol) in NMP (0.8 mL) was added EDC (0.051 g, 0.26 mmol), HOBt (0.005 g, 0.04 mmol), and triethylamine (0.05 mL, 0.4 mmol). The mixture was stirred at room temperature for 10 minutes. To this mixture was added (S)-2-amino-2-(3-chlorophenyl)ethanol (0.027 g, 0.16 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with brine, dried over sodium sulfate, and evaporated under reduced pressure. The residue was purified by column chromatography using methanol in DCM as eluent to give (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-(cyclopropylamino)-5-methylpyrimidin-4-yl)-1H-pyrazole-4-carboxamide (0.011 g, 20%) as a colorless solid. 1H NMR (400 MHz, DMSO-d6): δ 9.00 (s, 1H), 8.61 (d, J = 8 Hz, 1H), 8.32 (s, 1H), 8.22 (s, 1H), 7.44 (d, J = 11.2 Hz, 2H), 7.36-7.27 (m, 3H), 5.07-5.01 (m, 1H), 4.98-4.95 (m, 1H), 3.66-3.65 (m, 2H), 2.76-2.73 (m, 1H), 2.34 (s, 3H), 0.68 (d, J = 5.2 Hz, 2H), 0.48 (d, J = 2.4 Hz, 2H). LC-MS calculated molecular weight: 412.14, found: m / z 413.2 [M+H]. + ; HPLC purity 99.32%, ChiralHPLC purity 99.76%.

[0550] Typical example of scheme 4:

[0551] Example 6: N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide (Compound #136).

[0552] Step 1: 1H-pyrrole-3-carboxylic acid methyl ester

[0553]

[0554] To a solution of 1H-pyrrole-3-carboxylic acid (4.3 g, 38.7 mmol) in methanol (40 mL) cooled to 0-5°C was added 6N HCl (9 mL). The mixture was stirred at room temperature for 5 minutes and then heated under reflux overnight. The reaction mixture was cooled, concentrated under reduced pressure, cooled to 0°C, and saturated sodium bicarbonate was added to adjust the pH to ~7. The mixture was extracted with ethyl acetate, and the organic layer was dried over sodium sulfate, filtered, and evaporated under reduced pressure to provide methyl 1H-pyrrole-3-carboxylate (4 g, 83%) as a brown solid. 1 HNMR (400 MHz, CDCl3): δ 8.56 (br s, 1H), 7.43 (s, 1H), 6.75 (s, 1H), 6.65 (s, 1H), 3.92 (s, 3H). LC-MS calculated molecular weight 125.05, found m / z 126.2 [M+H] + .

[0555] Step 2: 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylic acid methyl ester

[0556]

[0557] To a solution of 1H-pyrrole-3-carboxylic acid methyl ester (1.4 g, 11.2 mmol) in acetonitrile (50 mL) was added potassium carbonate (3.09 g, 22.4 mmol). The mixture was stirred at room temperature for 15 minutes, and 2,4-dichloro-5-methylpyrimidine (2.738 g, 16.8 mmol) was added. The resulting mixture was heated under reflux overnight. The reaction mixture was cooled, evaporated under reduced pressure, mixed with water, and extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in n-hexane as the eluent to afford 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylic acid methyl ester (1.2 g, 43%) as a white solid. 1 HNMR (400 MHz, CDCl3): δ8.50 (s, 1H), 7.99 (s, 1H), 7.40-7.39 (m, 1H), 6.78-6.77 (m, 1H), 3.85 (s, 3H), 2.51 (s, 3H). LC-MS calculated molecular weight 251.05, found m / z 252.3 [M+H] + .

[0558] Step 3: 1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylic acid methyl ester

[0559]

[0560] Dissolve in two To a solution of methyl 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylate (3.1 g, 12.31 mmol) in 1,2-dioxane (20 mL) were added potassium carbonate (2.549 g, 18.47 mmol), 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (0.766 g, 1.231 mmol), and 2,2-difluorobenzo[d][1,3]dioxol-5-amine (2.23 g, 12.92 mmol). The reaction mixture was degassed with argon for 15 minutes, and tris(dibenzylideneacetone)dipalladium(0) (0.563 g, 0.615 mmol) was added. The resulting mixture was stirred in a sealed glass tube at 100°C for 9 hours. The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. The residue was dissolved in water and extracted with ethyl acetate. The combined organic phases were washed with water and brine. The combined organic phases were dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in n-hexane as the eluent to afford methyl 1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylate (2.3 g, 48%) as an off-white solid. 1 HNMR (400 MHz, CDCl3): δ8.34 (s, 1H), 7.95 (s, 1H), 7.69 (d, J = 1.6 Hz, 1H), 7.34 (t, J = 2.8 Hz, 1H), 7.23 (s, merged with CDCl3 peak, 1H), 7.06–6.99 (m, 2H), 6.78–6.77 (m, 1H), 3.86 (s, 3H), 2.40 (s, 3H). LC-MS calculated molecular weight 388.10, found m / z 389.3 [M+H] + .

[0561] Step 4: 1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylic acid

[0562]

[0563] To a solution of methyl 1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylate (1.0 g, 2.5 mmol) in THF (40 mL) and water (20 mL) was added lithium hydroxide monohydrate (0.648 g, 15.4 mmol). The resulting mixture was heated to reflux at 70°C for 12 h. The reaction mixture was cooled, concentrated under reduced pressure, and adjusted to pH ~6 by adding 1N HCl. The solid was filtered and washed with n-pentane and diethyl ether to afford 1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylic acid (0.85 g, 88%) as a white solid. 1 HNMR (400 MHz, DMSO-d6): δ 11.98 (br s, 1H), 9.58 (s, 1H), 8.38 (s, 1H), 7.94-7.82 (m, 2H), 7.36 (d, 2H J = 8 Hz), 7.0 (d, 1H J = 8.4 Hz), 6.69 (s, 1H), 2.38 (s, 3H). LC-MS calculated molecular weight 374.08, found m / z 375.1 [M+H] + .

[0564] Step 5: N-((3-chlorophenyl)(cyano)methyl)-1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide

[0565]

[0566] To a solution of 1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxylic acid (0.2 g, 0.53 mmol) in DCM (15 mL) and THF (3 mL) was added triethylamine (0.2 mL, 1.6 mmol). The mixture was stirred under a nitrogen atmosphere for 5 minutes. 2-amino-2-(3-chlorophenyl)acetonitrile (0.1 g, 0.64 mmol), EDC (0.2 g, 1.06 mmol), and HOBt (0.021 g, 0.16 mmol) were then added to the mixture. The resulting mixture was stirred at room temperature overnight. The reaction mixture was quenched with water and extracted with DCM. The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in n-hexane as eluent to give N-((3-chlorophenyl)(cyano)methyl)-1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide (0.1 g, 36%) as a white solid. 1HNMR (400 MHz, CDCl3): δ8.35 (s, 1H), 7.95 (s, 1H), 7.6 (s, 1H), 7.56 (s, 1H), 7.4 (d, J = 6.8 Hz, 1H), 7.41-7.38 (m, 3H), 7.0-6.99 (m, 2H), 6.6 (s, 1H), 6.4 (d, J = 8.8 Hz, 2H), 6.34 (d, J = 8.8 Hz, 2H), 2.4 (s, 3H). LC-MS calculated molecular weight 522.10, found m / z 523.2 [M+H] + ,HPLC purity 98.03%.

[0567] Step 6: N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((2,2-difluorobenzo[1][1,3]dioxol-5-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide

[0568]

[0569] To a solution of N-(3-chlorophenyl)(cyano)methyl)-1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide (0.1 g, 0.191 mmol) in methanol (10 mL) was added methanolamine (20 mL) followed by Raney nickel (0.05 g) at 0°C. The resulting reaction mixture was stirred at room temperature under a hydrogen atmosphere provided by a balloon overnight. The reaction mixture was filtered through celite and the filtrate was evaporated under reduced pressure. The residue was purified by gradient column chromatography using methanol in DCM as eluent to afford N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((2,2-difluorobenzo[I][1,3]dioxol-5-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide as an off-white solid (0.03 g, 30%). 1HNMR (400 MHz, CDCl3): δ8.34 (s, 1H), 7.95 (s, 1H), 7.69 (d, J = 1.6 Hz, 1H), 7.34 (t, J = 2.8 Hz, 1H), 7.23 (s, merged with CDCl3 peak, 1H), 7.06–6.99 (m, 2H), 6.78–6.77 (m, 1H), 3.86 (s, 3H), 2.40 (s, 3H). LC-MS calculated molecular weight 526.13, found m / z 527.5 [M+H] + .

[0570] Example 7: N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (Compound #225).

[0571] Step 1: 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylic acid methyl ester

[0572]

[0573] To a solution of 1H-imidazole-4-carboxylic acid methyl ester (10.37 g, 74.0 mmol) in acetonitrile (200 mL) were added 2,4-dichloro-5-methylpyrimidine (10 g, 61.7 mmol) and potassium carbonate (25.5 g, 185.2 mmol). The mixture was stirred at room temperature under an inert atmosphere for 16 h. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in hexane as the eluent to afford 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylic acid methyl ester (11 g, 75%) as a white solid. 1HNMR (400 MHz, DMSO-d6): δ8.88 (s, 1H), 8.38 (s, 2H), 3.80 (s, 3H), 2.41 (s, 3H). LC-MS calculated molecular weight 252.04, found m / z 253.2 [M+H] + .

[0574] Step 2: Methyl 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylate

[0575] To a solution of 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylate (5 g, 19.7 mmol) in isopropanol (30 mL) was added DIPEA (7.658 g, 59.0 mmol) and tetrahydro-2H-pyran-4-amine (2.402 g, 23.0 mmol). The resulting mixture was stirred in a sealed glass tube at 100°C for 17 h. The reaction mixture was cooled to room temperature and crystallized. The crystals were filtered, washed with hexane, and dried under vacuum to give methyl 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylate (5.2 g, 83%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ 8.36 (s, 1H), 8.30 (s, 1H), 8.27 (s, 1H), 7.39 (d, J = 7.6 Hz, 1H), 3.90-3.83 (m, 3H), 3.78 (s, 3H), 3.37 (t, J = 11.6 Hz, 2H), 2.16 (s, 3H), 1.82 (d, J = 12 Hz, 2H), 1.54–1.45 (m, 2H). LC-MS accurate molecular weight calculated value 317.15, found value m / z 318.2[M+H] + .

[0576] Step 3: N-((3-chlorophenyl)(cyano)methyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide

[0577]

[0578] To a solution of methyl 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylate (0.500 g, 1.57 mmol) in toluene (20 mL) was added 2-amino-2-(3-chlorophenyl)acetonitrile (0.392 g, 2.3 mmol) and trimethylaluminum (2 M solution in toluene; 1.96 mL, 2.5 eq). The resulting mixture was stirred at 100°C under CEM microwave conditions for 1 h. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with cold water, dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified twice by gradient column chromatography using methanol dissolved in DCM as the eluent to give N-((3-chlorophenyl)(cyano)methyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide (0.29 g) as a yellow solid. LC-MS exact molecular weight calculated value 451.15, found value m / z 452.2 [M+H] + .

[0579] Step 4: N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide

[0580]

[0581] To a solution of N-((3-chlorophenyl)(cyano)methyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (0.700 g, 1.54 mmol) in methanol (15 mL) was added nickel chloride hexahydrate (0.552 g, 2.3 mmol) under an inert atmosphere at 0°C. The mixture was stirred to obtain a clear solution. Sodium borohydride (0.175 g, 4.6 mmol) was slowly added to the reaction mixture at 0°C, and the mixture was stirred at 0°C for 10 minutes. The reaction mixture was filtered through celite, and the filtrate was evaporated under reduced pressure. The residue was purified by gradient column chromatography using methanol in dichloromethane as eluent to give N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide (racemic mixture) as an off-white solid (0.050 g, 7%), which was directly used for chiral HPLC separation. Data for a separate batch prepared in a similar manner were obtained as follows: 1H NMR (400 MHz, DMSO-d6): δ 8.53 (d, J = 8 Hz 1H), 8.32 (s, 1H), 8.25 (s, 1H), 8.06 (s, 1H), 7.40 (s, 1H), 7.32-7.27 (m, 4H), 4.98-4.88 (m, 1H), 3.83-3.81 (m, 3H), 3.37-3.35 (m, 2H), 2.95-2.88 (m, 2H), 2.16 (s, 3H), 1.79 (d, J = 11.2 Hz, 2H), 1.50-1.40 (m, 2H). LC-MS exact molecular weight calculated value 455.18, found value m / z 456.5 [M+H] + .

[0582] Example 8a: Enantiomer #1, (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide; and

[0583] Example 8b: Enantiomers, (R)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (Compound #225a and Compound #225b, respectively).

[0584] Racemic N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-carboxamide (50 mg) was dissolved in 1 mL of 50:50 methanol / DCM and subjected to chiral HPLC purification using An IA column (250 mm × 4.6 mm × 5 μm) was used with a mobile phase of 100% isopropanol-0.01% diethylamine at a flow rate of 1 mL / min. The two enantiomers were separated by collection and evaporation to yield 12 mg (48% recovery) of Enantiomer #1 ((S), Compound 225a) as the first-eluting enantiomer and 10 mg (40% recovery) of Enantiomer #2 ((R), Compound 225b) as the second-eluting counterpart, with enantiomeric excesses of >98.1% and >98.7%, respectively.

[0585] Example 8a, Compound 225a (Enantiomer #1, (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide): 1H NMR (400 MHz, DMSO-d6): δ 8.58 (d, J = 6.8 Hz, 1H), 8.33 (s, 1H), 8.27 (s, 1H), 8.07 (s, 1H), 7.41 (s, 1H), 7.36–7.28 (m, 4H), 4.97 (br s, 1H), 3.84-3.82 (m, 3H), 3.38–3.33 (m, 2H), 3.01–2.94 (m, 2H), 2.16 (s, 3H), 1.80 (d, J=11.6 Hz, 2H), 1.52–1.44 (m, 2H). LC-MS calculated molecular weight: 455.18, observed value: m / z 456.2 [M+H] + .

[0586] Example 8b, Compound 225b (Enantiomer #2, (R)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide): 1H NMR (400 MHz, DMSO-d6): δ 8.58 (d, J = 8 Hz, 1H), 8.33 (s, 1H), 8.27 (s, 1H), 8.07 (s, 1H), 7. 42 (s, 1H), 7.36–7.27 (m, 4H), 5.02–4.91 (m, 1H), 3.84-3.82 (m, 3H), 3.35 (m, 2H), 3.05–2.91 (m, 2H), 2.16 (s, 3H), 1.79 (d, J=11.6 Hz, 2H), 1.51–1.4 (m, 2H). LC-MS calculated molecular weight: 455.18, observed value: m / z 456.2 [M+H] + .

[0587] Typical example of scheme 5:

[0588] Example 9: 1-(2-((4-Fluorophenyl)amino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-2-methyl-1H-imidazole-4-carboxamide (Compound #153).

[0589] Step 1: 1-(2-chloro-5-methylpyrimidin-4-yl)-2-methyl-1H-imidazole-4-carbaldehyde

[0590]

[0591] A mixture of 2,4-dichloro-5-methylpyrimidine (2.50 g, 15.33 mmol), 2-methyl-1H-imidazole-4-carbaldehyde (1.85 g, 16.87 mmol), and potassium carbonate (4.65 g, 33.74 mmol) dissolved in DMF (30 mL) was stirred at room temperature for 18 h. The mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The organic layer was dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (100-200 mesh) using 80-90% ethyl acetate in hexane as the eluent to provide 1-(2-chloro-5-methylpyrimidin-4-yl)-2-methyl-1H-imidazole-4-carbaldehyde (0.5 g, 15%). 1HNMR (400 MHz, DMSO-d6): δ9.76 (s, 1H), 8.99 (s, 1H), 8.40 (s, 1H), 2.35 (s, 1H), 2.22 (s, 3H). LC-MS: calculated molecular weight 236.05, observed m / z 237.07 [M+H]+ , purity: 99.23%.

[0592] Step 2: 1-(2-chloro-5-methylpyrimidin-4-yl)-2-methyl-1H-imidazole-4-carboxylic acid

[0593]

[0594] To a solution of 1-(2-chloro-5-methylpyrimidin-4-yl)-2-methyl-1H-imidazole-4-carbaldehyde (0.5 g, 2.11 mmol) in t-butanol (1.5 mL) and THF (7 mL) was added 2-methyl-2-butanol at room temperature. Sodium chlorite (1.87 g, 20.7 mmol) and sodium dihydrogen phosphate solution (1.5 g, 12.28 mmol) dissolved in water (5 mL) were slowly added to the mixture. After TLC indicated the reaction was complete, the mixture was diluted with water (25 mL) and washed with ethyl acetate (2 x 10 mL). The aqueous layer was concentrated under vacuum and extracted with 10% methanol in DCM (3 x 50 mL). The organic layer was concentrated under reduced pressure to yield 1-(2-chloro-5-methylpyrimidin-4-yl)-2-methyl-1H-imidazole-4-carboxylic acid (0.70 g) as a white solid. LC-MS accurate molecular weight calculated value 252.04, experimental value m / z 253.0 [M+H] + .

[0595] Step 3: 1-(2-chloro-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-2-methyl-1H-imidazole-4-carboxamide

[0596] To a solution of 1-(2-chloro-5-methylpyrimidin-4-yl)-2-methyl-1H-imidazole-4-carboxylic acid (0.5 g, 1.98 mmol) and triethylamine (0.5 mL, 3.96 mmol) in DCM was slowly added (DL)-2-amino-2-phenylethan-1-ol (0.288 g, 2.18 mmol). T3P (2.5 mL, 3.96 mmol, 50% solution in ethyl acetate) was added to the mixture and stirred at room temperature for 18 h. After TLC indicated the reaction was complete, the mixture was quenched with water (30 mL). The mixture was extracted with DCM (3 x 30 mL), and the organic layer was washed with brine, dried over sodium sulfate, and evaporated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (230-400 mesh) using 5% MeOH in DCM as eluent to give 1-(2-chloro-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-2-methyl-1H-imidazole-4-carboxamide as an off-white solid (0.580 g, 79%). 1H NMR (400 MHz, DMSO-d6): δ 8.95 (s, 1H), 8.26 (d, J = 8.4 Hz, 1H), 7.98 (s, 1H), 7.36-7.35 (m, 2H), 7.33-7.34 (m, 3H), 7.22-7.21 (m, 1H), 5.02-4.98 (m, 2H), 3.74-3.69 (m, 2H), 2.36 (s, 3H), 2.21 (s, 3H). LC-MS calculated molecular weight 371.11, found m / z 372.0 [M+H] + .

[0597] Step 4: 1-(2-((4-Fluorophenyl)amino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-2-methyl-1H-imidazole-4-carboxamide

[0598]

[0599] Dissolve two in the glass tube A mixture of 1-(2-chloro-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-2-methyl-1H-imidazole-4-carboxamide (0.5 g, 1.42 mmol), 4-fluoroaniline (0.173 g, 1.56 mmol), and potassium carbonate (0.39 g, 2.84 mmol) in 1% paraffin (20 mL) was purged with argon for 10 minutes. Tris(dibenzylideneacetone)dipalladium(0) (0.130 g, 0.142 mmol) and BINAP (0.0.089 g, 0.142 mmol) were added to the reaction mixture, which was then purged with argon for another 10 minutes. The mixture was heated at 90°C in a sealed glass tube for 6 hours. After completion of the reaction, the reaction mixture was cooled, diluted with water, and extracted with ethyl acetate (3 x 100 mL). The organic layer was dried over sodium sulfate and evaporated, and the residue was purified by flash column chromatography on silica gel (230-400 mesh) using 80% ethyl acetate in hexane as eluent to give 1-(2-((4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-2-methyl-1H-imidazole-4-amide (0.109 g, 17%) as a white solid. 1H NMR (400 MHz, DMSO-d6): δ9.89 (s, 1H), 8.60 (s, 1H), 8.21 (d, J = 8.4 Hz, 1H), 7.92 (s, 1H), 7.70-7.67 (m, 2H), 7.37 (d, J = 7.2 Hz, 2H), 7.31 (t, J = 7.2 Hz, 2H), 7.24 (d, J = 7.2 Hz, 1H), 7.16 (t, J = 8.8 Hz, 2H), 5.02 (d, J = 4.8 Hz, 2H), 3.77-3.69 (m, 2H), 2.35 (s, 3H), 2.03 (s, 3H). LC-MS calculated molecular weight: 446.19, found: m / z 447.52 [M+H]. + , purity: 96.12%.

[0600] Typical example of scheme 6:

[0601] Example 10: N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(((S)-tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-4-carboxamide (Compound #192).

[0602] Step 1: 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylic acid methyl ester

[0603]

[0604] To a stirred solution of methyl 1H-imidazole-4-carboxylate (7 g, 42.9 mmol) in acetonitrile (50 mL) was added potassium carbonate (11.87 g, 85.88 mmol). The mixture was stirred at room temperature, and 2,4-dichloro-5-methylpyrimidine (5.41 g, 42.9 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was mixed with water (50 mL) and extracted with ethyl acetate (3 x 150 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in n-hexane as the eluent to afford methyl 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylate (4.5 g, 41%) as a white solid. 1HNMR (400 MHz, DMSO-d6): δ8.88 (s, 1H), 8.38 (s, 1H), 3.8 (s, 3H), 2.41 (s, 3H). LC-MS calculated molecular weight 252.04, found m / z 253.2 [M+H] + .

[0605] Step 2: (S)-methyl 1-(5-methyl-2-((tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylate

[0606] To a solution of methyl 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylate (0.6 g, 2.37 mmol) in isopropanol (30 mL) was added (S)-tetrahydrofuran-3-amine (0.310 g, 3.56 mmol) and DIPEA (1.53 g, 11.8 mmol). The mixture was stirred in a sealed glass tube at 100°C for 36 h. The mixture was cooled, concentrated under reduced pressure, diluted with water (50 mL), and extracted with ethyl acetate (2 x 100 mL). The organic layer was washed with brine (5 mL), dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in hexanes as eluent to afford (S)-methyl 1-(5-methyl-2-((tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylate (0.45 g, 63% yield) as a white solid. 1HNMR (400 MHz, CDCl3): δ8.28 (s, 1H), 8.16 (d, J = 2.4 Hz, 2H,), 5.47 (s, 1H), 4.56 (s, 1H), 4.0-3.88 (m, 5H), 3.87-3.85 (m, 1H), 3.75-3.71 (m, 1H), 2.31 (s, 3H), 2.36-2.33 (m, 1H), 1.92-1.85 (m, 2H), LC-MS accurate molecular weight calculated value 303.13, found value m / z 304.4 [M+H] + .

[0607] Step 3: N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(((S)-tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide

[0608]

[0609] To a stirred solution of (S)-methyl-1-(5-methyl-2-(tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylate (0.45 g, 1.48 mmol) in toluene (25 mL) at 0°C in a CEM microwave vial was added (S)-2-amino-2-(3-chlorophenyl)ethanol (0.509 g, 2.96 mmol) and trimethylaluminum (2M solution in toluene; 2.2 mL, 4.45 mmol). The vial was sealed and the reaction mixture was stirred at 100°C in a CEM microwave for 2 h. The mixture was cooled, quenched with water, and extracted with ethyl acetate (3 x 200 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using methanol in DCM as eluent to give N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(S)-tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (0.23 g, 35%) as a white solid. 1H NMR (400 MHz, DMSO-d6): δ 8.38 (t, J = 8.4 Hz, 2H) 8.29 (s, 1H), 8.11 (s, 1H), 7.60 (d, J = 5.2 Hz, 1H), 7.43 (s, 1H), 7.31 (d, J = 15.6 Hz, 3H), 5.02 (d, J = 5.2 Hz, 2H), 4.34 (s, 1H), 3.87-3.78 (m, 2H), 3.72-3.67 (m, 3H), 3.55-3.28 (m, 1H), 2.19 (s, 3H), 2.19-2.08 (m, 1H), 1.89-1.85 (m, 1H). LC-MS calculated molecular weight: 442.15, found: m / z 443.5 [M+H]. + HPLC purity 99.2%, chiral HPLC purity 99.7%; mp 117℃.

[0610] Example 11: N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)-amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (Compound #201).

[0611] Step 1: 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylic acid methyl ester

[0612]

[0613] To a stirred solution of 1H-imidazole-4-carboxymethyl ester (2.32 g, 18.4 mmol) in acetonitrile (75 mL) was added potassium carbonate (5.08 g, 36.8 mmol). The reaction mixture was stirred at room temperature for 5 minutes, followed by the addition of 2,4-dichloro-5-methylpyrimidine (2 g, 18.4 mmol). The resulting mixture was stirred at room temperature overnight. The mixture was quenched with water (50 mL) and extracted with ethyl acetate (3 x 150 mL). The combined organic layers were dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in n-hexane as the eluent to afford methyl 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylate (53.7%) as an off-white solid. 1 HNMR (400 MHz, CDCl3): δ 8.63 (s, 1H), 8.25 (d, J = 5.2 Hz, 2H), 3.95 (s, 3H), 2.52 (s, 3H). LC-MS calculated molecular weight 252.04, found m / z 253.1 [M+H] + .

[0614] Step 2: Methyl 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylate

[0615]

[0616] To a solution of 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylate (0.27 g, 1.07 mmol) in isopropanol (5 mL) was added DIPEA (0.58 mL, 3.21 mmol) and tetrahydro-2H-pyran-4-amine (0.16 mL, 1.60 mmol). The resulting mixture was stirred at 100°C in a sealed glass tube for 20 h. The reaction mixture was quenched with water (10 mL) and extracted with ethyl acetate (50 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using methanol in DCM as eluent to afford methyl 1-(5-methyl-2-(tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylate (0.25 g, 76%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ8.35 (s, 1H), 8.29 (s, 1H), 8.26 (s, 1H), 7.38 (d, J = 7.6 Hz, 1H), 3.85-3.82 (m, 3H), 3.77 (s, 3H), 3.37 (t, J = 10 Hz, 2H), 2.15 (s, 3H), 1.80 (d, J = 10.4 Hz, 2H), 1.50-1.46 (m, 2H). LC-MS calculated molecular weight 317.15, found m / z 318.4 [M+H] + .

[0617] Step 3: N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)-amino)pyrimidin-4-yl)-1H-imidazole-4-amide

[0618]

[0619] To a solution of methyl 1-(5-methyl-2-(tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylate (0.1 g, 0.315 mmol) in toluene (10 mL) was added 2-amino-2-(3-chlorophenyl)ethanol (0.10 g, 0.63 mmol) and trimethylaluminum (2 M solution in toluene; 0.78 mL, 1.57 mmol). The resulting mixture was stirred at 100°C under CEM microwave conditions for 1.5 h. The mixture was cooled, quenched with water (10 mL), and extracted with ethyl acetate (50 mL). The organic layer was washed with water (10 mL), dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using methanol in DCM as eluent to give N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)-amino)pyrimidin-4-yl)-1H-imidazole-4-amide (0.12 g, 86%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ8.41 (d, J=7.8 Hz, 1H), 8.34 (s, 1H), 8.28 (s, 1H), 8.09 (s, 1H), 7.42 (s, 1H), 7.38 (d, J=9.6 Hz, 1H), 7.32-7.27 (m, 3H), 5.05-4.98 (m, 2H), 3.85-3.77 (m, 3H), 3.71 (t, J=4 Hz, 2H), 3.38 (t, J=8 Hz, 2H), 2.16 (s, 3H), 1.80 (d, J=11.2 Hz, 2H), 1.51-1.44 (m, 2H). LC-MS calculated molecular weight: 456.17, found: m / z 457.5 [M+H]. + ; HPLC purity 99.53%.

[0620] Example 12: (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (Compound #211).

[0621] Step 1 and Step 2: The steps are similar to those described in Example 11.

[0622] Step 3: (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide

[0623]

[0624] To a solution of methyl 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylate (0.07 g, 0.22 mmol) in toluene (2 mL) was added (S)-2-amino-2-(3-chlorophenyl)ethanol (0.075 g, 0.44 mmol) and trimethylaluminum (2 M solution in toluene; 0.22 mL, 0.44 mmol). The resulting mixture was stirred at 100°C under CEM microwave conditions for 1.5 h. The mixture was cooled, quenched with water (10 mL), and extracted with ethyl acetate (50 mL). The organic layer was washed with water (10 mL), dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using methanol in DCM as eluent and the isolated product was eluted with n-pentane to give (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide (0.060 g, 60%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ 8.39 (d, J = 8 Hz, 1H), 8.34 (s, 1H), 8.28 (s, 1H), 8.09 (s, 1H), 7.43 (s, 1H), 7.37-7.32 (m, 3H), 7.29 (br s, 1H), 5.02 (d, J = 8 Hz, 2H), 3.85-3.82 (m, 3H), 3.72 (t, J = 8 Hz, 2H), 3.39-3.26 (m, 2H), 2.17 (s, 3H), 1.81 (d, J = 8 Hz, 2H), 1.48 (d, J = 8 Hz, 2H). LC-MS calculated molecular weight: 456.17, found: m / z 457.2 [M+H]. + HPLC purity 99.81%, chiral HPLC purity 99.92%; mp 145℃.

[0625] Typical examples of the combination of methods used in schemes 4 and 3:

[0626] Example 13: N-(3-chloro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (Compound #93).

[0627] Step 1 and Step 2: The steps are similar to those described in Example 11.

[0628] Step 3: 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylic acid

[0629]

[0630] To a stirred solution of methyl 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylate (1.5 g, 4.731 mmol) in tetrahydrofuran (30 mL) at 0°C was added potassium trimethylsilanol (1.82 g, 14.18 mmol). The reaction mixture was stirred at 45°C for 1.5 h, then quenched with water (25 mL) and washed with ethyl acetate (2 x 10 mL). The aqueous layer was adjusted to pH ~5-6 by adding 4N HCl solution. The aqueous layer was extracted with ethyl acetate (3 x 60 mL), and the combined organic layers were concentrated under reduced pressure to afford 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylic acid (1.2 g, 84%) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6): δ 12.47 (br s, 1H), 8.33 (s, 1H), 8.23 ​​(br s, 1H), 8.20 (s, 1H), 7.36 (d, J = 7.6 Hz, 1H), 3.88 (br s, 1H), 3.83 (d, J = 11.6 Hz, 2H), 3.36 (t, J = 10.8 Hz, 2H), 2.15 (s, 3H), 1.80 (d, J = 10.4 Hz, 2H), 1.52-1.42 (m, 2H). LC-MS calculated molecular weight 303.13, found m / z 304.4 [M+H] + .

[0631] Step 4: Methyl 2-(bromomethyl)-6-chlorobenzoate

[0632]

[0633] To a solution of methyl 2-chloro-6-methylbenzoate (1 g, 5.4 mmol) in carbon tetrachloride (50 mL) was added N-bromosuccinimide (1 g, 5.9 mmol) and benzoyl peroxide (0.131 g, 0.5 mmol). The resulting mixture was stirred at 80°C for 10 h. The reaction mixture was filtered through celite and the filtrate was evaporated under reduced pressure to give methyl 2-(bromomethyl)-6-chlorobenzoate (1.2 g). LC-MS calculated molecular weight: 261.94, observed m / z: 263.0 [M+H]. + .

[0634] Step 5: Methyl 2-(azidomethyl)-6-chlorobenzoate

[0635]

[0636] To a solution of methyl 2-(bromomethyl)-6-chlorobenzoate (1 g, 3.8 mmol) in DMF (10 mL) was added sodium azide (0.494 g, 7.6 mmol) at 0°C. The resulting mixture was stirred at 70°C for 12 h. The reaction mixture was diluted with ice water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered, and evaporated under reduced pressure to give methyl 2-(azidomethyl)-6-chlorobenzoate (1.2 g). LC-MS calculated exact molecular weight: 225.03, observed m / z: 198.1 [M+H-N2]. + .

[0637] Step 6: (2-(Aminomethyl)-6-chlorophenyl)methanol

[0638]

[0639] To a solution of methyl 2-(azidomethyl)-6-chlorobenzoate (0.5 g, 2.2 mmol) in tetrahydrofuran (10 mL) was slowly added lithium aluminum hydride (0.337 g, 8.8 mmol) at 0°C. The resulting mixture was stirred at room temperature for 12 h. The reaction mixture was diluted with ice water (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered, and evaporated under reduced pressure to give (2-(aminomethyl)-6-chlorophenyl)methanol (0.4 g). LC-MS calculated exact molecular weight: 171.05, observed m / z: 172.1 [M+H] + .

[0640] Step 7: N-(3-chloro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide

[0641]

[0642] To a solution of 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylic acid (0.1 g, 0.3 mmol) in DCM (10 mL) was added (2-(aminomethyl)-6-chlorophenyl)methanol (0.84 g, 0.4 mmol) and DIPEA (0.17 mL, 0.9 mmol), followed by T3P (0.24 mL, 0.8 mmol). The resulting mixture was stirred at room temperature for 6 h. The reaction mixture was diluted with ice water (50 mL) and extracted with DCM (2 x 100 mL). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified on Biotage Isolera using methanol in DCM as eluent to give N-(3-chloro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide as an off-white solid (0.43 g, 29%). H NMR (400 MHz, DMSO-d6): δ 8.62 (t, J = 6 Hz, 1H), 8.33 (s, 1H), 8.25 (s, 1H), 8.10 (s, 1H), 7.36-7.23 (m, 4H), 5.24 (t, J = 5.0 Hz, 1H), 4.76 (d, J = 5.2 Hz, 2H), 4.61 (d, J = 6 Hz, 2H), 3.9 (br s, 1H), 3.83 (d, J = 11.2 Hz, 2H), 3.36 (t, J = 11.0 Hz, 2H), 2.17 (s, 3H), 1.80 (d, J = 11.6 Hz, 2H), 1.52-1.43 (m, 2H). LC-MS calculated molecular weight: 456.17, found: m / z 457.0 [M+H]. + ; HPLC purity 99.05%.

[0643] Typical example of scheme 7:

[0644] Example 14: N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-carboxamide (Compound #77).

[0645] Step 1: 4-Bromo-N-phenylpyridin-2-amine

[0646]

[0647] Dissolve in 1,4-dichlorobenzene A solution of 4-bromopyridin-2-amine (1.0 g, 5.7 mmol), iodobenzene (2.35 g, 11.56 mmol), and cesium carbonate (8.82 g, 24.855 mmol) in dextrin was degassed with argon for 30 minutes. 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (0.66 g, 1.156 mmol) and tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct (0.528 g, 0.578 mmol) were added. The resulting mixture was stirred at 150°C in a sealed glass tube for 12 hours. The reaction mixture was cooled, combined with water (50 mL), and extracted with ethyl acetate (3 x 200 mL). The combined organic layers were washed with water (100 mL) and brine (50 mL), dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate dissolved in n-hexane as the eluent to afford 4-bromo-N-phenylpyridin-2-amine (0.81 g, 56%) as a yellow solid. LC-MS calculated molecular weight values ​​were 247.99 and 249.99, and the observed value was m / z 251.1 [M+H]. + .

[0648] Step 2: Methyl 1-(2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-carboxylate

[0649]

[0650] To a solution of 4-bromo-N-phenylpyridin-2-amine (0.5 g, 2.00 mmol) in DMF (3 mL) was added methyl 1H-imidazole-4-carboxylate (0.37 g, 3.01 mmol) and potassium phosphate (2.12 g, 10.00 mmol). The mixture was degassed with argon for 15 minutes, and copper (I) iodide (0.076 g, 0.40 mmol) and L-proline (0.046 g, 0.40 mmol) were added. The resulting mixture was stirred in a sealed glass tube at 150°C for 12 hours. The reaction mixture was cooled, mixed with water (30 mL), and extracted with ethyl acetate (50 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in n-hexane as eluent to give methyl 1-(2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-carboxylate (0.15 g, 25%) as a colorless solid. 1HNMR (400 MHz, DMSO-d6): δ9.18 (s, 1H), 8.45 (d, J = 11.6 Hz, 2H), 8.25 (d, J = 5.6 Hz, 1H), 7.64 (d, J = 8 Hz, 2H), 7.28 (t, J = 7.2 Hz, 2H), 7.15 (d, J = 4 Hz, 1H), 7.03 (s, 1H), 6.93 (t, J = 6.8 Hz, 1H), 3.79 (s, 3H) LC-MS calculated molecular weight 294.11, found m / z 295.2 [M+H] + .

[0651] Step 3: 1-(2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-carboxylic acid

[0652]

[0653] To a solution of methyl 1-(2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-carboxylate (0.1 g, 0.77 mmol) in THF (6 mL) and water (6 mL) was added lithium hydroxide monohydrate (0.057 g, 1.36 mmol). The resulting mixture was stirred at room temperature for 6 h. The mixture was evaporated under reduced pressure and adjusted to pH ~6 by adding 1N HCl. The resulting solid was removed by filtration, washed with water (5 mL), and then dried under reduced pressure to afford 1-(2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-carboxylic acid (0.08 g, 88%) as a colorless solid. 1H NMR (400 MHz, DMSO-d6): δ12 (br s, 1H), 9.30 (s, 1H), 8.42 (s, 1H), 8.37 (s, 1H), 8.24 (d, J = 5.6 Hz, 1H), 7.64 (d, J = 8 Hz, 2H), 7.28 (t, J = 7.6 Hz, 2H), 7.17 (d, J = 1.6 Hz, 1H), 7.06 (s, 1H), 6.94 (t, J = 7.2 Hz, 1H). LC-MS calculated molecular weight 280.10, found m / z 281.1 [M+H] + .

[0654] Step 4: N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-amide

[0655] To a solution of 1-(2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-carboxylic acid (0.04 g, 0.178 mmol) in DCM (6 mL) and DMF (0.2 mL) were added triethylamine (0.053 mL, 0.534 mmol), EDC (0.068 g, 0.356 mmol), and HOBt (0.007 g, 0.053 mmol). The reaction mixture was stirred at room temperature for 15 minutes, and 2-amino-2-(3-chlorophenyl)ethanol (0.036 g, 0.213 mmol) was added. The mixture was stirred at room temperature for 12 hours. The reaction mixture was mixed with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate under reduced pressure, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using methanol in DCM as eluent to give N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-amide as a white solid (0.015 g, 24%). 1H NMR (400 MHz, DMSO-d6): δ9.17 (s, 1H), 8.45 (s, 1H), 8.40 (d, J = 8.4 Hz, 1H), 8.24 (d, J = 7.6 Hz, 2H), 7.64 (d, J = 7.6 Hz, 2H), 7.42 (s, 1H), 7.32-7.28 (m, 2H), 7.27-7.25 (m, 3H), 7.15 (d, J = 5.6 Hz, 1H), 7.02 (s, 1H), 6.92 (t, J = 7.2 Hz, 1H), 5.04-4.99 (m, 2H), 3.73 (t, J = 5.6 Hz, 2H). LC-MS calculated molecular weight: 433.13, found: m / z 434.2 [M+H]. + .HPLC purity 99.52%; mp 130.0℃.

[0656] Typical example of scheme 8:

[0657] Example 15: 1-(2-(Benzo[d][1,3]dioxol-5-ylamino)-5-methylpyrimidin-4-yl)-N-(1-(3,5-dichlorophenyl)-2-hydroxyethyl)-1H-pyrrole-3-carboxamide (Compound #74).

[0658] Step 1: 2-Chloro-5-methylpyridine 1-oxide

[0659]

[0660] To a solution of 2-chloro-5-methylpyridine (2.0 g, 15.7 mmol) in CHCl₃ (20 mL) was added portionwise m-chloroperbenzoic acid (3.2 g, 18.89 mmol), and the mixture was heated at 50°C for 16 h. The reaction mixture was cooled to -10°C, and the solid was filtered through celite. The filtrate was evaporated, and the residue was purified by column chromatography on silica gel using 80% ethyl acetate in hexane as the eluent to give 2-chloro-5-methylpyridine 1-oxide (1.9 g, 84%). 1H NMR (400 MHz, DMSO-d₆): δ 8.33 (s, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 2.22 (s, 3H). LC-MS calculated exact molecular weight: 143.01, found m / z 144.1 [M+H]. + .

[0661] Step 2: 2-Chloro-5-methyl-4-nitropyridine 1-oxide

[0662]

[0663] To a mixture of fuming nitric acid (4.5 mL) and sulfuric acid (6 mL) was slowly added 2-chloro-5-methylpyridine 1-oxide (1.4 g, 9.7 mmol). The mixture was then heated at 100°C for 2 h. The mixture was cooled to room temperature, poured into crushed ice, and neutralized by the addition of solid sodium carbonate. The mixture was extracted with ethyl acetate, and the organic layer was dried over sodium sulfate and evaporated under reduced pressure to give 2-chloro-5-methyl-4-nitropyridine 1-oxide (1.3 g, 72%). 1H NMR (400 MHz, CDCl3): δ 8.27 (s, 1H), 8.26 (s, 1H), 2.60 (s, 3H). LC-MS exact molecular weight calculated: 188.00, found: m / z 189.1 [M+H]. + .

[0664] Step 3: 5-Methyl-4-nitro-2-(phenylamino)pyridine 1-oxide

[0665]

[0666] Purify with nitrogen and dissolve in A mixture of 2-chloro-5-methyl-4-nitropyridine 1-oxide (0.5 g, 2.6 mmol), aniline (0.5 g, 5.3 mmol), and potassium carbonate (0.73 g, 5.3 mmol) in 1,2-dioxane (10 mL) was stirred for 30 minutes. Tris(dibenzylideneacetone)dipalladium(0) (0.12 g, 0.13 mmol) and BINAP (0.16 g, 0.26 mmol) were added to the mixture, which was then purged with nitrogen for another 20 minutes and heated at 100°C for 16 hours. The mixture was filtered through celite, and the filtrate was evaporated under reduced pressure. The residue was suspended in water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on a silica gel column using 60% ethyl acetate in hexane as the eluent to obtain 5-methyl-4-nitro-2-(phenylamino)pyridine 1-oxide. (0.4 g, 56%). 1H NMR (400 MHz, CDCl 3 ): δ 8.48 (s, 1H), 8.17 (s, 1H), 7.73 (s, 1H), 7.45 (t, J = 8.4 Hz, 2H), 7.29-7.25 (m, 3H), 2.50 (s, 3H). LC-MS calculated molecular weight 245.08, found m / z 246.1 [M+H] + .

[0667] Step 4: 5-Methyl-N-phenylpyridine-2,4-diamine

[0668]

[0669] Iron powder (0.53 g, 9.57 mmol) was added to a solution of 5-methyl-4-nitro-2-(phenyl-amino)pyridine-1-oxide (0.35 g, 1.42 mmol) dissolved in acetic acid (7 mL). The mixture was heated at 100°C for 20 minutes. The mixture was cooled, poured into a 1M NaOH solution, and extracted with DCM. The organic layer was washed with water and brine, dried over sodium sulfate, and evaporated under reduced pressure to yield 5-methyl-N-phenylpyridine-2,4-diamine (0.26 g, 93%). 1H NMR (400 MHz, DMSO-d6): 8.75 (s, 1H), 7.52 (s, 1H), 7.38 (d, J = 8 Hz, 2H), 7.25 (t, J = 7.6 Hz, 2H), 6.92 (t, J = 7.2 Hz, 1H), 6.26 (br s, 2H), 6.07 (s, 1H), 1.93 (s, 3H). LC-MS calculated molecular weight 199.11, found m / z 200.2 [M+H] + .

[0670] Step 5: 4-Bromo-5-methyl-N-phenylpyridin-2-amine

[0671]

[0672] A mixture of copper(II) bromide (0.56 g, 2.51 mmol) and tert-butyl nitrite (0.25 mL, 3.12 mmol) dissolved in acetonitrile (5 mL) was stirred at room temperature for 30 minutes, cooled to 0°C, and 5-methyl-N-phenylpyridine-2,4-diamine (0.25 g, 1.25 mmol) was added. The mixture was stirred at room temperature for 1 hour. The mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with anhydrous ammonium hydroxide solution (until the blue color disappeared), water, and brine. The organic layer was dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using 6% ethyl acetate in hexane as the eluent to provide 4-bromo-5-methyl-N-phenylpyridin-2-amine (0.07 g, 18%). 1HNMR (400 MHz, CDCl3): 8.21 (s, 1H), 8.15 (s, 1H), 7.53-7.39 (m, 4H), 7.04 (d, J = 7.2 Hz, 2H), 2.39 (s, 3H). LC-MS calculated molecular weight values ​​are 262.01 and 264.01, found m / z 265.1 [M+H] + .

[0673] Step 6: N-(2-Hydroxy-1-phenylethyl)-1-(5-methyl-2-(phenylamino)pyridin-4-yl)-1H-pyrrole-3-carboxamide

[0674]

[0675] A mixture of 4-bromo-5-methyl-N-phenylpyridin-2-amine (0.07 g, 0.26 mmol), N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide (0.07 g, 0.29 mmol), and potassium phosphate (0.16 g, 0.79 mmol) dissolved in DMF (2 mL) was purged with nitrogen for 15 minutes. L-proline (0.006 g, 0.053 mmol) and copper iodide (0.01 g, 0.053 mmol) were added to the reaction mixture, which was then purged with nitrogen for an additional 10 minutes and then heated at 100°C in a sealed glass tube for 16 hours. The mixture was cooled, suspended in water, and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, evaporated under reduced pressure, and the residue was purified by column chromatography on silica gel using 2% methanol in DCM as eluent to give N-(2-hydroxy-1-phenylethyl)-1-(5-methyl-2-(phenylamino)pyridin-4-yl)-1H-pyrrole-3-carboxamide (0.04 g, 40%). 1HNMR (400 MHz, DMSO-d6): 9.04 (s, 1H), 8.13 (s, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.66 (s, 1H), 7.61 (d, J = 8 Hz, 2H), 7.31 (t, J = 7.2 Hz, 2H) 7.29-7.22 (m, 5H), 7.19-7.08 (m, 1H), 6.87 (t, J = 7.6 Hz, 1H), 6.74 (d, J = 7.6 Hz, 2H), 5.06-5.01 (m, 1H), 4.85 (t, J = 5.6 Hz, 1H), 3.66-3.63 (m, 2H), 2.14 (s, 3H). LC-MS calculated molecular weight: 412.19, observed value: m / z 413.3[M+H] + .HPLC purity 99.39%.

[0676] Typical example of scheme 9:

[0677] Example 16: N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide (Compound #159).

[0678] Step 1: 1-(2-chloro-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxylic acid methyl ester

[0679]

[0680] To a stirred solution of 1H-pyrrole-3-carboxymethyl ester (1.24 g, 9.97 mmol) in DMF (15 mL) was added cesium carbonate (1.22 g, 3.72 mmol). The reaction mixture was stirred at room temperature for 15 minutes, followed by the addition of 2,4-dichloro-5-methylpyridine (2 g, 1.24 mmol). The resulting mixture was heated at 100°C for 10 hours. The mixture was mixed with water (200 mL) and extracted with ethyl acetate (800 mL). The organic layer was dried over sodium sulfate, filtered under reduced pressure, and evaporated. The residue was purified by gradient column chromatography using ethyl acetate in n-hexane as the eluent to afford 1-(2-chloro-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxylic acid methyl ester (1.3 g, 43%) as a colorless solid. 1 HNMR (400 MHz, DMSO-d6): δ8.44 (s, 1H), 7.80 (s, 1H), 7.59 (s, 1H), 7.22 (t, J = 2.0 Hz, 1H), 6.66-6.65 (m, 1H), 3.73 (s, 3H), 2.25 (s, 3H). LC-MS calculated molecular weight 250.05, found m / z 251.1 [M+H] + .

[0681] Step 2: 1-(2-((4-Fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxylic acid methyl ester

[0682]

[0683] Dissolve in two To a solution of methyl 1-(2-chloro-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxylate (0.4 g, 1.60 mmol) in 1,2-dioxane (10 mL) were added potassium carbonate (0.66 g, 4.8 mmol) and 4-fluoroaniline (0.26 g, 2.40 mmol). The mixture was degassed with argon for 15 minutes, followed by the addition of tris(dibenzylideneacetone)dipalladium(0) (0.073 g, 0.08 mmol) and 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (0.09 g, 0.16 mmol). The resulting mixture was stirred in a sealed glass tube at 100°C for 12 hours. The mixture was cooled, quenched with water (50 mL), and extracted with ethyl acetate (200 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in n-hexane as the eluent to afford methyl 1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxylate (0.4 g, 76%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ 9.06 (s, 1H), 8.12 (s, 1H), 7.69 (s, 1H), 7.64-7.60 (m, 2H), 7.14-7.07 (m, 3H), 6.69 (s, 1H), 6.64-6.63 (m, 1H), 3.73 (s, 3H), 2.10 (s, 3H). LC-MS exact molecular weight calculated: 325.12, found: m / z 326.2 [M+H]. + .

[0684] Step 3: 1-(2-((4-Fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxylic acid

[0685]

[0686] To a mixture of methyl 1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxylate (0.5 g, 1.33 mmol) in THF (10 mL) and water (10 mL) was added lithium hydroxide monohydrate (0.25 g, 6.15 mmol). The resulting mixture was heated to reflux for 12 h. The mixture was cooled, concentrated under reduced pressure, and adjusted to pH ~6 by adding 1N HCl. The solid was removed by filtration, washed with water, and dried under vacuum to afford 1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxylic acid (0.45 g, 94%) as an off-white solid. 1HNMR (400 MHz, DMSO-d6): δ9.16 (s, 1H), 8.11 (s, 1H), 7.62 (t, J = 7.6 Hz, 3H), 7.11 (t, J = 8.4 Hz, 3H), 6.71 (s, 1H), 6.59 (s, 1H), 2.12 (s, 3H). LC-MS calculated molecular weight 311.11, found m / z 312.2 [M+H] + .

[0687] Step 4: N-((3-chlorophenyl)(cyano)methyl)-1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxamide

[0688]

[0689] To a solution of 1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxylic acid (0.1 g, 0.32 mmol) in NMP (5 mL) were added triethylamine (0.09 g, 0.96 mmol), EDC (0.12 g, 0.69 mmol), and HOBt (0.013 g, 0.096 mmol). The reaction mixture was stirred at room temperature for 15 minutes, followed by the addition of 2-amino-2-(3-chlorophenyl)acetonitrile (0.064 g, 0.38 mmol), and the resulting mixture was stirred at room temperature for 12 hours. The reaction mixture was quenched with water (100 mL) and extracted with ethyl acetate (100 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using methanol in DCM as eluent to give N-((3-chlorophenyl)(cyano)methyl)-1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxamide as a colorless solid (0.03 g, 20%). 1H NMR (400 MHz, DMSO-d6): δ9.21 (d, J=8 Hz, 1H), 9.07 (s, 1H), 8.12 (s, 1H), 7.71 (s, 1H), 7.64-7.60 (m, 2H), 7.54 (s, 1H), 7.49 (s, 3H), 7.13 (s, 1H), 7.10 (t, J=8.8 Hz, 2H), 6.75 (s, 1H), 6.68 (s, 1H), 6.40 (d, J=7.6 Hz, 1H), 2.13 (s, 3H). LC-MS calculated molecular weight: 459.13, found: m / z 460.2 [M+H]. + .

[0690] Step 5: N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxamide

[0691]

[0692] To a solution of N-((3-chlorophenyl)(cyano)methyl)-1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxamide (0.03 g, 0.065 mmol) in methanol (15 mL) was added Raney nickel (~0.05 g) and methanolamine (10 mL) under argon. The resulting mixture was stirred at room temperature under a hydrogen atmosphere provided by a balloon for 12 h. The reaction mixture was filtered through celite, washed with methanol (100 mL), and the filtrate was evaporated under reduced pressure. The residue was purified by gradient column chromatography using methanol in DCM as eluent to afford N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-pyrrole-3-carboxamide (0.015 g, 50%) as a colorless solid. 1H NMR (400 MHz, DMSO-d6): δ9.07 (s, 1H), 8.15-8.12 (m, 2H), 7.67-7.61 (m, 3H), 7.39 (s, 1H), 7.36-7.26 (m, 3H), 7.09-7.06 (m, 3H), 6.75 (s, 1H), 6.69 (s, 1H), 4.90 (d, J = 6.8 Hz, 1H), 2.84 (d, J = 7.2 Hz, 2H), 1.88 (br s, 2H), 2.14 (s, 3H). LC-MS calculated molecular weight: 463.16, found: m / z 464.5 [M+H]. + , HPLC purity 99.71%, mp 118.1℃.

[0693] Typical example of scheme 10:

[0694] Example 17: 1-(5-Chloro-2-(phenylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl-1H-imidazole-4-carboxamide (Compound #106).

[0695] Step 1: tert-Butyl (4-chloropyridin-2-yl)carbamate

[0696]

[0697] To a stirred solution of 4-chloropyridin-2-amine (1.5 g, 1.16 mmol) in pyridine (15 mL) was added trimethylacetyl chloride (1.688 g, 1.4 mmol). The mixture was stirred at room temperature overnight. The mixture was mixed with water (20 mL) and extracted with ethyl acetate (3 x 40 ml). The combined organic layers were dried over sodium sulfate and evaporated under reduced pressure. Purification was performed by gradient column chromatography on a basic alumina column using ethyl acetate in n-hexane as the eluent to yield t-N-(4-chloropyridin-2-yl)trimethylethylamine (1.7 g, 69%) as a white solid. 1 HNMR (400MHz, CDCl3): δ8.35 (s, 1H), 8.14 (d, J = 5.6Hz, 1H), 8.02 (br s, 1H), 7.04 -7.02 (m, 1H), 1.32 (s, 9H).

[0698] Step 2: tert-Butyl (4,5-dichloropyridin-2-yl)carbamate

[0699]

[0700] To a stirred solution of N-(4-chloropyridin-2-yl)trimethylethylamine (1.6 g, 7.5 mmol) in acetonitrile (40 mL) was added N-chlorosuccinimide (5.02 g, 3.76 mmol). The mixture was stirred at reflux overnight. The mixture was cooled, mixed with water (10 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over sodium sulfate and evaporated under reduced pressure. Purification by gradient column chromatography using ethyl acetate in n-hexane as the eluent afforded N-(4,5-dichloropyridin-2-yl)trimethylethylamine (1.3 g, 70%) as a white solid. 1 HNMR (400MHz, CDCl3): δ8.48(s,1H),8.25(s,1H),7.98(br s,1H),1.32(s,9H).

[0701] Step 3: 4,5-Dichloropyridin-2-amine

[0702]

[0703] A mixture of N-(4,5-dichloropyridin-2-yl)trimethylethylamine (1.25 g, 5.04 mmol) dissolved in 6N HCl (20 mL) was stirred at 100°C for 10 h. The mixture was cooled, mixed with water (20 mL), and basified by the addition of sodium bicarbonate solution (20 mL). The mixture was extracted with ethyl acetate (3 x 40 mL), and the combined organic layers were dried over sodium sulfate and evaporated under reduced pressure. Purification by gradient column chromatography using ethyl acetate in n-hexane as the eluent gave 4,5-dichloropyridin-2-amine (0.7 g, 85%) as a white solid. 1H NMR (400 MHz, CDCl3): δ 8.06 (s, 1H), 6.60 (s, 1H), 4.48 (br s, 2H). LC-MS calculated exact molecular weight: 161.98, observed m / z 162.8 [M+H]. + .

[0704] Step 4: 4,5-Dichloro-N-phenylpyridin-2-amine

[0705]

[0706] Dissolve in stirring To a solution of 4,5-dichloropyridin-2-amine (0.1 g, 0.61 mmol) in dextrin (5 mL) were added iodobenzene (0.25 g, 1.22 mmol), cesium carbonate (0.597 g, 1.83 mmol), and Xantphos (4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; 0.035 g, 0.06 mmol). The mixture was degassed with argon for 10 minutes, tris(dibenzylideneacetone)dipalladium(0) (0.029 g, 0.03 mmol) was added, and the mixture was degassed with argon for another 10 minutes. The mixture was stirred at 100°C for 3 hours. The mixture was cooled, concentrated under reduced pressure, diluted with water (10 mL), and extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in hexane as the eluent to afford 4,5-dichloro-N-phenylpyridin-2-amine (82 mg, 56% yield) as an off-white solid. 1H NMR (400 MHz, CDCl3): δ 8.17 (s, 1H), 7.36 (t, J = 7.2 Hz, 2H), 7.28 (s, 2H), 7.12 (t, J = 7.6 Hz, 1H), 6.92 (s, 1H), 6.51 (br s, 1H). LC-MS calculated molecular weight: 238.01, observed m / z: 239.1 [M+H]. + .

[0707] Step 5: 1-(5-chloro-2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-carboxylic acid methyl ester

[0708]

[0709] To a stirred solution of 4,5-dichloro-N-phenylpyridin-2-amine (0.3 g, 1.25 mmol) in DMF (7 mL) was added potassium carbonate (0.867 g, 6.2 mmol). The mixture was stirred at room temperature for 15 minutes, followed by the addition of methyl 1H-imidazole-4-carboxylate (0.159 g, 1.25 mmol), and the mixture was stirred at 100°C for 10 hours. The mixture was cooled, mixed with water (40 mL), and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in n-hexane as the eluent to afford methyl 1-(5-chloro-2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-carboxylate (103 mg, 25% yield) as an off-white solid. 1HNMR (400 MHz, DMSO-d6): δ9.44 (s, 1H), 8.39 (s, 1H), 8.26 (d, J = 1.6 Hz, 1H), 8.14 (d, J = 1.2 Hz, 1H), 7.62-7.59 (m, 2H), 7.3 (t, J = 5.2 Hz, 2H), 6.96 (t, J = 8 Hz, 2H), 3.78 (s, 3H). LC-MS calculated molecular weight 328.07, found m / z 329.1 [M+H] + .

[0710] Step 4: 1-(5-chloro-2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-carboxylic acid

[0711]

[0712] To a stirred mixture of methyl 1-(5-chloro-2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-carboxylate (0.075 g, 0.22 mmol) in THF (14 mL) and water (4 mL) was added lithium hydroxide monohydrate (0.039 g, 0.91 mmol). The reaction mixture was stirred at 50°C overnight. The mixture was concentrated under reduced pressure and neutralized to pH ~7 by adding 1N HCl. The resulting solid was removed by filtration to give 1-(5-chloro-2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-carboxylic acid (35 mg, 49% yield) as a gray solid. 1H NMR (400 MHz, DMSO): δ 9.45 (s, 1H), 8.38 (s, 1H), 8.16 (s, 1H), 8.11 (s, 1H), 7.61 (d, J = 8 Hz, 2H), 7.29 (t, J = 7.6 Hz, 2H), 6.97-6.93 (m, 2H). LC-MS exact molecular weight calculated value 314.06, found value m / z 315.1 [M+H] + .

[0713] Step 7: 1-(5-chloro-2-(phenylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl-1H-imidazole-4-carboxamide

[0714] To a stirred solution of 1-(5-chloro-2-(phenylamino)pyridin-4-yl)-1H-imidazole-4-carboxylic acid (0.035 g, 0.11 mmol) in NMP (1.5 mL) were added EDC (0.065 g, 0.33 mmol), HOBt (0.005 g, 0.033 mmol), triethylamine (0.02 mL, 0.22 mmol), and 2-amino-2-(3-chlorophenyl)ethanol (0.022 g, 0.13 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 x 15 mL). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, and evaporated under reduced pressure. The crude residue was purified by preparative TLC using methanol in DCM as eluent to afford 1-(5-chloro-2-(phenylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl-1H-imidazole-4-carboxamide (19 mg, 36% yield) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ 9.44 (s, 1H), 8.41 (s, 1H), 8.38 (d, J = 4.0 Hz). , 1H), 8.16(s, 1H), 8.02(s, 1H), 7.61(d, J=7.6Hz, 2H), 7.44(s, 1H), 7.33-7.30(m, 2H), 7.29-7.27(m, 3H), 6.93(s, 2H), 5.02-5.01(m, 2H), 3.72(t, J=5.6Hz, 2H). LC-MS accurate molecular weight calculated value 467.09, found value m / z 468.1[M+H] + ; HPLC purity 99.88%.

[0715] Typical examples of Scheme 11:

[0716] Example 18: N-(2-amino-1-phenylethyl)-1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-imidazole-4-carboxamide (Compound #191).

[0717] Step 1: 1-(2-chloro-5-methylpyridin-4-yl)-1H-imidazole-4-carboxylic acid methyl ester

[0718]

[0719] To a solution of 2,4-dichloro-5-methylpyridine (1.285 g, 7.93 mmol) in DMF (15 mL) was added methyl 1H-imidazole-4-carboxylate (1 g, 7.93 mmol) and KCO (5.476 g, 39.68 mmol), and the mixture was stirred at 100°C for 6 h. The mixture was cooled, diluted with water, and the resulting solid was filtered and dried to provide a crude product. The crude product was purified using Biotage Isolera (using 50% ethyl acetate in hexanes as eluent) to provide methyl 1-(2-chloro-5-methylpyridin-4-yl)-1H-imidazole-4-carboxylate (0.670 g, 34%). 1HNMR (400 MHz, CDCl3): δ8.44 (s, 1H), 7.79 (s, 1H), 7.69 (s, 1H), 7.27 (s, 1H), 3.94 (s, 3H), 2.28 (s, 3H). LC-MS calculated molecular weight 251.05, found m / z 252.1 [M+H] + .

[0720] Step 2: 1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-imidazole-4-carboxylic acid methyl ester

[0721] Dissolve in two To a solution of methyl 1-(2-chloro-5-methylpyridin-4-yl)-1H-imidazole-4-carboxylate (0.4 g, 1.59 mmol) in dextrin (10 mL) were added 4-fluoroaniline (0.353 g, 3.18 mmol) and KCO (0.439 g, 3.18 mmol). The reaction mixture was degassed with argon, and tris(dibenzylideneacetone)dipalladium(0) (0.072 g, 0.079 mmol) and BINAP (0.099 g, 0.15 mmol) were added. The mixture was heated at 100°C in a CEM microwave system for 1 h. The mixture was cooled, diluted with water, and extracted with ethyl acetate. The combined organic phases were washed with water and brine, dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by column chromatography using 4% methanol in DCM as eluent to give methyl 1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-imidazole-4-carboxylate (0.4 g, 77%). 1H NMR (400 MHz, CDCl3): δ 8.18 (s, 1H), 7.74 (s, 1H), 7.61 (s, 1H), 7.29-7.25 (m, 2H), 7.06 (t, J = 8 Hz, 2H), 6.55 (s, 1H), 5.29 (s, 1H), 3.92 (s, 3H), 2.14 (s, 3H). LC-MS exact molecular weight calculated: 326.12, found: m / z 327.2 [M+H].+ .

[0722] Step 3: 1-(2-((4-Fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-imidazole-4-carboxylic acid

[0723]

[0724] To a solution of methyl 1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-imidazole-4-carboxylate (0.450 g, 1.38 mmol) in THF (12 mL) was added LiOH (0.289 g, 6.90 mmol) dissolved in water (8 mL). The mixture was stirred under reflux overnight, cooled, concentrated under reduced pressure, and neutralized by adding 2N HCl. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic phases were dried over sodium sulfate, filtered, and evaporated under reduced pressure to give 1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-imidazole-4-carboxylic acid (0.210 g, 49%). 1HNMR (400 MHz, CDCl3): δ12.0 (br s, 1H), 9.15 (s, 1H), 8.15 (d, J = 11.2 Hz, 2H), 8.04 (s, 1H), 7.64-7.60 (m, 2H), 7.09 (t, J = 17.2 Hz, 2H), 6.73 (s, 1H), 2.08 (s, 3H), LC-MS accurate molecular weight calculated value 312.10, found value m / z 313.1 [M+H] + .

[0725] Step 4: N-(Cyano(phenyl)methyl)-1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-imidazole-4-amide

[0726] To a solution of 1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-imidazole-4-carboxylic acid (0.2 g, 0.0641 mmol) in DCM (16 mL) was added 2-amino-2-phenylacetonitrile (0.151 g, 0.0769 mmol), EDC (0.345 g, 0.128 mmol), HOBt (0.040 g, 0.019 mmol), and TEA (0.194 g, 0.192 mmol). The reaction mixture was stirred at room temperature for 24 h. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate, filtered, and evaporated under reduced pressure to yield the crude product. The crude product was purified using Biotage Isolera (6% methanol in DCM as eluent) to give N-(cyano(phenyl)methyl)-1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-imidazole-4-amide (0.040 g, 15%). 1HNMR (400 MHz, CDCl3): δ8.36 (s, 1H), 8.12 (d, J = 14.4 Hz, 2H,), 7.63-7.60 (m, 3H), 7.52 (d, J = 12 Hz, 2H), 7.45-7.34 (m, 4H), 7.09 (t, J = 8 Hz, 2H), 6.73 (s, 1H), 6.34 (d, J = 8 Hz, 1H), 2.87 (s, 1H), 2.08 (s, 3H). LC-MS calculated molecular weight 426.16, found m / z 427.2 [M+H] + .

[0727] Step 5: N-(2-amino-1-phenylethyl)-1-(2-((4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-imidazole-4-amide

[0728]

[0729] To a solution of N-(cyano(phenyl)methyl)-1-(2-(4-fluorophenyl)amino)-5-methylpyridin-4-yl)-1H-imidazole-4-carboxamide (0.04 g, 0.0094 mmol) in methanol (5 mL) was added Raney nickel (0.060 g) and ammonium hydroxide (5 mL). The resulting reaction mixture was stirred at room temperature under a hydrogen atmosphere provided by a balloon for 6 h. The reaction mixture was filtered through a pad of celite, washed with methanol, and the filtrate was evaporated under reduced pressure. The residue was purified by preparative TLC using 3.5% methanol in DCM as the eluent to afford the desired product (0.010 g, 25%). 1H NMR (400 MHz, DMSO-d6): δ9.14 (s, 1H), 8.45 (d, J = 8.4 Hz, 8.15 (s, 1H), 8.08 (s, 1H), 7.97 (s, 1H), 7.61 (t, J = 8.4 Hz, 2H), 7.37-7.29 (m, 4H), 7.24-7.22 (m, 1H), 7.11-7.06 (m, 2H), 6.72 (s, 1H), 4.98 (d, J = 5.2 Hz, 1H), 3.06-2.93 (m, 2H), 2.09 (s, 3H). LC-MS calculated molecular weight: 430.19, found: m / z 431.5 [M+H]. + , HPLC purity 98.54%, mp 154.7℃.

[0730] Typical example of Scheme 12:

[0731] Example 19: N-(1-cyano-2-phenylethyl)-1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyridin-4-yl)-1H-1,2,3-triazole-4-carboxamide (Compound #134).

[0732] Step 1: 4-Azido-2-chloro-5-methylpyridine

[0733]

[0734] To a stirred solution of 2,4-dichloro-5-methylpyridine (1.0 g, 6.7 mmol) in DMF (15 mL) was added sodium azide (0.52 g, 8.1 mmol). The resulting solution was stirred at 100°C for 4 h. The mixture was cooled to 0°C, quenched with water (35 mL), and extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue (crude product, 1.2 g) was used directly in the next step without purification.

[0735] Step 2: 1-(2-chloro-5-methylpyridin-4-yl)-1H-1,2,3-triazole-4-carboxylic acid methyl ester

[0736]

[0737] To a stirred solution of 4-azido-2-chloro-5-methylpyridine (1.0 g, 5.93 mmol, crude) in DMSO (10 mL) and H2O (2 mL) at room temperature were added CuSO4.5H2O (0.074 g, 0.0297 mmol), methyl propiolate (0.499 g, 5.95 mmol), sodium ascorbate (0.117 g, 0.595 mmol), sodium carbonate (0.126 g, 1.19 mmol), and DL-proline (0.126 g, 1.19 mmol). The resulting mixture was stirred at 65°C for 18 h. The reaction mixture was then cooled to 0°C, quenched with water (35 mL), and extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography using 40% ethyl acetate in n-hexane as the eluent to afford the desired product (0.87 g, 56%) as a white solid. LC-MS calculated molecular weight: 252.04, observed m / z: 253.06 [M+H] + .

[0738] Step 3: 1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyridin-4-yl)-1H-1,2,3-triazole-4-carboxylic acid methyl ester

[0739]

[0740] At room temperature, dissolve in To a solution of methyl 1-(2-chloro-5-methylpyridin-4-yl)-1H-1,2,3-triazole-4-carboxylate (0.4 g, 1.58 mmol) in dane (20 mL) were added KCO (0.438 g, 3.17 mmol), BINAP (0.098 g, 0.158 mmol), and 2,2-difluorobenzo[d][1,3]dioxol-5-amine (0.549 g, 3.17 mmol). The resulting solution was degassed with argon for 20 minutes, followed by the addition of Pd(dba) (0.145 g, 0.18 mmol). The reaction mixture was stirred in a sealed glass tube at 100°C for 8 hours. The reaction mixture was then cooled to 0°C, quenched with water (35 mL), and extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was purified by column chromatography using ethyl acetate in n-hexane as eluent to give the desired product (0.43 g, 70%) as a white solid. LC-MS exact molecular weight calculated value: 389.09, found value: m / z 388.19 [MH]-.

[0741] Step 4: 1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyridin-4-yl)-1H-1,2,3-triazole-4-carboxylic acid

[0742]

[0743] To a stirred solution of methyl 1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyridin-4-yl)-1H-1,2,3-triazole-4-carboxylate (0.24 g, 1.02 mmol) in THF:H₂O (5 mL:2 mL) was added LiOH (0.215 g, 5.14 mmol), and the reaction mixture was stirred at 80°C for 4 h. The mixture was cooled to 0°C, acidified by the addition of 2N HCl solution (10 mL), and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford the desired product as a pale yellow solid (0.21 g, 91%). LC-MS exact molecular weight calculated: 375.08, found: m / z 376.0 [M+H] + .

[0744] Step 5: N-(1-cyano-2-phenylethyl)-1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyridin-4-yl)-1H-1,2,3-triazole-4-carboxamide

[0745]

[0746] To a stirred solution of 1-(2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyridin-4-yl)-1H-1,2,3-triazole-4-carboxylic acid (0.2 g, 0.533 mmol) in DCM (10 mL) was added EDC (0.2 g, 1.06 mmol), triethylamine (0.18 mL, 1.33 mmol), and HOBt (0.1 g, 0.799 mmol). 2-Amino-3-phenylpropionitrile (0.155 g, 1.066 mmol) was then added, and the resulting mixture was stirred at room temperature for 18 h. The mixture was quenched with water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by gradient chromatography using a 60-120 mesh silica gel column eluting with 25% ethyl acetate in n-hexane to give the desired product (0.15 g, 56%) as a pale yellow solid.

[0747] Step 6: N-(1-amino-3-phenylpropan-2-yl)-1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyridin-4-yl)-1H-1,2,3-triazole-4-carboxamide

[0748]

[0749] To a stirred solution of N-(1-cyano-2-phenylethyl)-1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)amino)-5-methylpyridin-4-yl)-1H-1,2,3-triazole-4-carboxamide (0.13 g, 0.258 mmol) in methanol (10 mL) was added DCM (2 mL) to form a clear solution. NiCl (0.006 g, 0.051 mmol) and NaBH (0.049 g, 1.29 mmol) were then added to the solution, and the mixture was stirred at room temperature for 14 h. The reaction mixture was quenched with water (20 mL), filtered through celite, and extracted with DCM (3 x 20 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was purified by gradient column chromatography on 60-120 mesh silica gel column eluting with 8% MeOH in DCM to give the desired product (0.03 g, 23%) as a pale yellow solid. 1H NMR (400 MHz, DMSO-d6): δ 11.29 (s, 1H), 9.49 (s, 1H), 9.04 (s, 1H), 8.59 (d, J = 8.8 Hz, 1H), 8.28 (s, 1H), 7.93 (d, J = 1.6 Hz, 1H), 7.33-7.14 (m, 8H), 6.94 (d, J = 9.6 Hz, 1H), 4.29 (s, 1H), 3.50 (s, 1H), 3.16-2.83 (m, 3H), 1.97 (s, 3H). LC-MS calculated molecular weight 507.18, found m / z 508.22 [M+H] + ; HPLC purity 97.94%.

[0750] Typical example of Scheme 13:

[0751] Example 20: N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-(((S)-1-hydroxybutan-2-yl)amino)pyridin-4-yl)-1H-imidazole-4-carboxamide (Compound #105).

[0752] Step 1: (S)-2-((4-iodopyridin-2-yl)amino)butan-1-ol

[0753]

[0754] To a stirred solution of 2-fluoro-4-iodopyridine (2.0 g, 8.97 mmol) in NMP (10 mL) was added (S)-2-aminobutan-1-ol (1.197 g, 13.45 mmol), and the mixture was stirred at 100°C in a sealed glass tube for 12 h. The reaction mixture was cooled, quenched with water (50 mL), and extracted with ethyl acetate (3 x 80 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by gradient column chromatography using 20% ​​ethyl acetate in n-hexane to afford (S)-2-((4-iodopyridin-2-yl)amino)butan-1-ol (0.8 g, 30%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ7.61 (d, J = 5.6 Hz, 1H), 6.91 (s, 1H), 6.74-6.72 (m, 1H), 6.34 (d, J = 8 Hz, 1H), 4.57 (t, J = 6 Hz, 1H), 3.73 (d, J = 5.2 Hz, 1H), 3.42–3.38 (m, 1H), 3.31 (s, 1H), 1.60 (t, J = 6 Hz, 1H), 1.36 (t, J = 7.2 Hz, 1H), 0.84 (t, J = 7.6 Hz, 3H). LC-MS calculated molecular weight: 292.01, found: m / z 293.0 [M+H]. + .

[0755] Step 2: (S)-methyl 1-(2-((1-hydroxybutan-2-yl)amino)pyridin-4-yl)-1H-imidazole-4-carboxylate

[0756]

[0757] To a stirred solution of (S)-2-((4-iodopyridin-2-yl)amino)butan-1-ol (0.8 g, 1.71 mmol) in DMF (5 mL) were added potassium phosphate (0.32 g, 2.57 mmol), methyl 1H-imidazole-4-carboxylate (0.323 g, 2.57 mmol), and L-proline (0.039 g, 0.34 mmol). The mixture was degassed with argon for 20 minutes, and copper (I) iodide (0.065 g, 0.34 mmol) was added. The mixture was stirred in a sealed glass tube at 150°C for 12 hours. The reaction mixture was then cooled, quenched with water (35 mL), and extracted with ethyl acetate (3×60 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure, and the residue was purified by gradient column chromatography eluting with 80% ethyl acetate in n-hexane to give (S)-methyl 1-(2-((1-hydroxybutan-2-yl)amino)pyridin-4-yl)-1H-imidazole-4-carboxylate (0.25 g, 32% yield) as an off-white semisolid. 1HNMR (400MHz, DMSO-d6): δ8.42(s,1H),8.38(s,1H),8.02(d,J=6Hz,1H,),7.67(m,1H ),6.85(m,1H),6.75(s,1H),6.36(d,J=8.4Hz,1H),5.72(s,1H),4.61(s,1H),4.12(m, 1H), 3.81 (d, J = 4 Hz, 1H), 3.78 (s, 3H), 3.46 (t, J = 5.6 Hz, 1H), 3.34 (t, J = 5.6 Hz, 2H), 1.60-1.44 (m, 1H), 1.33-1.24 (m, 1H), 0.89-0.83 (m, 3H). LC-MS calculated molecular weight 290.14, found m / z 291.2 [M+H] + .

[0758] Step 3: (S)-1-(2-((1-hydroxybutan-2-yl)amino)pyridin-4-yl)-1H-imidazole-4-carboxylic acid

[0759]

[0760] To a stirred solution of (S)-methyl 1-(2-((1-hydroxybutan-2-yl)amino)pyridin-4-yl)-1H-imidazole-4-carboxylate (0.25 g, 0.86 mmol) in THF:water (5 mL:5 mL) was added lithium hydroxide monohydrate (0.179 g, 4.29 mmol), and the mixture was stirred at 50°C for 12 h. The mixture was cooled, concentrated under reduced pressure, combined with water (15 mL), and washed with ethyl acetate (2 x 5 mL). The aqueous layer was adjusted to pH ~6-6.5 by the addition of 4N HCl, and the resulting solid was removed by filtration and dried under high vacuum to afford the desired product as an off-white solid (0.15 g, 63% yield). 1H NMR (400 MHz, DMSO-d,): δ 12.5 (br s, 1H), 8.32 (d, J = 12 Hz, 2H), 8.02 (d, J = 5.2 Hz, 1H), 6.84-6.82 (m, 1H), 6.74 (s, 1H), 6.37 (d, J = 8.4 Hz, 1H), 3.81 (d, J = 5.6 Hz, 1H), 3.48-3.44 (m, 1H), 1.67-1.60 (m, 1H), 1.46-1.40 (m, 1H), 1.37-1.31 (m, 1H), 1.26-1.24 (m, 1H), 0.89-0.86 (m, 3H). LC-MS exact molecular weight calculated value 276.12, found value m / z 277.2 [M+H] + .

[0761] Step 4: N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-(((S)-1-hydroxybutan-2-yl)amino)pyridin-4-yl)-1H-imidazole-4-amide

[0762]

[0763] To a stirred solution of (S)-1-(2-((1-hydroxybutan-2-yl)amino)pyridin-4-yl)-1H-imidazole-4-carboxylic acid (0.07 g, 0.25 mmol) in NMP (3 mL) was added triethylamine (0.076 g, 0.76 mmol), followed by EDC (0.097 g, 0.51 mmol) and HOBt (0.01 g, 0.075 mmol). The mixture was stirred at room temperature for 20 minutes, followed by the addition of 2-amino-2-(3-chlorophenyl)ethanol (0.052 g, 0.30 mmol), and the reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was quenched with water (25 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography eluting with 3% methanol in DCM to give N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-(((S)-1-hydroxybutan-2-yl)amino)pyridin-4-yl)-1H-imidazole-4-amide as an off-white solid (15 mg, 14%). 1HNMR (400MHz, DMSO-d6): δ8.38(t,J=7.2Hz,2H),8.18(s,1H),8.01(d,J=5.6Hz,1H),7.42(s,1H),7. 32-7.26(m,3H),6.84(d,J=5.6Hz,1H),6.74(s,1H),6.36(d,J=7.6Hz,1H),5.02-4.99(m,2H),4.61(d , J = 5.6 Hz, 1H), 3.81 (s, 1H), 3.71 (t, J = 5.6 Hz, 1H), 3.47-3.44 (m, 1H), 3.34-3.27 (m, 1H), 1.67–1.65 (m, 1H), 1.63-1.61 (m, 1H), 1.07 (t, J = 7.2 Hz, 1H), 0.87 (t, J = 6.8 Hz, 3H). LC-MS accurate molecular weight calculated value 429.16, found value m / z 430.2 [M+H] + ; HPLC purity 99.46%.

[0764] Example 21: N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-((2,3-dihydrobenzofuran-5-yl)amino)pyridin-4-yl)-1H-imidazole-4-carboxamide (Compound #163).

[0765] Step 1: N-(2,3-dihydrobenzofuran-5-yl)-4-iodopyridin-2-amine

[0766]

[0767] Dissolved in 1:1 di To a suspension of 2,3-dihydrobenzofuran-5-amine (1 g, 7.4 mmol) in 200 mL of oxane:water was added 2-fluoro-4-iodopyridine (1.982 g, 8.8 mmol) and aqueous hydrochloric acid (2 mL, 35%). The mixture was stirred in a sealed glass tube at 100°C for 15 h. The reaction mixture was cooled, basified by the addition of saturated aqueous sodium bicarbonate, and extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, filtered, and evaporated under reduced pressure to obtain a crude residue. The residue was purified by column gradient chromatography using ethyl acetate in n-hexane as the eluent to afford N-(2,3-dihydrobenzofuran-5-yl)-4-iodopyridin-2-amine (600 mg, 24%) as a yellow solid. 1HNMR (400 MHz, CDCl3): δ7.76 (d, J = 4.8 Hz, 1H), 7.13 (s, 1H), 7.00–6.97 (m, 3H), 6.77 (d, J = 8.4 Hz, 1H), 6.48 (s, 1H), 4.60 (t, J = 8.8 Hz, 2H), 3.23 (t, J = 8.8 Hz, 2H). LC-MS calculated molecular weight 337.99, found m / z 339.0 [M+H] + .

[0768] Step 2: Methyl 1-(2-((2,3-dihydrobenzofuran-5-yl)amino)pyridin-4-yl)-1H-imidazole-4-carboxylate

[0769]

[0770] Under a nitrogen atmosphere, to a solution of N-(2,3-dihydrobenzofuran-5-yl)-4-iodopyridin-2-amine (300 mg, 0.88 mmol) in DMF (3 mL) were added methyl 1H-imidazole-4-carboxylate (167 mg, 1.3 mmol), potassium phosphate (564 mg, 2.6 mmol), and L-proline (20 mg, 0.17 mmol). The reaction mixture was purged with nitrogen for 10 minutes, followed by the addition of copper iodide (33 mg, 0.17 mmol). The reaction mixture was stirred in a sealed glass tube at 140°C for 15 hours. The reaction mixture was cooled, filtered through celite, and the filtrate was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered, and evaporated under reduced pressure. The residue was purified by gradient column chromatography using ethyl acetate in n-hexane as the eluent to afford methyl 1-(2-((2,3-dihydrobenzofuran-5-yl)amino)pyridin-4-yl)-1H-imidazole-4-carboxylate (0.10 g, 17%) as a yellow semisolid. LC-MS calculated molecular weight: 336.12, observed m / z: 337.2 [M+H] + .

[0771] Step 3: N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-((2,3-dihydrobenzofuran-5-yl)amino)pyridin-4-yl)-1H-imidazole-4-amide

[0772]

[0773] Under a nitrogen atmosphere, to a solution of methyl 1-(2-((2,3-dihydrobenzofuran-5-yl)amino)pyridin-4-yl)-1H-imidazole-4-carboxylate (90 mg, 0.26 mmol) in toluene (3 mL) was added 2-amino-2-(3-chlorophenyl)ethanol (91 mg, 5.3 mmol) and trimethylaluminum (2 M, 0.26 mL, 2 eq) in toluene. The mixture was stirred at 100°C under a CEM microwave for 45 minutes. The reaction mixture was poured into ice water and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered, and evaporated under reduced pressure to give a residue which was purified by gradient column chromatography using methanol in DCM as eluent to give N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-((2,3-dihydrobenzofuran-5-yl)amino)pyridin-4-yl)-1H-imidazole-4-amide (20 mg, 16%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ8.88 (s, 1H), 8.42–8.37 (m, 2H), 8.20–8.16 (m, 2H), 7.51 (s, 1H), 7.42 (s, 1H), 7.32–7.28 (m, 4H), 7.21 (d, J = 8.4 Hz, 1H), 7.05 (d, J = 4.8 Hz, 1H), 6.88 (s, 1H), 6.8 (d, J = 8.4 Hz, 1H), 5.02 (br s, 2H), 4.47 (t, J = 8.8 Hz, 2H), 3.72 (s, 2H), 3.15 (t, J = 8.4 Hz, 2H). LC-MS calculated molecular weight: 475.14, found: m / z 476.1 [M+H]. + .

[0774] Typical example of Scheme 20:

[0775] Example 22: (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (alternative synthesis of compound #225a).

[0776] Step 1: tert-Butyl (S)-(1-(3-chlorophenyl)-2-hydroxyethyl)carbamate

[0777]

[0778] To a stirred solution of (S)-2-amino-2-(3-chlorophenyl)ethanol (1.0 g, 5.83 mmol) in t-butanol (15 mL) was added 2 M sodium hydroxide solution (0.29 g, 7.28 mmol) and di-tert-butyl dicarbonate (1.92 mL, 8.16 mmol). The reaction mixture was stirred at 70°C for 16.0 h. The progress of the reaction was monitored by TLC (30% ethyl acetate in n-hexane, activated with KMnO4). The reaction mixture was quenched with water (40 mL) and extracted with ethyl acetate (3 x 40 mL). The combined organic layers were concentrated under reduced pressure. The residue was purified by gradient column chromatography using a 60-120 mesh silica gel column with 20% ethyl acetate in n-hexane as the eluent. Fractions were collected and concentrated under reduced pressure to yield tert-butyl (S)-(1-(3-chlorophenyl)-2-hydroxyethyl)carbamate (1.0 g, 63%) as a white solid. 1 HNMR (400MHz, DMSO-d6): δ7.32–7.21(m,5H),4.78(t,J=5.6Hz,1H),4.49(d,J=5.6Hz,1H),3.51–3.41(m,2H),1.34(s,9H).

[0779] Step 2: (S)-2-((tert-Butoxycarbonyl)amino)-2-(3-chlorophenyl)ethyl methanesulfonate

[0780]

[0781] To a stirred solution of tert-butyl (S)-(1-(3-chlorophenyl)-2-hydroxyethyl)carbamate (1.0 g, 3.68 mmol) in dichloromethane (15 mL) was added triethylamine (0.62 mL, 4.42 mmol), and the mixture was cooled to 0°C. Methanesulfonyl chloride (0.313 mL, 4.049 mmol) was added at 0°C, and the mixture was stirred at room temperature for 1.5 h. The progress of the reaction was monitored by TLC (25% ethyl acetate in n-hexane). The reaction mixture was quenched with saturated ammonium chloride (20 mL) and extracted with dichloromethane (3 x 30 mL). The combined organic layers were dried over sodium sulfate, filtered, concentrated, washed with n-pentane, and dried under vacuum to afford (S)-2-((tert-butoxycarbonyl)amino)-2-(3-chlorophenyl)ethyl methanesulfonate (0.65 g, 51%) as a yellow oil.

[0782] Step 3: (S)-tert-Butyl (2-azido-1-(3-chlorophenyl)ethyl)carbamate

[0783]

[0784] To a stirred solution of (S)-2-((tert-butoxycarbonyl)amino)-2-(3-chlorophenyl)ethyl methanesulfonate (0.65 g, 1.86 mmol) in N,N-dimethylformamide (10 mL) was added sodium azide (0.242 g, 3.72 mmol), and the mixture was stirred at 50°C for 16 h. The progress of the reaction was monitored by TLC (20% ethyl acetate in n-hexane). The reaction mixture was quenched with saturated ammonium chloride (15 mL) and water (30 mL), extracted with ethyl acetate (3 x 30 mL), and the combined organic layers were concentrated under reduced pressure. The residue was purified by gradient column chromatography using a 60-120 mesh silica gel column and 8% ethyl acetate in hexane as the eluent. Appropriate fractions were collected and concentrated under reduced pressure to give tert-butyl (S)-(2-azido-1-(3-chlorophenyl)ethyl)carbamate (0.5 g, 91%) as a colorless oil. 1 HNMR (400MHz, DMSO-d6): δ7.67–7.58(m,1H),7.42(br s,1H),7.37–7.31(m,3H),4.73(br s,1H),3.44(t,J=8.4Hz,2H),1.35(s,9H).

[0785] Step 4: (S)-2-Azido-1-(3-chlorophenyl)ethylamine hydrochloride

[0786]

[0787] At 0℃, add the stirred To a solution of (S)-(2-azido-1-(3-chlorophenyl)ethyl)carbamic acid tert-butyl ester (0.5 g, 1.69 mmol) in 2-nitropropane (5 mL) was added 2-nitropropane-1-(3-chlorophenyl)ethyl)carbamate (0.5 g, 1.69 mmol). The mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure, triturated with n-pentane, and dried under vacuum to give (S)-2-azido-1-(3-chlorophenyl)ethanamine hydrochloride (0.43 g, HCl salt) as an off-white solid. The calculated molecular weight by LCMS was 196.05, and the observed m / z was 197.1 [M+H]. + .

[0788] Step 5: 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylic acid

[0789]

[0790] To a stirred solution of methyl 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylate (10.0 g, 31.53 mmol) in tetrahydrofuran (450 mL) was added potassium trimethylsilanol (12.13 g, 94.60 mmol) at 0° C. The resulting mixture was stirred at 45° C. for 1.5 h. The progress of the reaction was monitored by TLC (5% methanol in dichloromethane). The reaction mixture was quenched with water (250 mL) and washed with ethyl acetate (3 x 50 mL). The aqueous layer was adjusted to pH 4–5 by addition of 4N HCl solution and extracted with 10% methanol in dichloromethane (8 x 250 mL). The combined organic layers were concentrated under reduced pressure to afford 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylic acid (7.0 g, 73%) as an off-white solid. 1 HNMR (400 MHz, DMSO-d6): δ 12.46 (br s, 1H), 8.34 (s, 1H), 8.23 ​​(br s, 1H), 8.20 (s, 1H), 7.36 (d, J = 7.6 Hz, 1H), 3.89 (br s, 1H), 3.83 (d, J = 11.6 Hz, 2H), 3.39–3.33 (m, 2H), 2.16 (s, 3H), 1.80 (d, J = 10.4 Hz, 2H), 1.52–1.42 (m, 2H). LCMS calculated molecular weight: 303.13, found: m / z 304.1 [M+H]. + .

[0791] Step 6: (S)-N-(2-azido-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide

[0792]

[0793] To a stirred solution of 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylic acid (6.0 g, 19.80 mmol) in dichloromethane (150 mL) and N,N-dimethylformamide (50 mL) was added triethylamine (13.81 mL, 98.97 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (5.99 g, 59.40 mmol), hydroxybenzotriazole (0.605 g, 3.96 mmol), and (S)-2-azido-1-(3-chlorophenyl)ethanamine hydrochloride (4.65 g, 19.80 mmol) under nitrogen. The reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC (5% methanol in dichloromethane). The reaction mixture was quenched with saturated sodium bicarbonate solution (50 mL), extracted with dichloromethane (3 x 50 mL), and washed with water (100 mL) and brine (50 mL). The combined organic layers were concentrated under reduced pressure. The residue was purified by gradient column chromatography using a 60-120 mesh silica gel column, eluting with 4% methanol in dichloromethane. Appropriate fractions were collected and concentrated under reduced pressure to yield (S)-N-(2-azido-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide (5.65 g, 59%) as an off-white solid. LCMS exact molecular weight calculated: 481.17, found: m / z 482.1 [M+H]. + .

[0794] Step 7: (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide

[0795]

[0796] To a stirred solution of (S)-N-(2-azido-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (7.12 g, 14.77 mmol) in methanol (75 mL) was added zinc powder (4.82 g, 73.87 mmol). The resulting solution was stirred at room temperature for 10 minutes, followed by the addition of ammonium chloride (3.95 g, 73.87 mmol) dissolved in water (15 mL). The reaction mixture was stirred at 55°C for 1 hour. The progress of the reaction was monitored by TLC (5% methanol in dichloromethane). The reaction mixture was quenched with saturated sodium bicarbonate solution (50 mL), filtered through celite, and washed with 10% methanol in dichloromethane. The organic layer was washed with water (2 x 25 mL), and the combined organic layers were concentrated under reduced pressure. The residue was purified by Biotage chromatography using a 60-120 mesh silica gel column eluting with 13% (methanol / isopropylamine) in dichloromethane. Appropriate fractions were collected and concentrated under reduced pressure to afford (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide (4.38 g, 65%) as an off-white solid. 1 HNMR (400MHz, DMSO-d6): δ8.52(d,J=8.0Hz,1H),8.33(s,1H),8.26(s,1H),8.07(s,1H),7.40(s,1H),7.36–7.25(m,4H),4.92–4.87(m,1H),3.86(br s, 1H), 3.84–3.81 (d, J = 11.2 Hz, 2H), 3.33 (t, J = 11.6 Hz, 2H), 2.97–2.92 (m, 1H), 2.88–2.85 (m, 1H), 2.17 (s, 3H), 1.80 (d, J = 11.6 Hz, 2H), 1.51–1.44 (m, 4H). LCMS exact molecular weight calculated value 455.18, found value m / z 456.1 [M+H] + .HPLC purity: 99.47%, chiral HPLC purity: 99.68%.

[0797] The following examples illustrate the preparation of some compounds:

[0798] Example 23: (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide (Compound #259).

[0799] Step 1: 1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylic acid methyl ester

[0800] To a solution of methyl 1-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylate (10.0 g, 39.59 mmol) in isopropanol (60 mL) was added N,N-diisopropylethylamine (28.36 mL) and 3,3-difluorocyclobutylamine hydrochloride (6.81 g, 47.50 mmol) with stirring. The reaction mixture was stirred at 100°C in a sealed glass tube for 20 h. The reaction progress was monitored by TLC (5% methanol in dichloromethane). The reaction mixture was cooled to 0°C, and the formed crystals were filtered and dried under reduced pressure to yield methyl 1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylate (23.0 g, 89%) as an off-white solid. LCMS accurate molecular weight calculated value 323.12, experimental value m / z 324.2 [M+H] + .

[0801] Step 2: 1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylic acid

[0802]

[0803] To a stirred solution of methyl 1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylate (30.5 g, 94.3 mmol) in THF (1.0 L) at 0°C was added potassium trimethylsilanol (48.38 g, 377.4 mmol). The resulting reaction mixture was stirred at room temperature using a mechanical stirrer for 1.5 h. The progress of the reaction was monitored by TLC (5% methanol in dichloromethane). The reaction mixture was quenched with water (1.0 L) and washed with ethyl acetate (3 x 200 mL). Concentrated HCl was added gradually to adjust the aqueous phase to pH ~3-4, and the mixture was extracted with 10% methanol in dichloromethane (8 x 1.5 L). The combined organic layers were concentrated under reduced pressure to give 1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylic acid (27.0 g, 93%) as an off-white solid. 1HNMR (400 MHz, DMSO-d6): δ 12.50 (br s, 1H), 8.38 (s, 1H), 8.26 (s, 1H), 8.22 (s, 1H), 7.88 (d, J = 6.0 Hz, 1H), 4.17 (t, J = 6.4 Hz, 1H), 2.98–2.88 (m, 2H), 2.68–2.57 (m, 2H), 2.18 (s, 3H). LCMS calculated molecular weight 309.10, found m / z 310.1 [M+H] + .

[0804] Step 3: (S)-N-(2-azido-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methyl-pyrimidin-4-yl)-1H-imidazole-4-amide

[0805]

[0806] To a stirred solution of 1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxylic acid (5.5 g, 17.79 mmol) in dichloromethane:N,N-dimethylformamide (150 mL:50 mL) were added N,N-diisopropylethylamine (15.49 mL, 88.98 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (6.82 g, 35.54 mmol), hydroxybenzotriazole (1.399 g, 88.99 mmol), and (S)-2-azido-1-(3-chlorophenyl)ethanamine hydrochloride (4.950 g, 19.41 mmol). The mixture was then stirred at room temperature for 16 h. The reaction progress was monitored by TLC (5% methanol in dichloromethane). The reaction mixture was quenched with water (500 mL), followed by the addition of saturated sodium bicarbonate solution (50 mL), and extracted with ethyl acetate (3 x 250 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by gradient column chromatography using a 60-120 mesh silica gel column, eluting with 3% methanol in dichloromethane. The collected fractions were concentrated under reduced pressure to yield (S)-N-(2-azido-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methyl-pyrimidin-4-yl)-1H-imidazole-4-amide (6.0 g, 69%) as a yellow gummy oil. 1HNMR (400MHz, DMSO-d6): δ8.87(d,J=9.2Hz,1H),8.38(s,1H),8.30(s,1H),8.13(s, 1H),7.86(d,J=6.0Hz,1H),7.55(s,1H),7.42(d,J=7.2Hz,1H),7.36–7.28(m,2H),5 .25 (d, J = 5.2 Hz, 1H), 4.17 (t, J = 6.4 Hz, 1H), 3.86 (t, J = 12.0 Hz, 1H), 3.65–3.60 (m, 1H), 2.95–2.90 (m, 2H), 2.67–2.60 (m, 2H), 2.20 (s, 3H). LCMS calculated molecular weight 487.14, found m / z 488.1 [M+H] + .

[0807] Step 4: (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-amide

[0808]

[0809] To a stirred solution of (S)-N-(2-azido-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide (6.0 g, 12.30 mmol) in methanol (100 mL) was added zinc powder (6.43 g, 98.38 mmol) and ammonium chloride (5.35 g, 98.38 mmol) in water (25 mL). The mixture was stirred at room temperature for 4 h. The progress of the reaction was monitored by TLC (5% methanol in dichloromethane). The reaction mixture was quenched with ammonia solution (50 mL), filtered through celite, washed with 5% methanol in dichloromethane (25 mL), and the organic layer was separated. The aqueous layer was extracted with 5% methanol in dichloromethane (3 x 80 mL), and the combined organic layers were concentrated under reduced pressure. The residue was purified by gradient chromatography using a 60-120 mesh silica gel column, eluting with 8% methanol / isopropylamine in dichloromethane. Fractions were collected and concentrated under reduced pressure to yield (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide (4.1 g, 72%) as a white solid. 1H NMR (400 MHz, DMSO-d6): δ8.54 (d, J=8.0 Hz, 1H), 8.38 (s, 1H), 8.29 (s, 1H), 8.10 (s, 1H), 7.86 (d, J=5.6 Hz, 1H), 7.40 (s, 1H), 7.35–7.25 (m, 3H), 4.93–4.88 (m, 1H), 4.17 (d, J=6.0 Hz, 1H), 2.90–2.84 (m, 4H), 2.68–2.55 (m, 2H), 2.20 (s, 3H), 1.54 (br s, 2H). LCMS calculated molecular weight: 461.15, found: m / z 462.1 [M+H]. + .HPLC purity: 99.98%, Chiral HPLC: 99.97%, mp 104.3℃.

[0810] Example 24: (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (Compound #275).

[0811] Step 1: tert-Butyl (S)-(1-(3-chloro-5-fluorophenyl)-2-hydroxyethyl)carbamate

[0812]

[0813] To a stirred solution of (S)-2-amino-2-(3-chloro-5-fluorophenyl)ethanol hydrochloride (10 g, 44.44 mmol) in t-butanol (100 mL) was added 2N NaOH (2.22 g, 55.55 mmol dissolved in 111 mL of water) and di-tert-butyl dicarbonate (13.56 g, 62.22 mmol). The resulting mixture was stirred at 70°C for 12 h. The progress of the reaction was monitored by TLC. The reaction was then quenched with water (2 x 100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed sequentially with water (30 mL) and brine (30 mL), dried over sodium sulfate, filtered, and evaporated under reduced pressure to yield 13 g of the crude product. The crude product was combined with two other batches of crude product prepared in a similar manner, and the combined materials were purified by gradient column chromatography using ethyl acetate in n-hexane as the eluent to give tert-butyl (S)-(1-(3-chloro-5-fluorophenyl)-2-hydroxyethyl)carbamate as an off-white solid (94% yield). 1HNMR (400 MHz, DMSO-d6): δ7.26–7.23 (m, 2H), 7.20 (s, 1H), 7.11 (d, J = 8 Hz, 1H), 4.83 (t, J = 4 Hz, 1H), 4.52–4.50 (m, 1H), 3.50–3.43 (m, 2H), 1.34 (s, 9H). LC-MS calculated molecular weight 289.74, found m / z 190.0 [M+H–Boc] + .

[0814] Step 2: (S)-2-((tert-Butoxycarbonyl)amino)-2-(3-chloro-5-fluorophenyl)ethyl methanesulfonate

[0815]

[0816] To a stirred solution of tert-butyl (S)-(1-(3-chloro-5-fluorophenyl)-2-hydroxyethyl)carbamate (12 g, 41.52 mmol) in dichloromethane (100 mL) at 0°C was added triethylamine (6.93 mL, 49.83 mmol), and the mixture was stirred at 0°C for 10 minutes. Methanesulfonyl chloride (3.73 mL, 45.674 mmol) was then added, and the mixture was stirred at room temperature for 1 hour. The progress of the reaction was monitored by TLC. The reaction was then quenched with water (100 mL) and extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with saturated ammonium chloride solution (100 mL) and brine (50 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated under reduced pressure to give (S)-2-((tert-butoxycarbonyl)amino)-2-(3-chloro-5-fluorophenyl)ethyl methanesulfonate (15.25 g) as a pale yellow solid, which was used in the next step without further purification. 1 HNMR (400 MHz, DMSO-d6): δ7.68 (d, J=8.4 Hz, 1H), 7.36 (s, 1H), 7.33 (s, 1H), 7.29 (d, J=9.6 Hz, 1H), 4.28–4.19 (m, 2H), 3.15 (s, 3H), 1.36 (s, 9H). LC-MS calculated molecular weight 367.07, found m / z 268.0 [M+H–Boc] + .

[0817] Step 3: tert-Butyl (S)-(2-azido-1-(3-chloro-5-fluorophenyl)ethyl)carbamate

[0818]

[0819] To a stirred solution of (S)-2-((tert-butoxycarbonyl)amino)-2-(3-chloro-5-fluorophenyl)ethyl methanesulfonate (15.25 g, 41.55 mmol) in N,N-dimethylformamide (100 mL) at room temperature was added sodium azide (5.4 g, 83.11 mmol). The reaction mixture was heated at 60°C for 12 h. The progress of the reaction was monitored by TLC. The reaction mixture was then cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed sequentially with water (100 mL) and brine (100 mL), dried over sodium sulfate, filtered, and evaporated under reduced pressure. This crude product was combined with two other batches of crude product prepared in a similar manner, and the combined material was purified by gradient column chromatography using ethyl acetate in n-hexane as the eluent to afford tert-butyl (S)-(2-azido-1-(3-chloro-5-fluorophenyl)ethyl)carbamate as an off-white solid (83% yield). 1 HNMR (400 MHz, DMSO-d6): δ7.66 (d, J = 8.0 Hz, 1H), 7.31 (bs, 2H), 7.21 (d, J = 12.0 Hz, 1H), 4.77–4.75 (m, 1H), 4.44 (d, J = 8.0 Hz, 2H), 1.36 (s, 9H). LC-MS calculated molecular weight 314.09, found m / z 259 [M+H–tBu] + .

[0820] Step 4: (S)-2-Azido-1-(3-chloro-5-fluorophenyl)ethanamine hydrochloride

[0821]

[0822] At 0℃, add the stirred solution of 1,4-dichlorobenzene to the To a solution of (S)-(2-azido-1-(3-chloro-5-fluorophenyl)ethyl)carbamic acid tert-butyl ester (10 g, 31.85 mmol) in 1,4-diol (100 mL) was added dropwise The product was added to a mixture of 4 M HCl in 100 mL of pentane. The reaction mixture was stirred at room temperature for 3 h. Excess solvent was evaporated under reduced pressure to yield a solid residue. The solid was washed with pentane (2 x 50 mL) and dried to yield (S)-2-azido-1-(3-chloro-5-fluorophenyl)ethanamine hydrochloride (7.87 g, 98.8%) as an off-white solid. 1HNMR (400 MHz, DMSO-d6): δ8.94 (br s, 3H), 7.56 (s, 1H), 7.49 (d, J = 4.8 Hz, 2H), 4.55 (t, J = 6.4 Hz, 1H), 3.92–3.81 (m, 2H). LC-MS calculated molecular weight: 214.04, observed m / z: 215.1 [M+H] + .

[0823] Step 5: (S)-N-(2-azido-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide

[0824]

[0825] Under argon, to a stirred solution of 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylic acid (12.2 g, 40.26 mmol) in N,N'-dimethylformamide (120 mL) were added triethylamine (16.8 mL, 120.79 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (15.44 g, 80.53 mmol), hydroxybenzotriazole (3.08 g, 20.13 mmol), and (S)-2-azido-1-(3-chloro-5-fluorophenyl)ethanamine hydrochloride (8.01 g, 32.21 mmol). The resulting mixture was stirred at room temperature for 16 h. The reaction progress was monitored by TLC (8% methanol in dichloromethane). The reaction mixture was diluted with water (2 x 100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with saturated ammonium chloride solution (1 x 200 mL), saturated sodium bicarbonate solution (1 x 200 mL), and brine (1 x 50 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to yield the desired crude product. This crude product was combined with two other batches of crude product prepared in a similar manner, and the combined material was purified by gradient column chromatography using methanol in dichloromethane as the eluent to yield (S)-N-(2-azido-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide as an off-white solid (69%). 1H NMR (400 MHz, DMSO-d6): δ 8.90 (d, J = 8.8 Hz, 1H), 8.34 (s, 1H), 8.28 (s, 1H), 8.11 (s, 1H), 7.42 (s, 1H), 7.34–7.31 (m, 3H), 5.29–5.23 (m, 1H), 3.86 (br s, 1H), 3.85–3.84 (m, 3H), 3.66–3.62 (m, 1H), 3.36 (t, J = 10.8 Hz, 2H), 2.17 (s, 3H), 1.80 (d, J = 10.8 Hz, 2H), 1.51–1.44 (m, 2H). LCMS calculated molecular weight: 499.16, found: m / z 500.1 [M+H]. + .

[0826] Step 6: (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide

[0827]

[0828] To a stirred solution of (S)-N-(2-azido-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (9.0 g, 18.04 mmol) in methanol (100 mL) was added zinc powder (5.89 g, 90.18 mmol). Ammonium chloride (4.823 g, 90.18 mmol) dissolved in water (20 mL) was added at 0°C, and the mixture was stirred at room temperature for 3 h. The progress of the reaction was monitored by TLC (8% methanol in dichloromethane). The reaction mixture was quenched with saturated sodium bicarbonate solution (100 mL) and methanol (100 mL), filtered through celite, and washed with methanol. The filtrate was evaporated, diluted with 50 mL of sodium bicarbonate, and extracted with DCM (3 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered, and evaporated to yield a crude product. This crude product was combined with two other batches of crude product prepared in a similar manner, and the combined materials were purified by gradient column chromatography using methanol in dichloromethane and 0.1% isopropylamine as eluents to yield (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (18.5 g, 55%) as an off-white solid. 1HNMR (400MHz, DMSO-d6): δ8.58(d,J=8Hz,1H),8.34(s,1H),8.27(s,1H),8.08(s,1H),7. 35(d,J=7.2Hz,1H),7.28–7.25(m,2H),7.19(d,J=9.2Hz,1H),4.93–4.90(m,1H),3.90(br s,1H),3.83(d,J=11.6Hz,2H),3.36(t,J=10.8Hz,2H),2.95–2.95(m,1H),2.91–2.88(m,1H),2.17(s,3H),1.98–1.9(br s, 2H), 1.80 (d, J = 12 Hz, 2H), 1.50–1.46 (m, 2H), LCMS accurate molecular weight calculated value 473.17, found value m / z 474.2 [M+H] + .HPLC purity: 99.79%, chiral HPLC purity: 99.92%.

[0829] Example 25: N-(3-Chloro-5-fluoro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (Compound #297).

[0830] Step 1: 2-Chloro-4-fluoro-6-methylbenzoic acid

[0831]

[0832] To a stirred solution of 4-fluoro-2-methylbenzoic acid (5.0 g, 32.46 mmol) in N,N-dimethylformamide (20 mL) were added palladium acetate (1.74 g, 2.59 mmol) and N-chlorosuccinimide (6.4 g, 48.70 mmol), and the mixture was stirred at 100°C for 16 h. The reaction mixture was cooled, diluted with saturated thiosulfate solution (200 mL), and extracted with ethyl acetate (2 x 500 mL). The combined organic layers were washed with brine (50 mL), concentrated under reduced pressure, and dried under vacuum to afford a brown solid mixture of 2-chloro-4-fluoro-6-methylbenzoic acid and 4-fluoro-6-methylbenzoic acid (5 g, crude product mixture), which was used directly in the next step without purification. The LC-MS accurate molecular weight of 2-chloro-4-fluoro-6-methylbenzoic acid was calculated to be 188.0, and the observed value was m / z 189.1 [M+H]. + .

[0833] Step 2: 2-Chloro-4-fluoro-6-methylbenzoic acid

[0834]

[0835] To a stirred solution of 2-chloro-4-fluoro-6-methylbenzoic acid and 4-fluoro-6-methylbenzoic acid (5 g) in methanol (100 mL) was added sulfite chloride (11.6 mL, 159.5 mmol) dropwise at 0°C. The reaction mixture was stirred at 85°C for 2 h. The reaction mixture was evaporated, quenched with saturated sodium bicarbonate solution (100 mL), and extracted with ethyl acetate (2 x 300 mL). Concentrated HCl was then added to adjust the aqueous layer to pH 6–7. The compound was extracted with ethyl acetate (2 x 300 mL). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄, and concentrated under reduced pressure to afford 2-chloro-4-fluoro-6-methylbenzoic acid (2 g) as a brown solid, which was used directly without further purification. LC-MS calculated exact molecular weight: 188.0, observed m / z: 189.0 [M+H] + .

[0836] Step 3: Methyl 2-chloro-4-fluoro-6-methylbenzoate

[0837]

[0838] To a stirred solution of 2-chloro-4-fluoro-6-methylbenzoic acid (2 g, 10.63 mmol) in N,N-dimethylformamide (15 mL) at 0°C were added potassium carbonate (2.9 g, 21.27 mmol) and methyl iodide (3.3 mL, 53.19 mmol), and the mixture was stirred at room temperature for 2 h. The reaction progress was monitored by TLC. The reaction mixture was quenched with water (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, and concentrated under reduced pressure to give methyl 2-chloro-4-fluoro-6-methylbenzoate (2 g) as a colorless oil, which was used directly without further purification. LC-MS calculated molecular weight: 202.02, observed value: m / z 203.0 [M+H] + .

[0839] Step 4: Methyl 2-(bromomethyl)-6-chloro-4-fluorobenzoate

[0840]

[0841] To a stirred solution of methyl 2-chloro-4-fluoro-6-methylbenzoate (2 g, 9.9 mmol) in carbon tetrachloride (5 mL) were added N-bromosuccinimide (1.9 g, 10.8 mmol) and benzoyl peroxide (0.239 g, 0.99 mmol). The resulting mixture was stirred at 80°C for 12 h. The reaction was monitored by TLC. The reaction mixture was quenched with 1% sodium hydroxide solution (50 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, and concentrated under reduced pressure to afford methyl 2-(bromomethyl)-6-chloro-4-fluorobenzoate (2 g, crude) as a brown liquid. LC-MS calculated molecular weight: 279.93, observed m / z: 281.0 [M+H] + .

[0842] Step 5: Methyl 2-(azidomethyl)-6-chloro-4-fluorobenzoate

[0843]

[0844] To a stirred solution of methyl 2-(bromomethyl)-6-chloro-4-fluorobenzoate (2 g, 7.16 mmol) in N,N-dimethylformamide (10 mL) at 0°C was added sodium azide (0.931 g, 14.33 mmol). The resulting mixture was stirred at 70°C for 6 h. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with ice water (100 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to give methyl 2-(azidomethyl)-6-chloro-4-fluorobenzoate (1.5 g, crude) as a brown solid. LC-MS calculated exact molecular weight: 243.02; observed m / z: 218.0 for [M–N2+H3]. + .

[0845] Step 6: (2-(Aminomethyl)-6-chloro-4-fluorophenyl)methanol

[0846]

[0847] To a stirred solution of methyl 2-(azidomethyl)-6-chloro-4-fluorobenzoate (0.2 g, 0.823 mmol) in THF (10 mL) at 0°C was slowly added lithium aluminum hydride (0.108 g, 3.29 mmol). The resulting mixture was stirred at room temperature for 12 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with ice water (50 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to give (2-(aminomethyl)-6-chloro-4-fluorophenyl)methanol (0.2 g, crude product). LC-MS calculated accurate molecular weight: 189.04, observed m / z: 190.1 [M+H] + .

[0848] Step 7: N-(3-chloro-5-fluoro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide

[0849]

[0850] To a stirred solution of 1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxylic acid (0.1 g, 0.33 mmol) in dichloromethane (10 mL) was added (2-(aminomethyl)-6-chloro-4-fluorophenyl)methanol (0.093 g, 0.495 mmol), N,N-diisopropylethylamine (0.16 mL, 0.9 mmol), and then 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.075 g, 0.396 mmol) and hydroxybenzotriazole (0.06 g, 0.396 mmol). The resulting mixture was stirred at room temperature for 12 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with ice water (50 mL) and extracted with dichloromethane (2 x 200 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. The residue was purified on a Biotage Isolera system using methanol in dichloromethane as eluent to provide N-(3-chloro-5-fluoro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (0.015 g, 9.5%) as an off-white solid. 1HNMR (400 MHz, DMSO-d6): δ8.73 (t, 1H), 8.33 (s, 1H), 8.26 (s, 1H), 8.11 (s, 1H), 7.35 (d, J = 7.6 Hz, 1H), 7.30–7.28 (m, 1H), 7.10–7.07 (m, 1H), 5.22 (t, 1H), 4.71 (d, J = 5.2 Hz, 2H), 4.60 (d, J = 6 Hz, 2H), 3.89 (s, 1H), 3.83 (d, J = 10.8 Hz, 2H), 3.39–3.32 (m, 2H), 2.17 (s, 3H), 1.82 (t, 2H), 1.53–1.44 (m, 2H). LC-MS calculated molecular weight: 474.16, observed value: m / z 475.1[M+H] + .HPLC purity 98.2%.

[0851] Example 26: (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide hydrochloride (Compound #298).

[0852] At 0℃, dissolve in 1,4-dichlorobenzene To a solution of (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (0.1 g, 0.21 mmol) in 1,4-dimethoxybenzyl alcohol (10 mL) was slowly added. The mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated, washed with diethyl ether, and dried to give (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide hydrochloride (0.1 g, 93%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ 8.90 (d, J = 9.2 Hz, 1H), 8.35 (s, 1H), 8.29 (s, 1H), 8.14 (s, 1H), 7.97 (br s, 3H), 7.51 (s, 1H), 7.42–7.37 (m, 4H), 5.32 (d, J = 4.4 Hz, 1H), 3.83 (d, J = 11.6 Hz, 3H), 3.38–3.35 (m, 2H), 3.31–3.23 (m, 2H), 2.16 (s, 3H), 1.80 (d, J = 12.8 Hz, 2H), 1.49 (t, 2H). LC-MS calculated molecular weight: 455.18, found: m / z 456.2 for [M+H]. + .HPLC purity 98.79%, melting point: 193-195℃.

[0853] Example 27: (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide p-toluenesulfonate (Compound #299).

[0854]

[0855] At 0℃, dissolve in 1,4-dichlorobenzene To a solution of (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (0.1 g, 0.21 mmol) in 1,2-dimethoxy-2-nitropropane (6 mL) was slowly added p-toluenesulfonic acid monohydrate (0.041 g, 0.22 mmol). The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated, washed with diethyl ether, and dried to give (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide p-toluenesulfonate (0.104 g, 74%) as an off-white solid. 1HNMR (400 MHz, DMSO-d6): δ8.81 (d, J=8.8 Hz, 1H), 8.35 (s, 1H), 8.29 (s, 1H), 8.11 (s, 1H), 7.46 (t, 2H), 7.41–7.35 (m, 4H), 7.09–7.07 (br s, 3H), 5.24 (d, J=4 Hz, 1H), 3.85–3.82 (m, 3H), 3.38–3.27 (m, 3H), 3.18–3.13 (m, 1H), 2.30 (s, 3H), 2.16 (s, 2H), 1.80 (d, J=11.6 Hz, 2H), 1.52–1.44 (m, 2H). LC-MS calculated molecular weight: 455.18, observed value: m / z 456.2for[M+H] + .HPLC purity 99.32%.

[0856] Example 28: (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide benzenesulfonate (Compound #300).

[0857] At 0℃, dissolve in 1,4-dichlorobenzene To a solution of (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (6 g, 13.18 mmol) in dextrin (360 mL) was slowly added benzenesulfonic acid (2.08 g, 13.18 mmol). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was evaporated, washed with diethyl ether, and dried to give (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide benzenesulfonate (6 g, 74%) as an off-white solid. Melting point: 141-142.5°C. 1HNMR (400 MHz, DMSO-d6): δ8.89 (d, J = 9.2 Hz, 1H), 8.35 (s, 1H), 8.29 (s, 1H), 8.12 (s, 1H), 7.91 (br s, 3H), 7.58 (d, J = 5.6 Hz, 2H), 7.51 (s, 1H), 7.42–7.35 (m, 4H), 7.28 (d, J = 6 Hz, 3H), 5.34–5.31 (m, 1H), 3.85–3.82 (m, 3H), 3.41–3.32 (m, 3H), 3.28 (s, 1H), 2.16 (s, 3H), 1.80 (d, J = 11.6 Hz, 2H), 1.49 (t, 2H). LC-MS calculated molecular weight: 455.18, observed value: m / z 456.2for[M+H] + .HPLC purity 98.63%.

[0858] Example 29: (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-amide hydrochloride (Compound #301).

[0859] At 0℃, add the stirred solution of 1,4-dichlorobenzene to the To a solution of (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide (1 g, 2.16 mmol) in dioxane (20 mL) was slowly added 2-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide (1 g, 2.16 mmol). The mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated, washed with diethyl ether, and dried to give (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-amide hydrochloride (1 g, 93%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ8.90 (d, J=8.8 Hz, 1H), 8.39 (s, 1H), 8.31 (s, 1H), 8.18 (s, 1H), 7.88 (d, J=4.8 Hz, 1H), 7.62 (br s, 3H), 7.50 (s, 1H), 7.38–7.35 (m, 3H), 5.29 (d, J=4 Hz, 1H), 4.16 (s, 1H), 3.39–3.28 (m, 1H), 3.18–3.14 (m, 1H), 2.92 (t, 2H), 2.61 (t, 2H), 2.19 (s, 3H). LC-MS calculated molecular weight: 461.15, found: m / z 462.1 for [M+H]. + .HPLC purity 99.81%, melting point: 213-216℃.

[0860] Example 30: (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide benzenesulfonate (Compound #302).

[0861] At 0℃, add the stirred solution of 1,4-dichlorobenzene to the To a solution of (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide (0.2 g, 0.422 mmol) in 1,2-dimethoxy-2-nitropropane (10 mL) was slowly added benzenesulfonic acid (0.066 g, 0.422 mmol). The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated, washed with diethyl ether, and dried to give (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide benzenesulfonate (0.22 g, 83%) as an off-white solid. 1HNMR (400 MHz, DMSO-d6): δ8.92 (d, J = 8.8 Hz, 1H), 8.35 (s, 1H), 8.30 (s, 1H), 8.13 (s, 1H), 7.83 (br s, 3H), 7.57 (d, J = 6.4 Hz, 2H), 7.37 (s, 3H), 7.28 (d, J = 6.4 Hz, 4H), 5.32 (d, J = 4.4 Hz, 1H), 3.83 (d, J = 11.6 Hz, 3H), 3.41–3.27 (m, 3H), 3.18–3.14 (m, 1H), 2.16 (s, 3H), 1.80 (d, J = 12 Hz, 2H), 1.52–1.44 (m, 2H). LC-MS calculated molecular weight: 473.17, observed value: m / z 474.2[M+H] + .HPLC purity 99.85%, melting point: 161-162℃.

[0862] Example 31: (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide p-toluenesulfonate (Compound #303).

[0863] At 0℃, add the stirred solution of 1,4-dichlorobenzene to the To a solution of (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide (0.1 g, 2.16 mmol) in 1,2-difluoro-1,4-dioxane (6 mL) was slowly added p-toluenesulfonic acid monohydrate (0.041 g, 2.16 mmol). The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated, washed with diethyl ether, and dried to give (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide p-toluenesulfonate (0.11 g, 78%) as an off-white solid. 1HNMR (400MHz, DMSO-d6): δ8.88(d,J=9.2Hz,1H),8.39(s,1H),8.32(s,1H),8.14(s,1H),7.87(d,J=5.2Hz,2H),7.75(br s, 3H), 7.51 (s, 1H), 7.46–7.42 (m, 2H), 7.40–7.35 (m, 3H), 7.08 (d, J = 7.6 Hz, 2H), 5.31 (d, J = 4.4 Hz, 1H), 4.16 (s, 1H), 3.40–3.27 (m, 1H), 3.24–3.19 (m, 1H), 2.92 (t, 2H), 2.61 (t, 2H), 2.26 (s, 3H), 2.19 (s, 3H). LC-MS calculated molecular weight 461.15, found m / z 462.1 for [M+H] + .HPLC purity 98.11%, melting point: 150-151℃.

[0864] Example 32: (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-amide benzenesulfonate (Compound #304).

[0865] At 0℃, add the stirred solution of 1,4-dichlorobenzene to the To a solution of (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-amide (0.25 g, 0.541 mmol) in 1,2-difluoro-1,4-dioxane (12 mL) was slowly added benzenesulfonic acid (0.085 g, 0.541 mmol). The reaction mixture was stirred at room temperature for 1.0 h. The reaction mixture was evaporated, washed with diethyl ether, and dried to give (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-amide benzenesulfonate (0.28 g, 83%) as an off-white solid. 1HNMR (400MHz, DMSO-d6): δ8.88(d,J=8.8Hz,1H),8.39(s,1H),8.32(s,1H),8.14(s,1H),7.87(d,J=4.8Hz,1H),7.72(br s, 3H), 7.57 (d, J = 6 Hz, 2H), 7.51 (s, 1H), 7.42–7.37 (m, 3H), 7.28 (d, J = 6.4 Hz, 3H), 5.31 (d, J = 4.4 Hz, 1H), 4.16 (s, 1H), 3.39–3.27 (m, 1H), 3.23 (d, J = 4.8 Hz, 1H), 2.92 (t, 2H), 2.63 (d, J = 12 Hz, 2H), 2.19 (s, 3H). LC-MS calculated molecular weight 461.15, found m / z 462.1 for [M+H] + .HPLC purity 99.82%, melting point: 155–156°C.

[0866] Example 33: (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide hydrochloride (Compound #305).

[0867] At 0℃, add the stirred solution of 1,4-dichlorobenzene to the To a solution of (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (0.05 g, 0.105 mmol) in dioxane (3 mL) was slowly added 2-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (0.05 g, 0.105 mmol). The mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated, washed with diethyl ether, and dried to give (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide hydrochloride (0.05 g, 94%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ 8.95 (d, J = 8.8 Hz, 1H), 8.35 (s, 1H), 8.30 (s, 1H), 8.15 (s, 1H), 8.00 (br s, 3H), 7.37 (br s, 3H), 7.28 (d, J = 9.6 Hz, 1H), 5.33 (t, 1H), 3.85–3.82 (m, 3H), 3.37–3.33 (m, 3H), 3.25 (t, 1H), 2.16 (s, 3H), 1.80 (d, J = 11.6 Hz, 2H), 1.52–1.44 (m, 2H). LC-MS calculated molecular weight: 473.17, found: m / z 474.2 for [M+H]. + .HPLC purity 99.86%, melting point: 210-211℃.

[0868] With reference to the schemes described above and the data obtained and used when characterizing the prepared compounds, Table 1 below summarizes the synthetic methods used to prepare the compounds described in the present invention. In some examples, the synthetic method used is a combination of two different methods, which is illustrated by citing two scheme numbers in the table below. In certain other examples, the method used is a slightly modified version of the method represented by the scheme number, and such modified versions are obvious to those skilled in the art. In other examples, the synthetic method is illustrated by the scheme number in the table and is slightly chemically modified by methods well known to those skilled in the art.

[0869] Table 1

[0870]

[0871]

[0872]

[0873]

[0874]

[0875]

[0876]

[0877]

[0878]

[0879]

[0880]

[0881]

[0882]

[0883]

[0884]

[0885]

[0886]

[0887]

[0888]

[0889]

[0890]

[0891]

[0892]

[0893]

[0894]

[0895]

[0896]

[0897]

[0898]

[0899]

[0900]

[0901]

[0902]

[0903]

[0904]

[0905]

[0906]

[0907]

[0908]

[0909]

[0910]

[0911]

[0912]

[0913]

[0914]

[0915]

[0916]

[0917]

[0918]

[0919]

[0920]

[0921]

[0922]

[0923]

[0924]

[0925]

[0926]

[0927]

[0928]

[0929]

[0930]

[0931]

[0932]

[0933]

[0934]

[0935]

[0936]

[0937]

[0938]

[0939]

[0940]

[0941]

[0942]

[0943]

[0944]

[0945]

[0946]

[0947]

[0948]

[0949]

[0950]

[0951]

[0952]

[0953]

[0954]

[0955]

[0956]

[0957]

[0958]

[0959]

[0960]

[0961]

[0962]

[0963]

[0964]

[0965]

[0966]

[0967]

[0968]

[0969]

[0970]

[0971]

[0972]

[0973]

[0974]

[0975]

[0976]

[0977]

[0978]

[0979]

[0980]

[0981]

[0982]

[0983]

[0984]

[0985]

[0986]

[0987]

[0988]

[0989]

[0990]

[0991]

[0992]

[0993]

[0994]

[0995]

[0996]

[0997]

[0998]

[0999]

[1000]

[1001]

[1002]

[1003]

[1004]

[1005]

[1006]

[1007]

[1008]

[1009]

[1010]

[1011]

[1012]

[1013]

[1014]

[1015]

[1016]

[1017]

[1018]

[1019]

[1020]

[1021] Example 34. Biological detection

[1022] ERK1 and ERK2 HTRF (biochemical) detection

[1023] Detection was performed using homogeneous time-resolved fluorescence (HTRF) technology. Compounds dissolved in assay buffer (50 mM Tris pH 7.5, 1 mM EGTA, 2 mM DTT, 10 mM MgCl2, 0.1% Tween-20) were serially diluted at half-log scales from 0.0005 to 10 μM. Twenty μL of a substrate-ATP mixture (1 μM biotin-LC-myelin basic protein (MBP)-derived peptide (Anaspec)-24 μM ATP (Sigma)) was added to each well of the assay plate. Subsequently, 10 μL of an enzyme mixture (25 nM ERK1 or ERK2 (Jubilant Biosys) dissolved in assay buffer) was added to each well. The plates were incubated with shaking at room temperature for 60 minutes. Prepare HTRF mixture [625 nM dissolved in HTRF buffer (50 mM Tris-HCl pH=7.5, 100 mM NaCl, 0.1% BSA, 0.05% Tween20, 0.5 mM EDTA) Ultra Europium-anti-phospho-MBP (PerkinElmer) and 2 nM Streptavidin-allophycocyanin (SA-APC) (digestive enzyme)], 75uL of the mixture was added to the HTRF plate. After incubation at room temperature for 60 minutes, 10uL of the reaction mixture was transferred to the HTRF detection plate and incubated at room temperature for 45 minutes. The plate was read using Pherastar in HTRF mode (excitation light 337nm, emission light 665&620nm). GraphPad was then used to analyze the plate. 5. Determine IC using a sigmoidal dose-response curve (variable slope) in the software 50 As shown in the assay, the compounds of the present invention inhibited both ERK1 and ERK2. Table 2 provides representative data.

[1024] Cell proliferation (AlamarBlue) detection

[1025] HT-29 (colon carcinoma, B-RafV600E), HCT116 (colon carcinoma, K Ras G13D), A375 (melanoma, B-RafV600E), and SK-Mel2 (melanoma, NRAS Q61R) cells (obtained from ATCC, USA) were plated into 96-well cell culture plates (5000 cells / well) and cultured at 37°C / 5% CO2 for 16-24 hours. The cells were then treated with the compounds, typically prepared by three-fold serial dilutions in a concentration range of 0.0005 to 10 uM. The plates were incubated at 37°C / 5% CO2 for 72 hours. Alamar Blue was added to each well. TM Reagent (final concentration 1X), incubate at 37°C / 5% CO2 for 1-3 hours. Then read the plate on a fluorescence reader at an excitation wavelength of 540 nm and an emission wavelength of 590 nm. 5. Determine IC using a sigmoidal dose-response curve (variable slope) in the software 50 As confirmed by the assay, the compounds of the present invention inhibited the proliferation of HT-29, HCT116, A375 and SK-Mel2 cells. Table 2 provides representative data of the HT-29 and HCT116 cell proliferation assays.

[1026] Phospho-RSK1 (S380) ELISA detection

[1027] HT-29 cells (colon cancer, B-RafV600E; obtained from ATCC, USA) were added to a 96-well plate (60,000 cells / well), cultured overnight at 37°C / 5% CO2, and then treated with the desired compound dilution for 2 hours. The medium was removed, the cells were rinsed once with ice 1X PBS, 0.070 mL of ice 1X cell lysis buffer containing 1 mM PMSF was added to each well, the plate was placed on a shaker and cultured for 2 hours and placed at 4°C for 30 minutes. The plate was centrifuged at 4°C for 20 minutes (x4000 rpm), and the supernatant was transferred to another new plate. The cell lysate was diluted with sample diluent at a ratio of 1:1. Then, the plate was shaken according to the manufacturer's instructions ( ELISA was performed using a phosphorylated-RSK1 (Ser380) Sandwich ELISA kit (Cell Signaling Technology). The plate was read at 450 nm within 30 minutes after adding the stop solution. GraphPad 5. Determine IC using a sigmoidal dose-response curve (variable slope) in the software 50 As confirmed by the assay, the compounds of the present invention inhibit the phosphorylation of RSK1(S380), a downstream target of ERK1 / 2. Table 2 provides representative data.

[1028] In vivo studies in tumor transplant models

[1029] Animal tumor cell transplantation and random distribution

[1030] Foxn1 nu / nu female mice (obtained from Charles River Laboratories, USA) aged 8-10 weeks and weighing 23-25 ​​g were used for tumor transplantation efficacy studies. Human tumor cell lines (e.g., melanoma A375, colorectal HT29, pancreatic BxPC3, colorectal HCT116, and lung A549) were initially grown in vitro and then inoculated with approximately 5 million (5x10) cells in 100 μL of serum-free medium. 6 The cells were mixed with an equal amount of matrigel and the entire mixture was injected subcutaneously into the right flank of the mouse. Tumor size was measured regularly with a vernier caliper during the first week after injection. Tumor volume reached 120-150 mm 3 At 4 hr (about 3-4 weeks after injection), the animals were randomly divided into different groups so that the tumor volumes of animals in all groups were approximately the same.

[1031] Determination of in vivo tumor growth inhibitory efficacy

[1032] For oral administration, the compound was formulated in 0.5% methylcellulose and 0.01% Tween 80. For intravenous, subcutaneous, or intraperitoneal administration, the compound was dissolved in 6% solutol-ethanol (1:1), 6% DMSO, and 88% saline. Animals were dosed once or twice daily at the desired dose, formulated for oral, intraperitoneal, or subcutaneous administration. Tumor size and body weight were measured two or three times weekly. At the end of the study, animals were euthanized and tumors removed according to approved procedures. A portion of the removed tumors was snap-frozen and submitted for PK studies, while another portion was homogenized and the lysate was tested for target inhibition by western blot. Blood (~200 μL) was collected for PK studies by ocular bleeding prior to tumor removal.

[1033] The tumor volume variable (Δvolumes) of each treatment group (T) and control group (C) was calculated by subtracting the average tumor volume on the first day of treatment (start day) from the average tumor volume on the designated observation day. The value was used to calculate the percentage of growth (% T / C) according to the following formula:

[1034] %T / C = (ΔT / ΔC) x 100, where ΔT > 0, or

[1035] %T / C=(ΔT / ΔTi)×100, where ΔT<0 and Ti is the average tumor volume at the beginning of the experiment.

[1036] The percentage of tumor growth inhibition was calculated as [100-%T / C]. The percentage of body weight change was calculated as [(body weight on the designated observation day - body weight on the starting day) / body weight on the starting day] x 100.

[1037] result

[1038] The compounds of the present invention were active in the aforementioned in vivo tumor transplantation studies. For example, in a human melanoma xenograft model (A375) harboring the B-RAF V600E mutation, oral administration of 50 mg / kg of the compounds of Examples 201 and 211 twice daily for 17 days resulted in approximately 70%-76% tumor growth inhibition. No significant weight loss was observed with any of the compounds at these doses. In an efficacy assay, the compounds of Examples 201 and 211 inhibited phosphorylated RSK (a downstream target of ERK1 / 2) by approximately 66% and 84%, respectively, compared to the control, as measured in A375 tumor specimens removed 1 hour after oral administration at 50 mg / kg. Furthermore, in the same A375 model, oral administration of 50 mg / kg of the compounds of Examples 255, 225a, and 259 twice daily for 19 days resulted in approximately 70%-90% tumor growth inhibition. No significant weight loss was observed with any of the compounds at these doses.

[1039] In a human colon cancer xenograft model (HT-29) with the B-RAF V600E mutation, oral administration of 50 mg / kg of Example 201 compound twice daily for 20 days resulted in approximately 50% tumor growth. The doses studied did not result in significant weight loss.

[1040] In the human pancreatic cancer xenograft model BxPC3 (wild-type KRAS), approximately 63% tumor growth inhibition was achieved by oral administration of 50 mg / kg of Example 201 compound twice daily for 25 days. The doses studied did not result in significant weight loss.

[1041] In a human colon cancer xenograft model (HCT116, with KRAS mutation), approximately 90%-100% tumor growth inhibition was achieved by oral administration of 50 mg / kg of the compounds of Examples 259, 225a, and 275 twice daily for 24 days. The doses studied did not result in significant weight loss.

[1042] In a human lung cancer xenograft model (A549, with KRAS mutation), approximately 65%-82% tumor growth inhibition was achieved by oral administration of 50 mg / kg twice daily for 20 days of the compounds of Examples 304, 302, and 300. The doses studied did not result in significant weight loss.

[1043] Table 2: Biochemical, kinetic, and cell-based proliferation assay results

[1044]

[1045]

[1046]

[1047]

[1048]

[1049]

[1050]

[1051]

[1052]

[1053]

[1054]

[1055]

[1056] 1 Biochemical testing: IC 50 Values: A:≤50nM, B:>50 to 100nM, C:>100 to 500nM, D:>500nM to 2.5uM, E:>2.5uM, NA: Data not available

[1057] 2 Kinetic cell assays and cell proliferation assays: IC 50 Values; A: ≤100nM, B: >100-250nM, C: >250-500nM, D: >500nM-2.5uM, E: >2.5uM; NA: data not available.

[1058] In one embodiment, the compound is selected from the following group:

[1059] (S)-1-(2)-(Benzo[d][1,3]dioxol-5-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide;

[1060] 1-(2-(Benzofuran-5-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide;

[1061] 1-(2-(Benzofuran-5-ylamino)-5-methylpyrimidin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-3-carboxamide;

[1062] N-(3-chloro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide; (S)-N-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide

[1063] 1-(2-((2,3-dihydrobenzofuran-5-yl)amino)5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-((2,3-dihydrobenzo[b][1,4]dihydro)pyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide (6-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1064] N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide; N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(((S)-tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1065] N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(((R)-tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1066] 1-(2-(Dihydrochromen-6-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-((4-fluoro-3-morpholinylphenyl)amino)-5-methyl-pyrimidin-4-yl)-1H-pyrrole-3-carboxamide; N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((4-fluorophenyl) -4-yl)-1H-imidazole-4-amide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((4-morpholinylphenyl)amino)pyrimidin-4-yl)-1H-pyrrole-3-amide;

[1067] (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[1068] (R)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[1069] (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[1070] (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-fluoro-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1071] N-(2-hydroxy-1-(thiophen-2-yl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1072] (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1073] (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1074] (S)-N-(2-(((1H-pyrrol-2-yl)methyl)amino)-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1075] (S)-N-(3-chloro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-(tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1076] (S)-N-(1-(3-chlorophenyl)-2-(methylamino)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1077] (S)-N-(1-(3-chlorophenyl)-2-((2-hydroxyethyl)amino)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide; and

[1078] N-(3-chloro-5-fluoro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide; or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, or stereoisomer thereof.

[1079] In one embodiment, the compound of formula (I) as defined in the preceding embodiments is substantially a pure stereoisomer.

[1080] In one embodiment, the composition comprises at least one compound of formula (I) as defined in the above embodiments or a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof and a pharmaceutically acceptable carrier.

[1081] In one embodiment, the composition comprises at least one compound selected from the group consisting of:

[1082] (S)-1-(2)-(Benzo[d][1,3]dioxol-5-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide;

[1083] 1-(2-(Benzofuran-5-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide;

[1084] 1-(2-(Benzofuran-5-ylamino)-5-methylpyrimidin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-3-carboxamide;

[1085] N-(3-chloro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide; (S)-N-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1086] 1-(2-((2,3-dihydrobenzofuran-5-yl)amino)5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-((2,3-dihydrobenzo[b][1,4]dihydro)pyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide (6-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1087] N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide; N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(((S)-tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1088] N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(((R)-tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1089] 1-(2-(Dihydrochromen-6-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-((4-fluoro-3-morpholinylphenyl)amino)-5-methyl-pyrimidin-4-yl)-1H-pyrrole-3-carboxamide; N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((4-fluorophenyl) -4-yl)-1H-imidazole-4-amide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((4-morpholinylphenyl)amino)pyrimidin-4-yl)-1H-pyrrole-3-amide;

[1090] (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[1091] (R)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[1092] (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[1093] (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-fluoro-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1094] N-(2-hydroxy-1-(thiophen-2-yl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1095] (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1096] (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1097] (S)-N-(2-(((1H-pyrrol-2-yl)methyl)amino)-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1098] (S)-N-(3-chloro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-(tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1099] (S)-N-(1-(3-chlorophenyl)-2-(methylamino)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide;

[1100] (S)-N-(1-(3-chlorophenyl)-2-((2-hydroxyethyl)amino)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide; and

[1101] N-(3-chloro-5-fluoro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof and a pharmaceutically acceptable carrier.

[1102] In one embodiment, each of the above compositions further comprises an additional therapeutic agent.

[1103] In one embodiment, a method for treating a disease that can be treated by inhibiting ERK1 / 2 comprises administering to a subject in need thereof a composition comprising a therapeutically effective amount of at least one compound of formula (I) as defined in the preceding embodiments, thereby at least slowing the progression of the disease.

[1104] In another embodiment, the condition is cancer, leukemia or lymphoma, including cancer of the prostate, head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, bladder, uterus, cervix, breast, ovary, vagina, testicle, skin, thyroid, blood, lymph node, kidney, liver, intestine, pancreas, brain, central nervous system, adrenal gland, skin, etc.

[1105] In one embodiment, a method for treating a condition treatable by inhibiting ERK1 / 2 comprises administering to a subject in need thereof a composition comprising a therapeutically effective amount of at least one compound selected from the following groups:

[1106] (S)-1-(2-(Benzo[d][1,3]dioxol-5-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide;

[1107] 1-(2-(Benzofuran-5-ylamino)-5-methylpyrimidin-4-yl)-N-(1-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide;

[1108] 1-(2-(Benzofuran-5-ylamino)-5-methylpyrimidin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-3-carboxamide;

[1109] N-(3-chloro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-carboxamide; (S)-N-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1110] 1-(2-((2,3-dihydrobenzofuran-5-yl)amino)5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-((2,3-dihydrobenzo[b][1,4]dihydro)pyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide (6-yl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1111] N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide; N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(((S)-tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1112] N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-(((R)-tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1113] 1-(2-(Dihydrochromen-6-ylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-3-carboxamide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(2-((4-fluoro-3-morpholinylphenyl)amino)-5-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide; N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((4-fluorophenyl) -amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-amide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)-amino)pyrimidin-4-yl)-1H-imidazole-4-amide; N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((4-morpholinylphenyl)-amino)pyrimidin-4-yl)-1H-pyrrole-3-amide;

[1114] (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)1H-imidazole-4-amide;

[1115] (R)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1116] (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[1117] (S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1-(5-fluoro-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-pyrrole-3-carboxamide;

[1118] N-(2-hydroxy-1-(thiophen-2-yl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[1119] (S)-N-(2-amino-1-(3-chlorophenyl)ethyl)-1-(2-((3,3-difluorocyclobutyl)amino)-5-methylpyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1120] (S)-N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1121] (S)-N-(2-(((1H-pyrrol-2-yl)methyl)amino)-1-(3-chlorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1122] (S)-N-(3-chloro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-(tetrahydrofuran-3-yl)amino)-pyrimidin-4-yl)-1H-imidazole-4-amide;

[1123] (S)-N-(1-(3-chlorophenyl)-2-(methylamino)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide;

[1124] (S)-N-(1-(3-chlorophenyl)-2-((2-hydroxyethyl)amino)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide; and

[1125] N-(3-chloro-5-fluoro-2-(hydroxymethyl)benzyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-amide, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof.

[1126] Although the present invention is described in conjunction with the specific embodiments listed above, some alternatives, modifications and changes are obvious to those skilled in the art. All such alternatives, modifications and changes are in line with the gist of the present invention and do not exceed the scope of the present invention.

Claims

1. A compound of formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl or 5- to 6-membered heteroaryl, wherein the phenyl or 5- to 6-membered heteroaryl is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl or -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, where C 1-6 The alkyl group is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, Hydroxyl C 1-6 Alkyl or amino C 1-6 alkyl; J is selected from -C(R 2 )(R 8 )(CH2)n- linking group; R 8 H or C 1-6 alkyl; R 2 It is H, C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclic group), -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)- N-(C 1-6 Alkyl)2 or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl, cycloalkyl, heterocyclyl or heteroaryl group is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, Hydroxyl C 1-6 Alkyl or amino C 1-6 alkyl; or R 2 , R 8 and R 2 and R 8 The linked carbon atoms together form a 3- to 6-membered cycloalkyl ring; n is 0-2; R 3 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; M is a key; X is CH; Y is CH or N; Z is CH or N, R 5 is H, halogen or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; R 6 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; and R 4 is a 4- to 6-membered monocyclic heterocyclic group which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, CN, C 1-6 Alkyl or hydroxyl.

2. A compound according to claim 1, which has the formula (II), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 2 It is C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclic group), -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N(C 1-6 Alkyl)2 or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl, heterocyclyl or heteroaryl group is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, cycloalkyl, NH2, hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl; and R 8 Is H or C 1-6 alkyl; or R 2 , R 8 and R 2 and R 8 The linked carbon atoms together form a 3- to 6-membered cycloalkyl ring; R 1 is phenyl or 5- to 6-membered heteroaryl, wherein the phenyl or 5- to 6-membered heteroaryl is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl or -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-3 halogens; n is 0 to 2; R 3 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; M is a key; X is CH; Y is CH or N; Z is CH or N; R 5 is H, halogen or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; R 6 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; and R 4 is a 4- to 6-membered monocyclic heterocyclic group which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, CN, C 1-6 Alkyl or hydroxyl.

3. A compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl or 5- or 6-membered heteroaryl, wherein the phenyl or 5- or 6-membered heteroaryl is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 halogens.

4. A compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl, pyridyl, thienyl or thiazolyl, wherein the phenyl, pyridyl, thienyl or thiazolyl is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 halogens.

5. A compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: n is 0 or 1.

6. A compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 2 It is C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclic group), -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl, heterocyclyl or heteroaryl group is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, Hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl, and R 8 It's H.

7. A compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 2 is CH3, CH2OH, CH2NH2, -CH2NH(CH3), -CH2NHCH2CH2OH, -CH2NH-(tetrahydro-2H-pyran) or -CH2NH-CH2-(1H-pyrrole), and R 8 It's H.

8. A compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 3 It is H or CH3.

9. The compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: X is CH; as well as Y is CH or N.

10. The compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Z is N.

11. A compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 5 is H, halogen or C 1-6 alkyl.

12. A compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 6 It's H.

13. A compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 4 yes 14. A compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl, pyridyl, thienyl or thiazolyl, wherein the phenyl, pyridyl, thienyl or thiazolyl is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 substituents selected from halogen; n is 0 or 1; R 2 It is C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-OC 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-N-(C 1-6 Alkyl)2, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH-C 1-6 Alkyl-C 3-10 Cycloalkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C(O)-C 1-6 Alkyl, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(tetrahydro-2H-pyran), -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N(C 1-6 Alkyl)2 or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(1H-pyrrole), where C 1-6 The alkyl group is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, Hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl; and R 8 Is H or C 1-6 alkyl; Or, R 2 , R 8 and R 2 and R 8 The attached carbon atoms together form a cyclobutyl group; R 3 Is H or C 1-6 alkyl; X is CH; Y is CH or N; Z is CH or N, R 5 is H, halogen or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; R 6 is H; and R 4 yes 15. The compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl, pyridyl, thienyl or thiazolyl, wherein the phenyl, pyridyl, thienyl or thiazolyl is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 substituents selected from halogen; n is 0; R 2 It is C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclic group), -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N(C 1-6 Alkyl)2 or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl group is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, Hydroxyl C 1-6 Alkyl or amino C 1-6 alkyl; R 8 It is H; R 3 It is H; X is CH; Y is N; Z is N; R 5 is H, halogen or C 1-6 alkyl; R 6 is H; and R 4 yes 16. A compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 substituents selected from halogen; n is 0; R 2 It is C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 0-6 Alkyl-(4- to 6-membered heterocyclic group), -C 1-6 Alkyl-NH-C 1-6 Alkyl, -C 1-6 Alkyl-NH-C 1-6 Alkyl-OH, -C(O)-NH2, -C(O)-NH-C 1-6 Alkyl, -C(O)-N(C 1-6 Alkyl)2 or -C 1-6 Alkyl-NH-C 0-6 Alkyl-(5- to 6-membered heteroaryl), wherein C 1-6 The alkyl group is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, NH2, Hydroxyl C 1-6 Alkyl or amino C 1-6 alkyl; R 8 It is H; R 3 It is H; X is CH; Y is N; Z is N; R 5 It is CH3; R 6 is H; and R 4 yes 17. A compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl, which is unsubstituted or substituted with 1-3 substituents selected from F or Cl; n is 0; R 2 is CH2OH, CH2NH2, -CH2NH(CH3), -CH2NHCH2CH2OH, -CH2NH-(tetrahydro-2H-pyran) or -CH2NH-CH2-(1H-pyrrole); R 8 It is H; R 3 It is H; X is CH; Y is N; Z is N; R 5 It is CH3; R 6 is H; and R 4 yes 18. The compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: The compounds are stereoisomers with a purity of at least 95% relative to other stereoisomers of the same structure.

19. The compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: The pharmaceutically acceptable salt is hydrochloride, p-toluenesulfonate, benzenesulfonate or trifluoroacetate.

20. A compound according to claim 2, which is: or a pharmaceutically acceptable salt or stereoisomer thereof.

21. A composition comprising at least one compound of claim 2 or a pharmaceutically acceptable salt or stereoisomer thereof, and at least one pharmaceutically acceptable carrier.

22. The composition according to claim 21, further comprising an additional therapeutic agent.

23. Use of a composition for the preparation of a medicament for treating a condition that can be treated by inhibiting ERK1 / 2, wherein the composition comprises a therapeutically effective amount of at least one compound of claim 2.

24. The use according to claim 23, wherein The condition is cancer, leukemia or lymphoma, and cancer includes cancer of the prostate, head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, bladder, uterus, cervix, breast, ovary, vagina, testicle, skin, thyroid, blood, lymph node, kidney, liver, intestine, pancreas, brain, central nervous system, adrenal gland, and skin.

25. The compound of claim 1 having the formula (III), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl or 5- to 6-membered heteroaryl, wherein the phenyl or 5- to 6-membered heteroaryl is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl or -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-3 halogens; n is 0 to 2; R 3 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; M is a key; X is CH; Y is CH or N; Z is CH or N; R 5 is H, halogen or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; R 6 Is H or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; and R 4 is a 4- to 6-membered monocyclic heterocyclic group which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, CN, C 1-6 Alkyl or hydroxyl.

26. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl, pyridyl, thienyl or thiazolyl, wherein the phenyl, pyridyl, thienyl or thiazolyl is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 The alkyl group is unsubstituted or substituted with 1 to 3 substituents selected from halogen.

27. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: n is 1.

28. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 3 It is H or CH3.

29. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: X is CH; and Y is CH or N.

30. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Z is N.

31. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 5 is H, halogen or C 1-6 alkyl.

32. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 6 It's H.

33. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 4 yes 34. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl, pyridyl, thienyl or thiazolyl, wherein the phenyl, pyridyl, thienyl or thiazolyl is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 substituents selected from halogen; n is 1; R 3 Is H or C 1-6 alkyl; X is CH; Y is CH or N; Z is CH or N, R 5 is H, halogen or C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1-5 halogens; R 6 is H; and R 4 yes 35. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl, pyridyl, thienyl or thiazolyl, wherein the phenyl, pyridyl, thienyl or thiazolyl is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 substituents selected from halogen; n is 1; R 3 It is H; X is CH; Y is N; Z is N; R 5 is H, halogen or C 1-6 alkyl; R 6 is H; and R 4 yes 36. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl or thienyl, said phenyl or thienyl being unsubstituted or substituted by 1-3 substituents selected from the group consisting of halogen, C 1-6 Alkyl, CN, -C 1-6 Alkyl-OC(O)-C 1-6 Alkyl, hydroxyl C 1-6 Alkyl or amino C 1-6 Alkyl, where C 1-6 Alkyl is unsubstituted or substituted with 1 to 3 substituents selected from halogen; n is 1; R 3 It is H; X is CH; Y is N; Z is N; R 5 It is CH3; R 6 is H; and R 4 yes 37. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl which is unsubstituted or substituted with 1-3 substituents selected from halogen, CH3, C(CH3)3, CF3, CH2C(O)CH3, CH2C(O)CH2CH3, CH2OH, CH2CH2OH, C(CH3)2OH or CH2NH2; n is 1; R 3 It is H; X is CH; Y is N; Z is N, R 5 It is CH3; R 6 is H; and R 4 yes 38. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl, which is substituted by 1-3 substituents selected from F, Cl, CH2OH or CH2NH2, and at least one ortho position is substituted; n is 1; R 3 It is H; X is CH; Y is N; Z is N, R 5 It is CH3; R 6 is H; and R 4 yes 39. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl, which is substituted by 1-3 substituents selected from F, Cl, CH2OH or CH2NH2, and at least one ortho position is substituted by CH2OH or CH2NH2; n is 1; R 3 It is H; X is CH; Y is N; Z is N, R 5 It is CH3; R 6 is H; and R 4 yes 40. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: The compounds are stereoisomers with a purity of at least 95% relative to other stereoisomers of the same structure.

41. A compound according to claim 25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: The pharmaceutically acceptable salt is hydrochloride, p-toluenesulfonate, benzenesulfonate or trifluoroacetate.

42. A compound according to claim 25, which is: or a pharmaceutically acceptable salt or stereoisomer thereof.

43. A composition comprising at least one compound of claim 25 or a pharmaceutically acceptable salt or stereoisomer thereof, and at least one pharmaceutically acceptable carrier.

44. The composition according to claim 43, further comprising an additional therapeutic agent.

45. Use of a composition for the preparation of a medicament for treating a condition treatable by inhibition of ERK1 / 2, wherein the composition comprises a therapeutically effective amount of at least one compound of claim 25.

46. ​​The use according to claim 45, wherein The condition is cancer, leukemia or lymphoma, and cancer includes cancer of the prostate, head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, bladder, uterus, cervix, breast, ovary, vagina, testicle, skin, thyroid, blood, lymph node, kidney, liver, intestine, pancreas, brain, central nervous system, adrenal gland, and skin.